{"id": "AIMed.d57.s503_AIMed.d57.s503.p0", "text": "Reconstitution of the multiprotein complex of pp60src, hsp90, and p50 in a cell-free system.", "text_with_entity_marker": "Reconstitution of the multiprotein complex of [E1]pp60src[/E1], [E2]hsp90[/E2], and p50 in a cell-free system.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pp60src", "entity_1_idx": [[46, 53]], "entity_1_idx_in_text_with_entity_marker": [50, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp90", "entity_2_idx": [[55, 60]], "entity_2_idx_in_text_with_entity_marker": [68, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s503_AIMed.d57.s503.p1", "text": "Reconstitution of the multiprotein complex of pp60src, hsp90, and p50 in a cell-free system.", "text_with_entity_marker": "Reconstitution of the multiprotein complex of [E1]pp60src[/E1], hsp90, and [E2]p50[/E2] in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pp60src", "entity_1_idx": [[46, 53]], "entity_1_idx_in_text_with_entity_marker": [50, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p50", "entity_2_idx": [[66, 69]], "entity_2_idx_in_text_with_entity_marker": [79, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s503_AIMed.d57.s503.p2", "text": "Reconstitution of the multiprotein complex of pp60src, hsp90, and p50 in a cell-free system.", "text_with_entity_marker": "Reconstitution of the multiprotein complex of pp60src, [E1]hsp90[/E1], and [E2]p50[/E2] in a cell-free system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp90", "entity_1_idx": [[55, 60]], "entity_1_idx_in_text_with_entity_marker": [59, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p50", "entity_2_idx": [[66, 69]], "entity_2_idx_in_text_with_entity_marker": [79, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s504_AIMed.d57.s504.p0", "text": "A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein (hsp90) has been used here to form complexes between the pp60src tyrosine kinase and hsp90.", "text_with_entity_marker": "A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein ([E1]hsp90[/E1]) has been used here to form complexes between the [E2]pp60src[/E2] tyrosine kinase and hsp90.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp90", "entity_1_idx": [[153, 158]], "entity_1_idx_in_text_with_entity_marker": [157, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp60src", "entity_2_idx": [[209, 216]], "entity_2_idx_in_text_with_entity_marker": [222, 229], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s504_AIMed.d57.s504.p1", "text": "A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein (hsp90) has been used here to form complexes between the pp60src tyrosine kinase and hsp90.", "text_with_entity_marker": "A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein ([E1]hsp90[/E1]) has been used here to form complexes between the pp60src tyrosine kinase and [E2]hsp90[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp90", "entity_1_idx": [[153, 158]], "entity_1_idx_in_text_with_entity_marker": [157, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp90", "entity_2_idx": [[237, 242]], "entity_2_idx_in_text_with_entity_marker": [250, 255], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s504_AIMed.d57.s504.p2", "text": "A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein (hsp90) has been used here to form complexes between the pp60src tyrosine kinase and hsp90.", "text_with_entity_marker": "A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein (hsp90) has been used here to form complexes between the [E1]pp60src[/E1] tyrosine kinase and [E2]hsp90[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pp60src", "entity_1_idx": [[209, 216]], "entity_1_idx_in_text_with_entity_marker": [213, 220], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp90", "entity_2_idx": [[237, 242]], "entity_2_idx_in_text_with_entity_marker": [250, 255], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s505_AIMed.d57.s505.p0", "text": "Reticulocyte lysate forms complexes between hsp90 and a temperature-sensitive mutant of Rous sarcoma virus pp60v-src, which is normally present in cytosol virtually entirely in the multiprotein complex form.", "text_with_entity_marker": "Reticulocyte lysate forms complexes between [E1]hsp90[/E1] and a temperature-sensitive mutant of Rous sarcoma virus [E2]pp60v-src[/E2], which is normally present in cytosol virtually entirely in the multiprotein complex form.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hsp90", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp60v-src", "entity_2_idx": [[107, 116]], "entity_2_idx_in_text_with_entity_marker": [120, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s506_AIMed.d57.s506.p0", "text": "In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.", "text_with_entity_marker": "In addition, [E1]hsp90[/E1] in the lysate complexes with wild-type [E2]pp60v-src[/E2], of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hsp90", "entity_1_idx": [[13, 18]], "entity_1_idx_in_text_with_entity_marker": [17, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp60v-src", "entity_2_idx": [[58, 67]], "entity_2_idx_in_text_with_entity_marker": [71, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s506_AIMed.d57.s506.p1", "text": "In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.", "text_with_entity_marker": "In addition, [E1]hsp90[/E1] in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, [E2]pp60c-src[/E2], which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "hsp90", "entity_1_idx": [[13, 18]], "entity_1_idx_in_text_with_entity_marker": [17, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp60c-src", "entity_2_idx": [[199, 208]], "entity_2_idx_in_text_with_entity_marker": [212, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s506_AIMed.d57.s506.p2", "text": "In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.", "text_with_entity_marker": "In addition, [E1]hsp90[/E1] in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with [E2]hsp90[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp90", "entity_1_idx": [[13, 18]], "entity_1_idx_in_text_with_entity_marker": [17, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp90", "entity_2_idx": [[302, 307]], "entity_2_idx_in_text_with_entity_marker": [315, 320], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s506_AIMed.d57.s506.p3", "text": "In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.", "text_with_entity_marker": "In addition, hsp90 in the lysate complexes with wild-type [E1]pp60v-src[/E1], of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, [E2]pp60c-src[/E2], which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pp60v-src", "entity_1_idx": [[58, 67]], "entity_1_idx_in_text_with_entity_marker": [62, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp60c-src", "entity_2_idx": [[199, 208]], "entity_2_idx_in_text_with_entity_marker": [212, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s506_AIMed.d57.s506.p4", "text": "In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.", "text_with_entity_marker": "In addition, hsp90 in the lysate complexes with wild-type [E1]pp60v-src[/E1], of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with [E2]hsp90[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pp60v-src", "entity_1_idx": [[58, 67]], "entity_1_idx_in_text_with_entity_marker": [62, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp90", "entity_2_idx": [[302, 307]], "entity_2_idx_in_text_with_entity_marker": [315, 320], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s506_AIMed.d57.s506.p5", "text": "In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.", "text_with_entity_marker": "In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, [E1]pp60c-src[/E1], which has never been recovered in cytosol in the form of a native multiprotein complex with [E2]hsp90[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pp60c-src", "entity_1_idx": [[199, 208]], "entity_1_idx_in_text_with_entity_marker": [203, 212], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp90", "entity_2_idx": [[302, 307]], "entity_2_idx_in_text_with_entity_marker": [315, 320], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s508_AIMed.d57.s508.p0", "text": "The native and reconstituted pp60src-hsp90 complexes have similar thermal stability and, like steroid receptor heterocomplexes, they are stabilized by molybdate.", "text_with_entity_marker": "The native and reconstituted [E1]pp60src[/E1]-[E2]hsp90[/E2] complexes have similar thermal stability and, like steroid receptor heterocomplexes, they are stabilized by molybdate.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pp60src", "entity_1_idx": [[29, 36]], "entity_1_idx_in_text_with_entity_marker": [33, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp90", "entity_2_idx": [[37, 42]], "entity_2_idx_in_text_with_entity_marker": [50, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s509_AIMed.d57.s509.p0", "text": "As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted pp60src multiprotein complex contains hsp70, which is a major candidate for providing the protein unfoldase activity required for hsp90 association.", "text_with_entity_marker": "As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted [E1]pp60src[/E1] multiprotein complex contains [E2]hsp70[/E2], which is a major candidate for providing the protein unfoldase activity required for hsp90 association.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pp60src", "entity_1_idx": [[119, 126]], "entity_1_idx_in_text_with_entity_marker": [123, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp70", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s509_AIMed.d57.s509.p1", "text": "As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted pp60src multiprotein complex contains hsp70, which is a major candidate for providing the protein unfoldase activity required for hsp90 association.", "text_with_entity_marker": "As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted [E1]pp60src[/E1] multiprotein complex contains hsp70, which is a major candidate for providing the protein unfoldase activity required for [E2]hsp90[/E2] association.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pp60src", "entity_1_idx": [[119, 126]], "entity_1_idx_in_text_with_entity_marker": [123, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp90", "entity_2_idx": [[249, 254]], "entity_2_idx_in_text_with_entity_marker": [262, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d57.s509_AIMed.d57.s509.p2", "text": "As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted pp60src multiprotein complex contains hsp70, which is a major candidate for providing the protein unfoldase activity required for hsp90 association.", "text_with_entity_marker": "As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted pp60src multiprotein complex contains [E1]hsp70[/E1], which is a major candidate for providing the protein unfoldase activity required for [E2]hsp90[/E2] association.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp70", "entity_1_idx": [[157, 162]], "entity_1_idx_in_text_with_entity_marker": [161, 166], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp90", "entity_2_idx": [[249, 254]], "entity_2_idx_in_text_with_entity_marker": [262, 267], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1204_AIMed.d143.s1204.p0", "text": "Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction.", "text_with_entity_marker": "Involvement of [E1]IL-6[/E1] signal transducer [E2]gp130[/E2] in IL-11-mediated signal transduction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[38, 43]], "entity_2_idx_in_text_with_entity_marker": [51, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1204_AIMed.d143.s1204.p1", "text": "Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction.", "text_with_entity_marker": "Involvement of [E1]IL-6[/E1] signal transducer gp130 in [E2]IL-11[/E2]-mediated signal transduction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-11", "entity_2_idx": [[47, 52]], "entity_2_idx_in_text_with_entity_marker": [60, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1204_AIMed.d143.s1204.p2", "text": "Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction.", "text_with_entity_marker": "Involvement of IL-6 signal transducer [E1]gp130[/E1] in [E2]IL-11[/E2]-mediated signal transduction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-11", "entity_2_idx": [[47, 52]], "entity_2_idx_in_text_with_entity_marker": [60, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1205_AIMed.d143.s1205.p0", "text": "IL-11 is a novel cytokine with a variety of biofunctions which overlap with those of IL-6.", "text_with_entity_marker": "[E1]IL-11[/E1] is a novel cytokine with a variety of biofunctions which overlap with those of [E2]IL-6[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[85, 89]], "entity_2_idx_in_text_with_entity_marker": [98, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1206_AIMed.d143.s1206.p0", "text": "We have previously identified IL-11 specific binding protein which is distinct from that of IL-6 in a number of cell lines.", "text_with_entity_marker": "We have previously identified [E1]IL-11[/E1] specific binding protein which is distinct from that of [E2]IL-6[/E2] in a number of cell lines.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[92, 96]], "entity_2_idx_in_text_with_entity_marker": [105, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1207_AIMed.d143.s1207.p0", "text": "The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.", "text_with_entity_marker": "The similarities in biofunctions and differences in ligand binding proteins between [E1]IL-11[/E1] and [E2]IL-6[/E2] prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[84, 89]], "entity_1_idx_in_text_with_entity_marker": [88, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[94, 98]], "entity_2_idx_in_text_with_entity_marker": [107, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1207_AIMed.d143.s1207.p1", "text": "The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.", "text_with_entity_marker": "The similarities in biofunctions and differences in ligand binding proteins between [E1]IL-11[/E1] and IL-6 prompted us to investigate whether [E2]IL-11[/E2] shares common signal transduction mechanisms with IL-6.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[84, 89]], "entity_1_idx_in_text_with_entity_marker": [88, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-11", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1207_AIMed.d143.s1207.p2", "text": "The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.", "text_with_entity_marker": "The similarities in biofunctions and differences in ligand binding proteins between [E1]IL-11[/E1] and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with [E2]IL-6[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[84, 89]], "entity_1_idx_in_text_with_entity_marker": [88, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[190, 194]], "entity_2_idx_in_text_with_entity_marker": [203, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1207_AIMed.d143.s1207.p3", "text": "The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.", "text_with_entity_marker": "The similarities in biofunctions and differences in ligand binding proteins between IL-11 and [E1]IL-6[/E1] prompted us to investigate whether [E2]IL-11[/E2] shares common signal transduction mechanisms with IL-6.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[94, 98]], "entity_1_idx_in_text_with_entity_marker": [98, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-11", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1207_AIMed.d143.s1207.p4", "text": "The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.", "text_with_entity_marker": "The similarities in biofunctions and differences in ligand binding proteins between IL-11 and [E1]IL-6[/E1] prompted us to investigate whether IL-11 shares common signal transduction mechanisms with [E2]IL-6[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[94, 98]], "entity_1_idx_in_text_with_entity_marker": [98, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[190, 194]], "entity_2_idx_in_text_with_entity_marker": [203, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1207_AIMed.d143.s1207.p5", "text": "The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6.", "text_with_entity_marker": "The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether [E1]IL-11[/E1] shares common signal transduction mechanisms with [E2]IL-6[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[134, 139]], "entity_1_idx_in_text_with_entity_marker": [138, 143], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[190, 194]], "entity_2_idx_in_text_with_entity_marker": [203, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1208_AIMed.d143.s1208.p0", "text": "We have examined early signals triggered by IL-11 or IL-6 in a multifactor-dependent human erythroleukemic cell line, TF-1.", "text_with_entity_marker": "We have examined early signals triggered by [E1]IL-11[/E1] or [E2]IL-6[/E2] in a multifactor-dependent human erythroleukemic cell line, TF-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[53, 57]], "entity_2_idx_in_text_with_entity_marker": [66, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1209_AIMed.d143.s1209.p0", "text": "The results showed that IL-11 and IL-6 can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene (junB) expression in TF-1 cells.", "text_with_entity_marker": "The results showed that [E1]IL-11[/E1] and [E2]IL-6[/E2] can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene (junB) expression in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1209_AIMed.d143.s1209.p1", "text": "The results showed that IL-11 and IL-6 can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene (junB) expression in TF-1 cells.", "text_with_entity_marker": "The results showed that [E1]IL-11[/E1] and IL-6 can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene ([E2]junB[/E2]) expression in TF-1 cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-11", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "junB", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1209_AIMed.d143.s1209.p2", "text": "The results showed that IL-11 and IL-6 can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene (junB) expression in TF-1 cells.", "text_with_entity_marker": "The results showed that IL-11 and [E1]IL-6[/E1] can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene ([E2]junB[/E2]) expression in TF-1 cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[34, 38]], "entity_1_idx_in_text_with_entity_marker": [38, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "junB", "entity_2_idx": [[176, 180]], "entity_2_idx_in_text_with_entity_marker": [189, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1210_AIMed.d143.s1210.p0", "text": "These findings imply that IL-11 and IL-6 share similar early signaling events with the possibility of using the same signal transducer, gp130.", "text_with_entity_marker": "These findings imply that [E1]IL-11[/E1] and [E2]IL-6[/E2] share similar early signaling events with the possibility of using the same signal transducer, gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[36, 40]], "entity_2_idx_in_text_with_entity_marker": [49, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1210_AIMed.d143.s1210.p1", "text": "These findings imply that IL-11 and IL-6 share similar early signaling events with the possibility of using the same signal transducer, gp130.", "text_with_entity_marker": "These findings imply that [E1]IL-11[/E1] and IL-6 share similar early signaling events with the possibility of using the same signal transducer, [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[136, 141]], "entity_2_idx_in_text_with_entity_marker": [149, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1210_AIMed.d143.s1210.p2", "text": "These findings imply that IL-11 and IL-6 share similar early signaling events with the possibility of using the same signal transducer, gp130.", "text_with_entity_marker": "These findings imply that IL-11 and [E1]IL-6[/E1] share similar early signaling events with the possibility of using the same signal transducer, [E2]gp130[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[36, 40]], "entity_1_idx_in_text_with_entity_marker": [40, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[136, 141]], "entity_2_idx_in_text_with_entity_marker": [149, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1211_AIMed.d143.s1211.p0", "text": "We next tested whether IL-11 induced signaling can be inhibited by anti-gp130 antibodies which blocked IL-6-mediated functions.", "text_with_entity_marker": "We next tested whether [E1]IL-11[/E1] induced signaling can be inhibited by anti-[E2]gp130[/E2] antibodies which blocked IL-6-mediated functions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[72, 77]], "entity_2_idx_in_text_with_entity_marker": [85, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1211_AIMed.d143.s1211.p1", "text": "We next tested whether IL-11 induced signaling can be inhibited by anti-gp130 antibodies which blocked IL-6-mediated functions.", "text_with_entity_marker": "We next tested whether [E1]IL-11[/E1] induced signaling can be inhibited by anti-gp130 antibodies which blocked [E2]IL-6[/E2]-mediated functions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[103, 107]], "entity_2_idx_in_text_with_entity_marker": [116, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1211_AIMed.d143.s1211.p2", "text": "We next tested whether IL-11 induced signaling can be inhibited by anti-gp130 antibodies which blocked IL-6-mediated functions.", "text_with_entity_marker": "We next tested whether IL-11 induced signaling can be inhibited by anti-[E1]gp130[/E1] antibodies which blocked [E2]IL-6[/E2]-mediated functions.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[72, 77]], "entity_1_idx_in_text_with_entity_marker": [76, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[103, 107]], "entity_2_idx_in_text_with_entity_marker": [116, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1212_AIMed.d143.s1212.p0", "text": "It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.", "text_with_entity_marker": "It was observed that anti-[E1]gp130[/E1] antibodies abolished cell proliferation, protein tyrosine phosphorylation, and [E2]junB[/E2] gene expression elicited by IL-11 or IL-6 in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "junB", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1212_AIMed.d143.s1212.p1", "text": "It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.", "text_with_entity_marker": "It was observed that anti-[E1]gp130[/E1] antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by [E2]IL-11[/E2] or IL-6 in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-11", "entity_2_idx": [[144, 149]], "entity_2_idx_in_text_with_entity_marker": [157, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1212_AIMed.d143.s1212.p2", "text": "It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.", "text_with_entity_marker": "It was observed that anti-[E1]gp130[/E1] antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or [E2]IL-6[/E2] in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1212_AIMed.d143.s1212.p3", "text": "It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.", "text_with_entity_marker": "It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and [E1]junB[/E1] gene expression elicited by [E2]IL-11[/E2] or IL-6 in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "junB", "entity_1_idx": [[111, 115]], "entity_1_idx_in_text_with_entity_marker": [115, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-11", "entity_2_idx": [[144, 149]], "entity_2_idx_in_text_with_entity_marker": [157, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1212_AIMed.d143.s1212.p4", "text": "It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.", "text_with_entity_marker": "It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and [E1]junB[/E1] gene expression elicited by IL-11 or [E2]IL-6[/E2] in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "junB", "entity_1_idx": [[111, 115]], "entity_1_idx_in_text_with_entity_marker": [115, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1212_AIMed.d143.s1212.p5", "text": "It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells.", "text_with_entity_marker": "It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by [E1]IL-11[/E1] or [E2]IL-6[/E2] in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[144, 149]], "entity_1_idx_in_text_with_entity_marker": [148, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1214_AIMed.d143.s1214.p0", "text": "Finally, anti-IL-6R antibody inhibited the ability of IL-6, but not IL-11, to transduce early signals in TF-1 cells.", "text_with_entity_marker": "Finally, anti-[E1]IL-6R[/E1] antibody inhibited the ability of [E2]IL-6[/E2], but not IL-11, to transduce early signals in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6R", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[54, 58]], "entity_2_idx_in_text_with_entity_marker": [67, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1214_AIMed.d143.s1214.p1", "text": "Finally, anti-IL-6R antibody inhibited the ability of IL-6, but not IL-11, to transduce early signals in TF-1 cells.", "text_with_entity_marker": "Finally, anti-[E1]IL-6R[/E1] antibody inhibited the ability of IL-6, but not [E2]IL-11[/E2], to transduce early signals in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6R", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-11", "entity_2_idx": [[68, 73]], "entity_2_idx_in_text_with_entity_marker": [81, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1214_AIMed.d143.s1214.p2", "text": "Finally, anti-IL-6R antibody inhibited the ability of IL-6, but not IL-11, to transduce early signals in TF-1 cells.", "text_with_entity_marker": "Finally, anti-IL-6R antibody inhibited the ability of [E1]IL-6[/E1], but not [E2]IL-11[/E2], to transduce early signals in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[54, 58]], "entity_1_idx_in_text_with_entity_marker": [58, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-11", "entity_2_idx": [[68, 73]], "entity_2_idx_in_text_with_entity_marker": [81, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1215_AIMed.d143.s1215.p0", "text": "These results demonstrate that IL-11 and IL-6 utilize different ligand binding proteins, but share common signal transducer, gp130, in TF-1 cells.", "text_with_entity_marker": "These results demonstrate that [E1]IL-11[/E1] and [E2]IL-6[/E2] utilize different ligand binding proteins, but share common signal transducer, gp130, in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[41, 45]], "entity_2_idx_in_text_with_entity_marker": [54, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1215_AIMed.d143.s1215.p1", "text": "These results demonstrate that IL-11 and IL-6 utilize different ligand binding proteins, but share common signal transducer, gp130, in TF-1 cells.", "text_with_entity_marker": "These results demonstrate that [E1]IL-11[/E1] and IL-6 utilize different ligand binding proteins, but share common signal transducer, [E2]gp130[/E2], in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-11", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[125, 130]], "entity_2_idx_in_text_with_entity_marker": [138, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d143.s1215_AIMed.d143.s1215.p2", "text": "These results demonstrate that IL-11 and IL-6 utilize different ligand binding proteins, but share common signal transducer, gp130, in TF-1 cells.", "text_with_entity_marker": "These results demonstrate that IL-11 and [E1]IL-6[/E1] utilize different ligand binding proteins, but share common signal transducer, [E2]gp130[/E2], in TF-1 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[41, 45]], "entity_1_idx_in_text_with_entity_marker": [45, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[125, 130]], "entity_2_idx_in_text_with_entity_marker": [138, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s733_AIMed.d87.s733.p0", "text": "Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.", "text_with_entity_marker": "Interaction of [E1]p85[/E1] subunit of [E2]PI 3-kinase[/E2] with insulin and IGF-1 receptors analysed by using the two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PI 3-kinase", "entity_2_idx": [[30, 41]], "entity_2_idx_in_text_with_entity_marker": [43, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s733_AIMed.d87.s733.p1", "text": "Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.", "text_with_entity_marker": "Interaction of [E1]p85[/E1] subunit of PI 3-kinase with [E2]insulin[/E2] and IGF-1 receptors analysed by using the two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[47, 54]], "entity_2_idx_in_text_with_entity_marker": [60, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s733_AIMed.d87.s733.p2", "text": "Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.", "text_with_entity_marker": "Interaction of [E1]p85[/E1] subunit of PI 3-kinase with insulin and [E2]IGF-1[/E2] receptors analysed by using the two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1", "entity_2_idx": [[59, 64]], "entity_2_idx_in_text_with_entity_marker": [72, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s733_AIMed.d87.s733.p3", "text": "Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.", "text_with_entity_marker": "Interaction of p85 subunit of [E1]PI 3-kinase[/E1] with [E2]insulin[/E2] and IGF-1 receptors analysed by using the two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PI 3-kinase", "entity_1_idx": [[30, 41]], "entity_1_idx_in_text_with_entity_marker": [34, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[47, 54]], "entity_2_idx_in_text_with_entity_marker": [60, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s733_AIMed.d87.s733.p4", "text": "Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.", "text_with_entity_marker": "Interaction of p85 subunit of [E1]PI 3-kinase[/E1] with insulin and [E2]IGF-1[/E2] receptors analysed by using the two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PI 3-kinase", "entity_1_idx": [[30, 41]], "entity_1_idx_in_text_with_entity_marker": [34, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1", "entity_2_idx": [[59, 64]], "entity_2_idx_in_text_with_entity_marker": [72, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s733_AIMed.d87.s733.p5", "text": "Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system.", "text_with_entity_marker": "Interaction of p85 subunit of PI 3-kinase with [E1]insulin[/E1] and [E2]IGF-1[/E2] receptors analysed by using the two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[47, 54]], "entity_1_idx_in_text_with_entity_marker": [51, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1", "entity_2_idx": [[59, 64]], "entity_2_idx_in_text_with_entity_marker": [72, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p0", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the [E1]p85[/E1] subunit of [E2]PI 3-kinase[/E2] with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PI 3-kinase", "entity_2_idx": [[34, 45]], "entity_2_idx_in_text_with_entity_marker": [47, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p1", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the [E1]p85[/E1] subunit of PI 3-kinase with the [E2]insulin[/E2] receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[55, 62]], "entity_2_idx_in_text_with_entity_marker": [68, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p2", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the [E1]p85[/E1] subunit of PI 3-kinase with the [E2]insulin receptor[/E2] (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[55, 71]], "entity_2_idx_in_text_with_entity_marker": [68, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p3", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the [E1]p85[/E1] subunit of PI 3-kinase with the insulin receptor ([E2]IR[/E2]) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[73, 75]], "entity_2_idx_in_text_with_entity_marker": [86, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p4", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the [E1]p85[/E1] subunit of PI 3-kinase with the insulin receptor (IR) and the [E2]IGF-1[/E2] receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p5", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the [E1]p85[/E1] subunit of PI 3-kinase with the insulin receptor (IR) and the [E2]IGF-1 receptor[/E2] (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1 receptor", "entity_2_idx": [[85, 99]], "entity_2_idx_in_text_with_entity_marker": [98, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p6", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the [E1]p85[/E1] subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor ([E2]IGF-1R[/E2]) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[101, 107]], "entity_2_idx_in_text_with_entity_marker": [114, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p7", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of [E1]PI 3-kinase[/E1] with the [E2]insulin[/E2] receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PI 3-kinase", "entity_1_idx": [[34, 45]], "entity_1_idx_in_text_with_entity_marker": [38, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[55, 62]], "entity_2_idx_in_text_with_entity_marker": [68, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p8", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of [E1]PI 3-kinase[/E1] with the [E2]insulin receptor[/E2] (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PI 3-kinase", "entity_1_idx": [[34, 45]], "entity_1_idx_in_text_with_entity_marker": [38, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[55, 71]], "entity_2_idx_in_text_with_entity_marker": [68, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p9", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of [E1]PI 3-kinase[/E1] with the insulin receptor ([E2]IR[/E2]) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PI 3-kinase", "entity_1_idx": [[34, 45]], "entity_1_idx_in_text_with_entity_marker": [38, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[73, 75]], "entity_2_idx_in_text_with_entity_marker": [86, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p10", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of [E1]PI 3-kinase[/E1] with the insulin receptor (IR) and the [E2]IGF-1[/E2] receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PI 3-kinase", "entity_1_idx": [[34, 45]], "entity_1_idx_in_text_with_entity_marker": [38, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p11", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of [E1]PI 3-kinase[/E1] with the insulin receptor (IR) and the [E2]IGF-1 receptor[/E2] (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PI 3-kinase", "entity_1_idx": [[34, 45]], "entity_1_idx_in_text_with_entity_marker": [38, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1 receptor", "entity_2_idx": [[85, 99]], "entity_2_idx_in_text_with_entity_marker": [98, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p12", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of [E1]PI 3-kinase[/E1] with the insulin receptor (IR) and the IGF-1 receptor ([E2]IGF-1R[/E2]) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PI 3-kinase", "entity_1_idx": [[34, 45]], "entity_1_idx_in_text_with_entity_marker": [38, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[101, 107]], "entity_2_idx_in_text_with_entity_marker": [114, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p13", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the [E1-E2]insulin[/E1] receptor[/E2] (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[55, 62]], "entity_1_idx_in_text_with_entity_marker": [62, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin[/E1] receptor", "entity_2_idx": [[55, 71]], "entity_2_idx_in_text_with_entity_marker": [62, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p14", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the [E1]insulin[/E1] receptor ([E2]IR[/E2]) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[55, 62]], "entity_1_idx_in_text_with_entity_marker": [59, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[73, 75]], "entity_2_idx_in_text_with_entity_marker": [86, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p15", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the [E1]insulin[/E1] receptor (IR) and the [E2]IGF-1[/E2] receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[55, 62]], "entity_1_idx_in_text_with_entity_marker": [59, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p16", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the [E1]insulin[/E1] receptor (IR) and the [E2]IGF-1 receptor[/E2] (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[55, 62]], "entity_1_idx_in_text_with_entity_marker": [59, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1 receptor", "entity_2_idx": [[85, 99]], "entity_2_idx_in_text_with_entity_marker": [98, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p17", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the [E1]insulin[/E1] receptor (IR) and the IGF-1 receptor ([E2]IGF-1R[/E2]) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[55, 62]], "entity_1_idx_in_text_with_entity_marker": [59, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[101, 107]], "entity_2_idx_in_text_with_entity_marker": [114, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p18", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the [E1]insulin receptor[/E1] ([E2]IR[/E2]) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[55, 71]], "entity_1_idx_in_text_with_entity_marker": [59, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[73, 75]], "entity_2_idx_in_text_with_entity_marker": [86, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p19", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the [E1]insulin receptor[/E1] (IR) and the [E2]IGF-1[/E2] receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[55, 71]], "entity_1_idx_in_text_with_entity_marker": [59, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p20", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the [E1]insulin receptor[/E1] (IR) and the [E2]IGF-1 receptor[/E2] (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[55, 71]], "entity_1_idx_in_text_with_entity_marker": [59, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1 receptor", "entity_2_idx": [[85, 99]], "entity_2_idx_in_text_with_entity_marker": [98, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p21", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the [E1]insulin receptor[/E1] (IR) and the IGF-1 receptor ([E2]IGF-1R[/E2]) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[55, 71]], "entity_1_idx_in_text_with_entity_marker": [59, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[101, 107]], "entity_2_idx_in_text_with_entity_marker": [114, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p22", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor ([E1]IR[/E1]) and the [E2]IGF-1[/E2] receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[73, 75]], "entity_1_idx_in_text_with_entity_marker": [77, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p23", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor ([E1]IR[/E1]) and the [E2]IGF-1 receptor[/E2] (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[73, 75]], "entity_1_idx_in_text_with_entity_marker": [77, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1 receptor", "entity_2_idx": [[85, 99]], "entity_2_idx_in_text_with_entity_marker": [98, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p24", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor ([E1]IR[/E1]) and the IGF-1 receptor ([E2]IGF-1R[/E2]) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[73, 75]], "entity_1_idx_in_text_with_entity_marker": [77, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[101, 107]], "entity_2_idx_in_text_with_entity_marker": [114, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p25", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the [E1-E2]IGF-1[/E1] receptor[/E2] (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1", "entity_1_idx": [[85, 90]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1[/E1] receptor", "entity_2_idx": [[85, 99]], "entity_2_idx_in_text_with_entity_marker": [92, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p26", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the [E1]IGF-1[/E1] receptor ([E2]IGF-1R[/E2]) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1", "entity_1_idx": [[85, 90]], "entity_1_idx_in_text_with_entity_marker": [89, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[101, 107]], "entity_2_idx_in_text_with_entity_marker": [114, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s734_AIMed.d87.s734.p27", "text": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "text_with_entity_marker": "Interaction of the p85 subunit of PI 3-kinase with the insulin receptor (IR) and the [E1]IGF-1 receptor[/E1] ([E2]IGF-1R[/E2]) was investigated using the two-hybrid system by assessing for his3 and lacZ activation in S. cerevisiae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1 receptor", "entity_1_idx": [[85, 99]], "entity_1_idx_in_text_with_entity_marker": [89, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[101, 107]], "entity_2_idx_in_text_with_entity_marker": [114, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s735_AIMed.d87.s735.p0", "text": "The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of IR and IGF-1R and p85 or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).", "text_with_entity_marker": "The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of [E1]IR[/E1] and [E2]IGF-1R[/E2] and p85 or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[97, 103]], "entity_2_idx_in_text_with_entity_marker": [110, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s735_AIMed.d87.s735.p1", "text": "The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of IR and IGF-1R and p85 or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).", "text_with_entity_marker": "The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of [E1]IR[/E1] and IGF-1R and [E2]p85[/E2] or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p85", "entity_2_idx": [[108, 111]], "entity_2_idx_in_text_with_entity_marker": [121, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s735_AIMed.d87.s735.p2", "text": "The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of IR and IGF-1R and p85 or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).", "text_with_entity_marker": "The experiments were performed with the cytoplasmic beta domain (wild type or mutated) of IR and [E1]IGF-1R[/E1] and [E2]p85[/E2] or its subdomains (N + C-SH2, N-SH2, C-SH2, SH3 + N-SH2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[97, 103]], "entity_1_idx_in_text_with_entity_marker": [101, 107], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p85", "entity_2_idx": [[108, 111]], "entity_2_idx_in_text_with_entity_marker": [121, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p0", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that [E1]p85[/E1], N + C-SH2 and C-SH2 interact with both [E2]IR[/E2] beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[90, 92]], "entity_2_idx_in_text_with_entity_marker": [103, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p1", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that [E1]p85[/E1], N + C-SH2 and C-SH2 interact with both [E2]IR beta[/E2] and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p85", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[90, 97]], "entity_2_idx_in_text_with_entity_marker": [103, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p2", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that [E1]p85[/E1], N + C-SH2 and C-SH2 interact with both IR beta and [E2]IGF-1R[/E2] beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p3", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that [E1]p85[/E1], N + C-SH2 and C-SH2 interact with both IR beta and [E2]IGF-1R beta[/E2], whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p85", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R beta", "entity_2_idx": [[102, 113]], "entity_2_idx_in_text_with_entity_marker": [115, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p4", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that [E1]p85[/E1], N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with [E2]IR[/E2] beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[164, 166]], "entity_2_idx_in_text_with_entity_marker": [177, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p5", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that [E1]p85[/E1], N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with [E2]IR beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[164, 171]], "entity_2_idx_in_text_with_entity_marker": [177, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p6", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both [E1-E2]IR[/E1] beta[/E2] and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [97, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR[/E1] beta", "entity_2_idx": [[90, 97]], "entity_2_idx_in_text_with_entity_marker": [97, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p7", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both [E1]IR[/E1] beta and [E2]IGF-1R[/E2] beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p8", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both [E1]IR[/E1] beta and [E2]IGF-1R beta[/E2], whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R beta", "entity_2_idx": [[102, 113]], "entity_2_idx_in_text_with_entity_marker": [115, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p9", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both [E1]IR[/E1] beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with [E2]IR[/E2] beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[164, 166]], "entity_2_idx_in_text_with_entity_marker": [177, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p10", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both [E1]IR[/E1] beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with [E2]IR beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[90, 92]], "entity_1_idx_in_text_with_entity_marker": [94, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[164, 171]], "entity_2_idx_in_text_with_entity_marker": [177, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p11", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both [E1]IR beta[/E1] and [E2]IGF-1R[/E2] beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[90, 97]], "entity_1_idx_in_text_with_entity_marker": [94, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p12", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both [E1]IR beta[/E1] and [E2]IGF-1R beta[/E2], whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[90, 97]], "entity_1_idx_in_text_with_entity_marker": [94, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R beta", "entity_2_idx": [[102, 113]], "entity_2_idx_in_text_with_entity_marker": [115, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p13", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both [E1]IR beta[/E1] and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with [E2]IR[/E2] beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[90, 97]], "entity_1_idx_in_text_with_entity_marker": [94, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[164, 166]], "entity_2_idx_in_text_with_entity_marker": [177, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p14", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both [E1]IR beta[/E1] and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with [E2]IR beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[90, 97]], "entity_1_idx_in_text_with_entity_marker": [94, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[164, 171]], "entity_2_idx_in_text_with_entity_marker": [177, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p15", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and [E1-E2]IGF-1R[/E1] beta[/E2], whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[102, 108]], "entity_1_idx_in_text_with_entity_marker": [109, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R[/E1] beta", "entity_2_idx": [[102, 113]], "entity_2_idx_in_text_with_entity_marker": [109, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p16", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and [E1]IGF-1R[/E1] beta, whereas N-SH2 and SH3 + N-SH2 interact only with [E2]IR[/E2] beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[102, 108]], "entity_1_idx_in_text_with_entity_marker": [106, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[164, 166]], "entity_2_idx_in_text_with_entity_marker": [177, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p17", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and [E1]IGF-1R[/E1] beta, whereas N-SH2 and SH3 + N-SH2 interact only with [E2]IR beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[102, 108]], "entity_1_idx_in_text_with_entity_marker": [106, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[164, 171]], "entity_2_idx_in_text_with_entity_marker": [177, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p18", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and [E1]IGF-1R beta[/E1], whereas N-SH2 and SH3 + N-SH2 interact only with [E2]IR[/E2] beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R beta", "entity_1_idx": [[102, 113]], "entity_1_idx_in_text_with_entity_marker": [106, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR", "entity_2_idx": [[164, 166]], "entity_2_idx_in_text_with_entity_marker": [177, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p19", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and [E1]IGF-1R beta[/E1], whereas N-SH2 and SH3 + N-SH2 interact only with [E2]IR beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R beta", "entity_1_idx": [[102, 113]], "entity_1_idx_in_text_with_entity_marker": [106, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[164, 171]], "entity_2_idx_in_text_with_entity_marker": [177, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s736_AIMed.d87.s736.p20", "text": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with IR beta.", "text_with_entity_marker": "The results of his3 activation indicated that p85, N + C-SH2 and C-SH2 interact with both IR beta and IGF-1R beta, whereas N-SH2 and SH3 + N-SH2 interact only with [E1-E2]IR[/E1] beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[164, 166]], "entity_1_idx_in_text_with_entity_marker": [171, 173], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR[/E1] beta", "entity_2_idx": [[164, 171]], "entity_2_idx_in_text_with_entity_marker": [171, 183], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p0", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of [E1]p85[/E1] and N+C-SH2 with [E2]IR beta[/E2] (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p85", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[36, 43]], "entity_2_idx_in_text_with_entity_marker": [49, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p1", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of [E1]p85[/E1] and N+C-SH2 with IR beta ([E2]delta C-43[/E2]) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[45, 55]], "entity_2_idx_in_text_with_entity_marker": [58, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p2", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of [E1]p85[/E1] and N+C-SH2 with IR beta (delta C-43) or [E2]IGF-1R[/E2] beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[60, 66]], "entity_2_idx_in_text_with_entity_marker": [73, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p3", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of [E1]p85[/E1] and N+C-SH2 with IR beta (delta C-43) or [E2]IGF-1R beta[/E2](delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p85", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R beta", "entity_2_idx": [[60, 71]], "entity_2_idx_in_text_with_entity_marker": [73, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p4", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of [E1]p85[/E1] and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta([E2]delta C-43[/E2]) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[72, 82]], "entity_2_idx_in_text_with_entity_marker": [85, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p5", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of p85 and N+C-SH2 with [E1]IR beta[/E1] ([E2]delta C-43[/E2]) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[36, 43]], "entity_1_idx_in_text_with_entity_marker": [40, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[45, 55]], "entity_2_idx_in_text_with_entity_marker": [58, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p6", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of p85 and N+C-SH2 with [E1]IR beta[/E1] (delta C-43) or [E2]IGF-1R[/E2] beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[36, 43]], "entity_1_idx_in_text_with_entity_marker": [40, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[60, 66]], "entity_2_idx_in_text_with_entity_marker": [73, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p7", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of p85 and N+C-SH2 with [E1]IR beta[/E1] (delta C-43) or [E2]IGF-1R beta[/E2](delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[36, 43]], "entity_1_idx_in_text_with_entity_marker": [40, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R beta", "entity_2_idx": [[60, 71]], "entity_2_idx_in_text_with_entity_marker": [73, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p8", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of p85 and N+C-SH2 with [E1]IR beta[/E1] (delta C-43) or IGF-1R beta([E2]delta C-43[/E2]) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[36, 43]], "entity_1_idx_in_text_with_entity_marker": [40, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[72, 82]], "entity_2_idx_in_text_with_entity_marker": [85, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p9", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of p85 and N+C-SH2 with IR beta ([E1]delta C-43[/E1]) or [E2]IGF-1R[/E2] beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "delta C-43", "entity_1_idx": [[45, 55]], "entity_1_idx_in_text_with_entity_marker": [49, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[60, 66]], "entity_2_idx_in_text_with_entity_marker": [73, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p10", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of p85 and N+C-SH2 with IR beta ([E1]delta C-43[/E1]) or [E2]IGF-1R beta[/E2](delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "delta C-43", "entity_1_idx": [[45, 55]], "entity_1_idx_in_text_with_entity_marker": [49, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R beta", "entity_2_idx": [[60, 71]], "entity_2_idx_in_text_with_entity_marker": [73, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p11", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of p85 and N+C-SH2 with IR beta ([E1]delta C-43[/E1]) or IGF-1R beta([E2]delta C-43[/E2]) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "delta C-43", "entity_1_idx": [[45, 55]], "entity_1_idx_in_text_with_entity_marker": [49, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[72, 82]], "entity_2_idx_in_text_with_entity_marker": [85, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p12", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or [E1-E2]IGF-1R[/E1] beta[/E2](delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[60, 66]], "entity_1_idx_in_text_with_entity_marker": [67, 73], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R[/E1] beta", "entity_2_idx": [[60, 71]], "entity_2_idx_in_text_with_entity_marker": [67, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p13", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or [E1]IGF-1R[/E1] beta([E2]delta C-43[/E2]) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[60, 66]], "entity_1_idx_in_text_with_entity_marker": [64, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[72, 82]], "entity_2_idx_in_text_with_entity_marker": [85, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s737_AIMed.d87.s737.p14", "text": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or IGF-1R beta(delta C-43) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "text_with_entity_marker": "Interaction of p85 and N+C-SH2 with IR beta (delta C-43) or [E1]IGF-1R beta[/E1]([E2]delta C-43[/E2]) in which the C-terminal 43 amino acids (including the YXXM motif) were deleted, persisted.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R beta", "entity_1_idx": [[60, 71]], "entity_1_idx_in_text_with_entity_marker": [64, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[72, 82]], "entity_2_idx_in_text_with_entity_marker": [85, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s738_AIMed.d87.s738.p0", "text": "The internal binding site thus revealed was not altered by further mutating Y960/F for IR or Y950/F for IGF-1R.", "text_with_entity_marker": "The internal binding site thus revealed was not altered by further mutating Y960/F for [E1]IR[/E1] or Y950/F for [E2]IGF-1R[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR", "entity_1_idx": [[87, 89]], "entity_1_idx_in_text_with_entity_marker": [91, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[104, 110]], "entity_2_idx_in_text_with_entity_marker": [117, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s739_AIMed.d87.s739.p0", "text": "Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.", "text_with_entity_marker": "Activation of lacZ upon interaction of [E1]p85[/E1] with [E2]IR beta[/E2](delta C-43) was 4-fold less as compared to IR beta.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p85", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[48, 55]], "entity_2_idx_in_text_with_entity_marker": [61, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s739_AIMed.d87.s739.p1", "text": "Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.", "text_with_entity_marker": "Activation of lacZ upon interaction of [E1]p85[/E1] with IR beta([E2]delta C-43[/E2]) was 4-fold less as compared to IR beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[56, 66]], "entity_2_idx_in_text_with_entity_marker": [69, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s739_AIMed.d87.s739.p2", "text": "Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.", "text_with_entity_marker": "Activation of lacZ upon interaction of [E1]p85[/E1] with IR beta(delta C-43) was 4-fold less as compared to [E2]IR beta[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p85", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[99, 106]], "entity_2_idx_in_text_with_entity_marker": [112, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s739_AIMed.d87.s739.p3", "text": "Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.", "text_with_entity_marker": "Activation of lacZ upon interaction of p85 with [E1]IR beta[/E1]([E2]delta C-43[/E2]) was 4-fold less as compared to IR beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[48, 55]], "entity_1_idx_in_text_with_entity_marker": [52, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[56, 66]], "entity_2_idx_in_text_with_entity_marker": [69, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s739_AIMed.d87.s739.p4", "text": "Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.", "text_with_entity_marker": "Activation of lacZ upon interaction of p85 with [E1]IR beta[/E1](delta C-43) was 4-fold less as compared to [E2]IR beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[48, 55]], "entity_1_idx_in_text_with_entity_marker": [52, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[99, 106]], "entity_2_idx_in_text_with_entity_marker": [112, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s739_AIMed.d87.s739.p5", "text": "Activation of lacZ upon interaction of p85 with IR beta(delta C-43) was 4-fold less as compared to IR beta.", "text_with_entity_marker": "Activation of lacZ upon interaction of p85 with IR beta([E1]delta C-43[/E1]) was 4-fold less as compared to [E2]IR beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "delta C-43", "entity_1_idx": [[56, 66]], "entity_1_idx_in_text_with_entity_marker": [60, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[99, 106]], "entity_2_idx_in_text_with_entity_marker": [112, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p0", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with [E1]p85[/E1] and [E2]IGF-1R[/E2] beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[29, 35]], "entity_2_idx_in_text_with_entity_marker": [42, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p1", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with [E1]p85[/E1] and [E2]IGF-1R beta[/E2] was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p85", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R beta", "entity_2_idx": [[29, 40]], "entity_2_idx_in_text_with_entity_marker": [42, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p2", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with [E1]p85[/E1] and IGF-1R beta was 4-fold less as compared to [E2]IR beta[/E2] and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p85", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[72, 79]], "entity_2_idx_in_text_with_entity_marker": [85, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p3", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with [E1]p85[/E1] and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for [E2]IGF-1R[/E2] beta (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[120, 126]], "entity_2_idx_in_text_with_entity_marker": [133, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p4", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with [E1]p85[/E1] and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for [E2]IGF-1R beta[/E2] (delta C-43).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p85", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R beta", "entity_2_idx": [[120, 131]], "entity_2_idx_in_text_with_entity_marker": [133, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p5", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with [E1]p85[/E1] and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta ([E2]delta C-43[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[133, 143]], "entity_2_idx_in_text_with_entity_marker": [146, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p6", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and [E1-E2]IGF-1R[/E1] beta[/E2] was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R[/E1] beta", "entity_2_idx": [[29, 40]], "entity_2_idx_in_text_with_entity_marker": [36, 52], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p7", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and [E1]IGF-1R[/E1] beta was 4-fold less as compared to [E2]IR beta[/E2] and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[72, 79]], "entity_2_idx_in_text_with_entity_marker": [85, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p8", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and [E1]IGF-1R[/E1] beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for [E2]IGF-1R[/E2] beta (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[120, 126]], "entity_2_idx_in_text_with_entity_marker": [133, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p9", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and [E1]IGF-1R[/E1] beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for [E2]IGF-1R beta[/E2] (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R beta", "entity_2_idx": [[120, 131]], "entity_2_idx_in_text_with_entity_marker": [133, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p10", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and [E1]IGF-1R[/E1] beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta ([E2]delta C-43[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[133, 143]], "entity_2_idx_in_text_with_entity_marker": [146, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p11", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and [E1]IGF-1R beta[/E1] was 4-fold less as compared to [E2]IR beta[/E2] and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R beta", "entity_1_idx": [[29, 40]], "entity_1_idx_in_text_with_entity_marker": [33, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IR beta", "entity_2_idx": [[72, 79]], "entity_2_idx_in_text_with_entity_marker": [85, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p12", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and [E1]IGF-1R beta[/E1] was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for [E2]IGF-1R[/E2] beta (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R beta", "entity_1_idx": [[29, 40]], "entity_1_idx_in_text_with_entity_marker": [33, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[120, 126]], "entity_2_idx_in_text_with_entity_marker": [133, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p13", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and [E1]IGF-1R beta[/E1] was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for [E2]IGF-1R beta[/E2] (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R beta", "entity_1_idx": [[29, 40]], "entity_1_idx_in_text_with_entity_marker": [33, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R beta", "entity_2_idx": [[120, 131]], "entity_2_idx_in_text_with_entity_marker": [133, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p14", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and [E1]IGF-1R beta[/E1] was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta ([E2]delta C-43[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R beta", "entity_1_idx": [[29, 40]], "entity_1_idx_in_text_with_entity_marker": [33, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[133, 143]], "entity_2_idx_in_text_with_entity_marker": [146, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p15", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and IGF-1R beta was 4-fold less as compared to [E1]IR beta[/E1] and was somewhat increased (2-fold) for [E2]IGF-1R[/E2] beta (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[72, 79]], "entity_1_idx_in_text_with_entity_marker": [76, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R", "entity_2_idx": [[120, 126]], "entity_2_idx_in_text_with_entity_marker": [133, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p16", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and IGF-1R beta was 4-fold less as compared to [E1]IR beta[/E1] and was somewhat increased (2-fold) for [E2]IGF-1R beta[/E2] (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[72, 79]], "entity_1_idx_in_text_with_entity_marker": [76, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R beta", "entity_2_idx": [[120, 131]], "entity_2_idx_in_text_with_entity_marker": [133, 144], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p17", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and IGF-1R beta was 4-fold less as compared to [E1]IR beta[/E1] and was somewhat increased (2-fold) for IGF-1R beta ([E2]delta C-43[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IR beta", "entity_1_idx": [[72, 79]], "entity_1_idx_in_text_with_entity_marker": [76, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[133, 143]], "entity_2_idx_in_text_with_entity_marker": [146, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p18", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for [E1-E2]IGF-1R[/E1] beta[/E2] (delta C-43).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[120, 126]], "entity_1_idx_in_text_with_entity_marker": [127, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IGF-1R[/E1] beta", "entity_2_idx": [[120, 131]], "entity_2_idx_in_text_with_entity_marker": [127, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p19", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for [E1]IGF-1R[/E1] beta ([E2]delta C-43[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[120, 126]], "entity_1_idx_in_text_with_entity_marker": [124, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[133, 143]], "entity_2_idx_in_text_with_entity_marker": [146, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s740_AIMed.d87.s740.p20", "text": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for IGF-1R beta (delta C-43).", "text_with_entity_marker": "This activation with p85 and IGF-1R beta was 4-fold less as compared to IR beta and was somewhat increased (2-fold) for [E1]IGF-1R beta[/E1] ([E2]delta C-43[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R beta", "entity_1_idx": [[120, 131]], "entity_1_idx_in_text_with_entity_marker": [124, 135], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta C-43", "entity_2_idx": [[133, 143]], "entity_2_idx_in_text_with_entity_marker": [146, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s741_AIMed.d87.s741.p0", "text": "Thus, the C-terminal domain in IGF-1R appears to exert a negative control on binding of p85 thereby providing a possible regulatory mechanism for direct activation of the PI 3-kinase pathway.", "text_with_entity_marker": "Thus, the C-terminal domain in [E1]IGF-1R[/E1] appears to exert a negative control on binding of [E2]p85[/E2] thereby providing a possible regulatory mechanism for direct activation of the PI 3-kinase pathway.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IGF-1R", "entity_1_idx": [[31, 37]], "entity_1_idx_in_text_with_entity_marker": [35, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p85", "entity_2_idx": [[88, 91]], "entity_2_idx_in_text_with_entity_marker": [101, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s741_AIMed.d87.s741.p1", "text": "Thus, the C-terminal domain in IGF-1R appears to exert a negative control on binding of p85 thereby providing a possible regulatory mechanism for direct activation of the PI 3-kinase pathway.", "text_with_entity_marker": "Thus, the C-terminal domain in [E1]IGF-1R[/E1] appears to exert a negative control on binding of p85 thereby providing a possible regulatory mechanism for direct activation of the [E2]PI 3-kinase[/E2] pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IGF-1R", "entity_1_idx": [[31, 37]], "entity_1_idx_in_text_with_entity_marker": [35, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PI 3-kinase", "entity_2_idx": [[171, 182]], "entity_2_idx_in_text_with_entity_marker": [184, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d87.s741_AIMed.d87.s741.p2", "text": "Thus, the C-terminal domain in IGF-1R appears to exert a negative control on binding of p85 thereby providing a possible regulatory mechanism for direct activation of the PI 3-kinase pathway.", "text_with_entity_marker": "Thus, the C-terminal domain in IGF-1R appears to exert a negative control on binding of [E1]p85[/E1] thereby providing a possible regulatory mechanism for direct activation of the [E2]PI 3-kinase[/E2] pathway.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p85", "entity_1_idx": [[88, 91]], "entity_1_idx_in_text_with_entity_marker": [92, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PI 3-kinase", "entity_2_idx": [[171, 182]], "entity_2_idx_in_text_with_entity_marker": [184, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s944_AIMed.d112.s944.p0", "text": "Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.", "text_with_entity_marker": "Human spleen tyrosine kinase [E1]p72Syk[/E1] associates with the Src-family kinase [E2]p53[/E2]/56Lyn and a 120-kDa phosphoprotein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p72Syk", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[74, 77]], "entity_2_idx_in_text_with_entity_marker": [87, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s944_AIMed.d112.s944.p1", "text": "Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.", "text_with_entity_marker": "Human spleen tyrosine kinase [E1]p72Syk[/E1] associates with the Src-family kinase p53/[E2]56Lyn[/E2] and a 120-kDa phosphoprotein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p72Syk", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "56Lyn", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s944_AIMed.d112.s944.p2", "text": "Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.", "text_with_entity_marker": "Human spleen tyrosine kinase [E1]p72Syk[/E1] associates with the Src-family kinase p53/56Lyn and a [E2]120-kDa phosphoprotein[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p72Syk", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "120-kDa phosphoprotein", "entity_2_idx": [[90, 112]], "entity_2_idx_in_text_with_entity_marker": [103, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s944_AIMed.d112.s944.p3", "text": "Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.", "text_with_entity_marker": "Human spleen tyrosine kinase p72Syk associates with the Src-family kinase [E1]p53[/E1]/[E2]56Lyn[/E2] and a 120-kDa phosphoprotein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[74, 77]], "entity_1_idx_in_text_with_entity_marker": [78, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "56Lyn", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s944_AIMed.d112.s944.p4", "text": "Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.", "text_with_entity_marker": "Human spleen tyrosine kinase p72Syk associates with the Src-family kinase [E1]p53[/E1]/56Lyn and a [E2]120-kDa phosphoprotein[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[74, 77]], "entity_1_idx_in_text_with_entity_marker": [78, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "120-kDa phosphoprotein", "entity_2_idx": [[90, 112]], "entity_2_idx_in_text_with_entity_marker": [103, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s944_AIMed.d112.s944.p5", "text": "Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.", "text_with_entity_marker": "Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/[E1]56Lyn[/E1] and a [E2]120-kDa phosphoprotein[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "56Lyn", "entity_1_idx": [[78, 83]], "entity_1_idx_in_text_with_entity_marker": [82, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "120-kDa phosphoprotein", "entity_2_idx": [[90, 112]], "entity_2_idx_in_text_with_entity_marker": [103, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s945_AIMed.d112.s945.p0", "text": "The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.", "text_with_entity_marker": "The 72-kDa spleen tyrosine kinase ([E1]Syk[/E1]) and Src-family kinase [E2]p53[/E2]/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[62, 65]], "entity_2_idx_in_text_with_entity_marker": [75, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s945_AIMed.d112.s945.p1", "text": "The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.", "text_with_entity_marker": "The 72-kDa spleen tyrosine kinase ([E1]Syk[/E1]) and Src-family kinase p53/[E2]56Lyn[/E2] (Lyn) contribute to signaling via the B-cell antigen receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "56Lyn", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s945_AIMed.d112.s945.p2", "text": "The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.", "text_with_entity_marker": "The 72-kDa spleen tyrosine kinase ([E1]Syk[/E1]) and Src-family kinase p53/56Lyn ([E2]Lyn[/E2]) contribute to signaling via the B-cell antigen receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[35, 38]], "entity_1_idx_in_text_with_entity_marker": [39, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s945_AIMed.d112.s945.p3", "text": "The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.", "text_with_entity_marker": "The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase [E1]p53[/E1]/[E2]56Lyn[/E2] (Lyn) contribute to signaling via the B-cell antigen receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[62, 65]], "entity_1_idx_in_text_with_entity_marker": [66, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "56Lyn", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s945_AIMed.d112.s945.p4", "text": "The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.", "text_with_entity_marker": "The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase [E1]p53[/E1]/56Lyn ([E2]Lyn[/E2]) contribute to signaling via the B-cell antigen receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[62, 65]], "entity_1_idx_in_text_with_entity_marker": [66, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s945_AIMed.d112.s945.p5", "text": "The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/56Lyn (Lyn) contribute to signaling via the B-cell antigen receptor complex.", "text_with_entity_marker": "The 72-kDa spleen tyrosine kinase (Syk) and Src-family kinase p53/[E1]56Lyn[/E1] ([E2]Lyn[/E2]) contribute to signaling via the B-cell antigen receptor complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "56Lyn", "entity_1_idx": [[66, 71]], "entity_1_idx_in_text_with_entity_marker": [70, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s946_AIMed.d112.s946.p0", "text": "Here we show that Syk and Lyn from human B lymphocytes can interact directly.", "text_with_entity_marker": "Here we show that [E1]Syk[/E1] and [E2]Lyn[/E2] from human B lymphocytes can interact directly.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Syk", "entity_1_idx": [[18, 21]], "entity_1_idx_in_text_with_entity_marker": [22, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[26, 29]], "entity_2_idx_in_text_with_entity_marker": [39, 42], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s947_AIMed.d112.s947.p0", "text": "Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.", "text_with_entity_marker": "[E1]Syk[/E1] and [E2]Lyn[/E2] coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Syk", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[8, 11]], "entity_2_idx_in_text_with_entity_marker": [21, 24], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s947_AIMed.d112.s947.p1", "text": "Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.", "text_with_entity_marker": "[E1]Syk[/E1] and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified [E2]Syk[/E2] and Lyn reassociated in vitro, demonstrating their direct interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Syk", "entity_2_idx": [[90, 93]], "entity_2_idx_in_text_with_entity_marker": [103, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s947_AIMed.d112.s947.p2", "text": "Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.", "text_with_entity_marker": "[E1]Syk[/E1] and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and [E2]Lyn[/E2] reassociated in vitro, demonstrating their direct interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[98, 101]], "entity_2_idx_in_text_with_entity_marker": [111, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s947_AIMed.d112.s947.p3", "text": "Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.", "text_with_entity_marker": "Syk and [E1]Lyn[/E1] coimmunoprecipitated from mature and activated B-cell lines, and gel-purified [E2]Syk[/E2] and Lyn reassociated in vitro, demonstrating their direct interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Lyn", "entity_1_idx": [[8, 11]], "entity_1_idx_in_text_with_entity_marker": [12, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Syk", "entity_2_idx": [[90, 93]], "entity_2_idx_in_text_with_entity_marker": [103, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s947_AIMed.d112.s947.p4", "text": "Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.", "text_with_entity_marker": "Syk and [E1]Lyn[/E1] coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and [E2]Lyn[/E2] reassociated in vitro, demonstrating their direct interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Lyn", "entity_1_idx": [[8, 11]], "entity_1_idx_in_text_with_entity_marker": [12, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[98, 101]], "entity_2_idx_in_text_with_entity_marker": [111, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s947_AIMed.d112.s947.p5", "text": "Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified Syk and Lyn reassociated in vitro, demonstrating their direct interaction.", "text_with_entity_marker": "Syk and Lyn coimmunoprecipitated from mature and activated B-cell lines, and gel-purified [E1]Syk[/E1] and [E2]Lyn[/E2] reassociated in vitro, demonstrating their direct interaction.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Syk", "entity_1_idx": [[90, 93]], "entity_1_idx_in_text_with_entity_marker": [94, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[98, 101]], "entity_2_idx_in_text_with_entity_marker": [111, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p0", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This [E1]Syk[/E1]-[E2]Lyn[/E2] interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Syk", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[9, 12]], "entity_2_idx_in_text_with_entity_marker": [22, 25], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p1", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This [E1]Syk[/E1]-Lyn interaction may be dependent on the stage of B-cell differentiation, since [E2]Syk[/E2]-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Syk", "entity_2_idx": [[88, 91]], "entity_2_idx_in_text_with_entity_marker": [101, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p2", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This [E1]Syk[/E1]-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-[E2]Lyn[/E2] associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[92, 95]], "entity_2_idx_in_text_with_entity_marker": [105, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p3", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This [E1]Syk[/E1]-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and [E2]Syk[/E2] from an immature B-cell line did not reassociate with Lyn in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Syk", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p4", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This [E1]Syk[/E1]-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with [E2]Lyn[/E2] in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[221, 224]], "entity_2_idx_in_text_with_entity_marker": [234, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p5", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This Syk-[E1]Lyn[/E1] interaction may be dependent on the stage of B-cell differentiation, since [E2]Syk[/E2]-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Lyn", "entity_1_idx": [[9, 12]], "entity_1_idx_in_text_with_entity_marker": [13, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Syk", "entity_2_idx": [[88, 91]], "entity_2_idx_in_text_with_entity_marker": [101, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p6", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This Syk-[E1]Lyn[/E1] interaction may be dependent on the stage of B-cell differentiation, since Syk-[E2]Lyn[/E2] associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Lyn", "entity_1_idx": [[9, 12]], "entity_1_idx_in_text_with_entity_marker": [13, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[92, 95]], "entity_2_idx_in_text_with_entity_marker": [105, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p7", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This Syk-[E1]Lyn[/E1] interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and [E2]Syk[/E2] from an immature B-cell line did not reassociate with Lyn in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Lyn", "entity_1_idx": [[9, 12]], "entity_1_idx_in_text_with_entity_marker": [13, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Syk", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p8", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This Syk-[E1]Lyn[/E1] interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with [E2]Lyn[/E2] in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Lyn", "entity_1_idx": [[9, 12]], "entity_1_idx_in_text_with_entity_marker": [13, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[221, 224]], "entity_2_idx_in_text_with_entity_marker": [234, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p9", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since [E1]Syk[/E1]-[E2]Lyn[/E2] associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Syk", "entity_1_idx": [[88, 91]], "entity_1_idx_in_text_with_entity_marker": [92, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[92, 95]], "entity_2_idx_in_text_with_entity_marker": [105, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p10", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since [E1]Syk[/E1]-Lyn associations were not detected in pre-B and myeloma cell lines and [E2]Syk[/E2] from an immature B-cell line did not reassociate with Lyn in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[88, 91]], "entity_1_idx_in_text_with_entity_marker": [92, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Syk", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p11", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since [E1]Syk[/E1]-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with [E2]Lyn[/E2] in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[88, 91]], "entity_1_idx_in_text_with_entity_marker": [92, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[221, 224]], "entity_2_idx_in_text_with_entity_marker": [234, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p12", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-[E1]Lyn[/E1] associations were not detected in pre-B and myeloma cell lines and [E2]Syk[/E2] from an immature B-cell line did not reassociate with Lyn in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Lyn", "entity_1_idx": [[92, 95]], "entity_1_idx_in_text_with_entity_marker": [96, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Syk", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p13", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-[E1]Lyn[/E1] associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with [E2]Lyn[/E2] in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Lyn", "entity_1_idx": [[92, 95]], "entity_1_idx_in_text_with_entity_marker": [96, 99], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[221, 224]], "entity_2_idx_in_text_with_entity_marker": [234, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s948_AIMed.d112.s948.p14", "text": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and Syk from an immature B-cell line did not reassociate with Lyn in vitro.", "text_with_entity_marker": "This Syk-Lyn interaction may be dependent on the stage of B-cell differentiation, since Syk-Lyn associations were not detected in pre-B and myeloma cell lines and [E1]Syk[/E1] from an immature B-cell line did not reassociate with [E2]Lyn[/E2] in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[163, 166]], "entity_1_idx_in_text_with_entity_marker": [167, 170], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Lyn", "entity_2_idx": [[221, 224]], "entity_2_idx_in_text_with_entity_marker": [234, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s950_AIMed.d112.s950.p0", "text": "Crosslinking of cell surface IgM led to rapid activation of both tyrosine and serine/threonine protein kinase activities that resulted in phosphorylation in vitro of proteins coprecipitating with Syk--in particular, a serine/threonine phosphorylated protein 120 kDa in size (pp120).", "text_with_entity_marker": "Crosslinking of cell surface IgM led to rapid activation of both tyrosine and serine/threonine protein kinase activities that resulted in phosphorylation in vitro of proteins coprecipitating with [E1]Syk[/E1]--in particular, a serine/threonine phosphorylated protein 120 kDa in size ([E2]pp120[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Syk", "entity_1_idx": [[196, 199]], "entity_1_idx_in_text_with_entity_marker": [200, 203], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp120", "entity_2_idx": [[275, 280]], "entity_2_idx_in_text_with_entity_marker": [288, 293], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s951_AIMed.d112.s951.p0", "text": "Several phosphoproteins, including one of 72 kDa and one of 120 kDa, coprecipitated with phospholipase C-gamma 1 (PLC gamma 1).", "text_with_entity_marker": "Several phosphoproteins, including one of 72 kDa and one of 120 kDa, coprecipitated with [E1]phospholipase C-gamma 1[/E1] ([E2]PLC gamma 1[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phospholipase C-gamma 1", "entity_1_idx": [[89, 112]], "entity_1_idx_in_text_with_entity_marker": [93, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PLC gamma 1", "entity_2_idx": [[114, 125]], "entity_2_idx_in_text_with_entity_marker": [127, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s952_AIMed.d112.s952.p0", "text": "Sequential immunoprecipitation identified the 72-kDa protein associated with PLC gamma 1 as Syk.", "text_with_entity_marker": "Sequential immunoprecipitation identified the 72-kDa protein associated with [E1]PLC gamma 1[/E1] as [E2]Syk[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PLC gamma 1", "entity_1_idx": [[77, 88]], "entity_1_idx_in_text_with_entity_marker": [81, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Syk", "entity_2_idx": [[92, 95]], "entity_2_idx_in_text_with_entity_marker": [105, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s953_AIMed.d112.s953.p0", "text": "The 120-kDa serine/threonine phosphorylated protein that coprecipitated with PLC gamma 1 resembled the Syk-associated pp120 by several criteria.", "text_with_entity_marker": "The 120-kDa serine/threonine phosphorylated protein that coprecipitated with [E1]PLC gamma 1[/E1] resembled the [E2]Syk[/E2]-associated pp120 by several criteria.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PLC gamma 1", "entity_1_idx": [[77, 88]], "entity_1_idx_in_text_with_entity_marker": [81, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Syk", "entity_2_idx": [[103, 106]], "entity_2_idx_in_text_with_entity_marker": [116, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s953_AIMed.d112.s953.p1", "text": "The 120-kDa serine/threonine phosphorylated protein that coprecipitated with PLC gamma 1 resembled the Syk-associated pp120 by several criteria.", "text_with_entity_marker": "The 120-kDa serine/threonine phosphorylated protein that coprecipitated with [E1]PLC gamma 1[/E1] resembled the Syk-associated [E2]pp120[/E2] by several criteria.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PLC gamma 1", "entity_1_idx": [[77, 88]], "entity_1_idx_in_text_with_entity_marker": [81, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp120", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s953_AIMed.d112.s953.p2", "text": "The 120-kDa serine/threonine phosphorylated protein that coprecipitated with PLC gamma 1 resembled the Syk-associated pp120 by several criteria.", "text_with_entity_marker": "The 120-kDa serine/threonine phosphorylated protein that coprecipitated with PLC gamma 1 resembled the [E1]Syk[/E1]-associated [E2]pp120[/E2] by several criteria.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Syk", "entity_1_idx": [[103, 106]], "entity_1_idx_in_text_with_entity_marker": [107, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pp120", "entity_2_idx": [[118, 123]], "entity_2_idx_in_text_with_entity_marker": [131, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s954_AIMed.d112.s954.p0", "text": "Thus, pp120 may serve as a link between Syk and PLC gamma 1, coupling the B-cell antigen receptor to the phosphatidylinositol pathway.", "text_with_entity_marker": "Thus, [E1]pp120[/E1] may serve as a link between [E2]Syk[/E2] and PLC gamma 1, coupling the B-cell antigen receptor to the phosphatidylinositol pathway.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pp120", "entity_1_idx": [[6, 11]], "entity_1_idx_in_text_with_entity_marker": [10, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Syk", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s954_AIMed.d112.s954.p1", "text": "Thus, pp120 may serve as a link between Syk and PLC gamma 1, coupling the B-cell antigen receptor to the phosphatidylinositol pathway.", "text_with_entity_marker": "Thus, [E1]pp120[/E1] may serve as a link between Syk and [E2]PLC gamma 1[/E2], coupling the B-cell antigen receptor to the phosphatidylinositol pathway.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pp120", "entity_1_idx": [[6, 11]], "entity_1_idx_in_text_with_entity_marker": [10, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PLC gamma 1", "entity_2_idx": [[48, 59]], "entity_2_idx_in_text_with_entity_marker": [61, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d112.s954_AIMed.d112.s954.p2", "text": "Thus, pp120 may serve as a link between Syk and PLC gamma 1, coupling the B-cell antigen receptor to the phosphatidylinositol pathway.", "text_with_entity_marker": "Thus, pp120 may serve as a link between [E1]Syk[/E1] and [E2]PLC gamma 1[/E2], coupling the B-cell antigen receptor to the phosphatidylinositol pathway.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Syk", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PLC gamma 1", "entity_2_idx": [[48, 59]], "entity_2_idx_in_text_with_entity_marker": [61, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s361_AIMed.d42.s361.p0", "text": "The BMP receptors belong to the family of serine/threonine kinase receptors, whose activation has been investigated intensively for the transforming growth factor-beta (TGF-beta) receptor subfamily.", "text_with_entity_marker": "The BMP receptors belong to the family of serine/threonine kinase receptors, whose activation has been investigated intensively for the [E1]transforming growth factor-beta[/E1] ([E2]TGF-beta[/E2]) receptor subfamily.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transforming growth factor-beta", "entity_1_idx": [[136, 167]], "entity_1_idx_in_text_with_entity_marker": [140, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TGF-beta", "entity_2_idx": [[169, 177]], "entity_2_idx_in_text_with_entity_marker": [182, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s364_AIMed.d42.s364.p0", "text": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).", "text_with_entity_marker": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ([E1]BR-Ia[/E1] and [E2]BR-Ib[/E2]) and the BMP type II receptor (BR-II).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[153, 158]], "entity_1_idx_in_text_with_entity_marker": [157, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[163, 168]], "entity_2_idx_in_text_with_entity_marker": [176, 181], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s364_AIMed.d42.s364.p1", "text": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).", "text_with_entity_marker": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ([E1]BR-Ia[/E1] and BR-Ib) and the [E2]BMP type II receptor[/E2] (BR-II).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[153, 158]], "entity_1_idx_in_text_with_entity_marker": [157, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP type II receptor", "entity_2_idx": [[178, 198]], "entity_2_idx_in_text_with_entity_marker": [191, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s364_AIMed.d42.s364.p2", "text": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).", "text_with_entity_marker": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors ([E1]BR-Ia[/E1] and BR-Ib) and the BMP type II receptor ([E2]BR-II[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[153, 158]], "entity_1_idx_in_text_with_entity_marker": [157, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[200, 205]], "entity_2_idx_in_text_with_entity_marker": [213, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s364_AIMed.d42.s364.p3", "text": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).", "text_with_entity_marker": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and [E1]BR-Ib[/E1]) and the [E2]BMP type II receptor[/E2] (BR-II).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[163, 168]], "entity_1_idx_in_text_with_entity_marker": [167, 172], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP type II receptor", "entity_2_idx": [[178, 198]], "entity_2_idx_in_text_with_entity_marker": [191, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s364_AIMed.d42.s364.p4", "text": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).", "text_with_entity_marker": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and [E1]BR-Ib[/E1]) and the BMP type II receptor ([E2]BR-II[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[163, 168]], "entity_1_idx_in_text_with_entity_marker": [167, 172], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[200, 205]], "entity_2_idx_in_text_with_entity_marker": [213, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s364_AIMed.d42.s364.p5", "text": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the BMP type II receptor (BR-II).", "text_with_entity_marker": "Using several complementary approaches, we investigated the formation of homomeric and heteromeric complexes between the two known BMP type I receptors (BR-Ia and BR-Ib) and the [E1]BMP type II receptor[/E1] ([E2]BR-II[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP type II receptor", "entity_1_idx": [[178, 198]], "entity_1_idx_in_text_with_entity_marker": [182, 202], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[200, 205]], "entity_2_idx_in_text_with_entity_marker": [213, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p0", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ([E1]BR-II[/E1]/[E2]BR-Ia[/E2] and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BR-II", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p1", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ([E1]BR-II[/E1]/BR-Ia and [E2]BR-II[/E2]/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p2", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ([E1]BR-II[/E1]/BR-Ia and BR-II/[E2]BR-Ib[/E2]) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p3", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ([E1]BR-II[/E1]/BR-Ia and BR-II/BR-Ib) and homomeric ([E2]BR-II[/E2]/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[190, 195]], "entity_2_idx_in_text_with_entity_marker": [203, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p4", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ([E1]BR-II[/E1]/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/[E2]BR-II[/E2], BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[196, 201]], "entity_2_idx_in_text_with_entity_marker": [209, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p5", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ([E1]BR-II[/E1]/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, [E2]BR-Ia[/E2]/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p6", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ([E1]BR-II[/E1]/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ [E2]BR-Ia[/E2], BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[210, 215]], "entity_2_idx_in_text_with_entity_marker": [223, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p7", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ([E1]BR-II[/E1]/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, [E2]BR-Ib[/E2]/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[217, 222]], "entity_2_idx_in_text_with_entity_marker": [230, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p8", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ([E1]BR-II[/E1]/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ [E2]BR-Ib[/E2], and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[224, 229]], "entity_2_idx_in_text_with_entity_marker": [237, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p9", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ([E1]BR-II[/E1]/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also [E2]BR-Ia[/E2]/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[240, 245]], "entity_2_idx_in_text_with_entity_marker": [253, 258], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p10", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric ([E1]BR-II[/E1]/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ [E2]BR-Ib[/E2]) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[146, 151]], "entity_1_idx_in_text_with_entity_marker": [150, 155], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p11", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/[E1]BR-Ia[/E1] and [E2]BR-II[/E2]/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p12", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/[E1]BR-Ia[/E1] and BR-II/[E2]BR-Ib[/E2]) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p13", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/[E1]BR-Ia[/E1] and BR-II/BR-Ib) and homomeric ([E2]BR-II[/E2]/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[190, 195]], "entity_2_idx_in_text_with_entity_marker": [203, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p14", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/[E1]BR-Ia[/E1] and BR-II/BR-Ib) and homomeric (BR-II/[E2]BR-II[/E2], BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[196, 201]], "entity_2_idx_in_text_with_entity_marker": [209, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p15", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/[E1]BR-Ia[/E1] and BR-II/BR-Ib) and homomeric (BR-II/BR-II, [E2]BR-Ia[/E2]/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p16", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/[E1]BR-Ia[/E1] and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ [E2]BR-Ia[/E2], BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[210, 215]], "entity_2_idx_in_text_with_entity_marker": [223, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p17", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/[E1]BR-Ia[/E1] and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, [E2]BR-Ib[/E2]/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[217, 222]], "entity_2_idx_in_text_with_entity_marker": [230, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p18", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/[E1]BR-Ia[/E1] and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ [E2]BR-Ib[/E2], and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[224, 229]], "entity_2_idx_in_text_with_entity_marker": [237, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p19", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/[E1]BR-Ia[/E1] and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also [E2]BR-Ia[/E2]/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[240, 245]], "entity_2_idx_in_text_with_entity_marker": [253, 258], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p20", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/[E1]BR-Ia[/E1] and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ [E2]BR-Ib[/E2]) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p21", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and [E1]BR-II[/E1]/[E2]BR-Ib[/E2]) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BR-II", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[168, 173]], "entity_2_idx_in_text_with_entity_marker": [181, 186], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p22", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and [E1]BR-II[/E1]/BR-Ib) and homomeric ([E2]BR-II[/E2]/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[190, 195]], "entity_2_idx_in_text_with_entity_marker": [203, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p23", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and [E1]BR-II[/E1]/BR-Ib) and homomeric (BR-II/[E2]BR-II[/E2], BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[196, 201]], "entity_2_idx_in_text_with_entity_marker": [209, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p24", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and [E1]BR-II[/E1]/BR-Ib) and homomeric (BR-II/BR-II, [E2]BR-Ia[/E2]/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p25", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and [E1]BR-II[/E1]/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ [E2]BR-Ia[/E2], BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[210, 215]], "entity_2_idx_in_text_with_entity_marker": [223, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p26", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and [E1]BR-II[/E1]/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, [E2]BR-Ib[/E2]/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[217, 222]], "entity_2_idx_in_text_with_entity_marker": [230, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p27", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and [E1]BR-II[/E1]/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ [E2]BR-Ib[/E2], and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[224, 229]], "entity_2_idx_in_text_with_entity_marker": [237, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p28", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and [E1]BR-II[/E1]/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also [E2]BR-Ia[/E2]/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[240, 245]], "entity_2_idx_in_text_with_entity_marker": [253, 258], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p29", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and [E1]BR-II[/E1]/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ [E2]BR-Ib[/E2]) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p30", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/[E1]BR-Ib[/E1]) and homomeric ([E2]BR-II[/E2]/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[168, 173]], "entity_1_idx_in_text_with_entity_marker": [172, 177], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[190, 195]], "entity_2_idx_in_text_with_entity_marker": [203, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p31", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/[E1]BR-Ib[/E1]) and homomeric (BR-II/[E2]BR-II[/E2], BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[168, 173]], "entity_1_idx_in_text_with_entity_marker": [172, 177], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[196, 201]], "entity_2_idx_in_text_with_entity_marker": [209, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p32", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/[E1]BR-Ib[/E1]) and homomeric (BR-II/BR-II, [E2]BR-Ia[/E2]/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[168, 173]], "entity_1_idx_in_text_with_entity_marker": [172, 177], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p33", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/[E1]BR-Ib[/E1]) and homomeric (BR-II/BR-II, BR-Ia/ [E2]BR-Ia[/E2], BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[168, 173]], "entity_1_idx_in_text_with_entity_marker": [172, 177], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[210, 215]], "entity_2_idx_in_text_with_entity_marker": [223, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p34", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/[E1]BR-Ib[/E1]) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, [E2]BR-Ib[/E2]/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[168, 173]], "entity_1_idx_in_text_with_entity_marker": [172, 177], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[217, 222]], "entity_2_idx_in_text_with_entity_marker": [230, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p35", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/[E1]BR-Ib[/E1]) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ [E2]BR-Ib[/E2], and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[168, 173]], "entity_1_idx_in_text_with_entity_marker": [172, 177], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[224, 229]], "entity_2_idx_in_text_with_entity_marker": [237, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p36", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/[E1]BR-Ib[/E1]) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also [E2]BR-Ia[/E2]/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[168, 173]], "entity_1_idx_in_text_with_entity_marker": [172, 177], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[240, 245]], "entity_2_idx_in_text_with_entity_marker": [253, 258], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p37", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/[E1]BR-Ib[/E1]) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ [E2]BR-Ib[/E2]) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[168, 173]], "entity_1_idx_in_text_with_entity_marker": [172, 177], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p38", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric ([E1]BR-II[/E1]/[E2]BR-II[/E2], BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BR-II", "entity_1_idx": [[190, 195]], "entity_1_idx_in_text_with_entity_marker": [194, 199], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[196, 201]], "entity_2_idx_in_text_with_entity_marker": [209, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p39", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric ([E1]BR-II[/E1]/BR-II, [E2]BR-Ia[/E2]/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[190, 195]], "entity_1_idx_in_text_with_entity_marker": [194, 199], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p40", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric ([E1]BR-II[/E1]/BR-II, BR-Ia/ [E2]BR-Ia[/E2], BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[190, 195]], "entity_1_idx_in_text_with_entity_marker": [194, 199], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[210, 215]], "entity_2_idx_in_text_with_entity_marker": [223, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p41", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric ([E1]BR-II[/E1]/BR-II, BR-Ia/ BR-Ia, [E2]BR-Ib[/E2]/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[190, 195]], "entity_1_idx_in_text_with_entity_marker": [194, 199], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[217, 222]], "entity_2_idx_in_text_with_entity_marker": [230, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p42", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric ([E1]BR-II[/E1]/BR-II, BR-Ia/ BR-Ia, BR-Ib/ [E2]BR-Ib[/E2], and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[190, 195]], "entity_1_idx_in_text_with_entity_marker": [194, 199], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[224, 229]], "entity_2_idx_in_text_with_entity_marker": [237, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p43", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric ([E1]BR-II[/E1]/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also [E2]BR-Ia[/E2]/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[190, 195]], "entity_1_idx_in_text_with_entity_marker": [194, 199], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[240, 245]], "entity_2_idx_in_text_with_entity_marker": [253, 258], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p44", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric ([E1]BR-II[/E1]/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ [E2]BR-Ib[/E2]) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[190, 195]], "entity_1_idx_in_text_with_entity_marker": [194, 199], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p45", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/[E1]BR-II[/E1], [E2]BR-Ia[/E2]/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[196, 201]], "entity_1_idx_in_text_with_entity_marker": [200, 205], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[203, 208]], "entity_2_idx_in_text_with_entity_marker": [216, 221], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p46", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/[E1]BR-II[/E1], BR-Ia/ [E2]BR-Ia[/E2], BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[196, 201]], "entity_1_idx_in_text_with_entity_marker": [200, 205], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[210, 215]], "entity_2_idx_in_text_with_entity_marker": [223, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p47", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/[E1]BR-II[/E1], BR-Ia/ BR-Ia, [E2]BR-Ib[/E2]/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[196, 201]], "entity_1_idx_in_text_with_entity_marker": [200, 205], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[217, 222]], "entity_2_idx_in_text_with_entity_marker": [230, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p48", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/[E1]BR-II[/E1], BR-Ia/ BR-Ia, BR-Ib/ [E2]BR-Ib[/E2], and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[196, 201]], "entity_1_idx_in_text_with_entity_marker": [200, 205], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[224, 229]], "entity_2_idx_in_text_with_entity_marker": [237, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p49", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/[E1]BR-II[/E1], BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also [E2]BR-Ia[/E2]/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[196, 201]], "entity_1_idx_in_text_with_entity_marker": [200, 205], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[240, 245]], "entity_2_idx_in_text_with_entity_marker": [253, 258], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p50", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/[E1]BR-II[/E1], BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ [E2]BR-Ib[/E2]) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-II", "entity_1_idx": [[196, 201]], "entity_1_idx_in_text_with_entity_marker": [200, 205], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p51", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, [E1]BR-Ia[/E1]/ [E2]BR-Ia[/E2], BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BR-Ia", "entity_1_idx": [[203, 208]], "entity_1_idx_in_text_with_entity_marker": [207, 212], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[210, 215]], "entity_2_idx_in_text_with_entity_marker": [223, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p52", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, [E1]BR-Ia[/E1]/ BR-Ia, [E2]BR-Ib[/E2]/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[203, 208]], "entity_1_idx_in_text_with_entity_marker": [207, 212], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[217, 222]], "entity_2_idx_in_text_with_entity_marker": [230, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p53", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, [E1]BR-Ia[/E1]/ BR-Ia, BR-Ib/ [E2]BR-Ib[/E2], and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[203, 208]], "entity_1_idx_in_text_with_entity_marker": [207, 212], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[224, 229]], "entity_2_idx_in_text_with_entity_marker": [237, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p54", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, [E1]BR-Ia[/E1]/ BR-Ia, BR-Ib/ BR-Ib, and also [E2]BR-Ia[/E2]/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[203, 208]], "entity_1_idx_in_text_with_entity_marker": [207, 212], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[240, 245]], "entity_2_idx_in_text_with_entity_marker": [253, 258], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p55", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, [E1]BR-Ia[/E1]/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ [E2]BR-Ib[/E2]) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[203, 208]], "entity_1_idx_in_text_with_entity_marker": [207, 212], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p56", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ [E1]BR-Ia[/E1], [E2]BR-Ib[/E2]/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[210, 215]], "entity_1_idx_in_text_with_entity_marker": [214, 219], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[217, 222]], "entity_2_idx_in_text_with_entity_marker": [230, 235], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p57", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ [E1]BR-Ia[/E1], BR-Ib/ [E2]BR-Ib[/E2], and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[210, 215]], "entity_1_idx_in_text_with_entity_marker": [214, 219], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[224, 229]], "entity_2_idx_in_text_with_entity_marker": [237, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p58", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ [E1]BR-Ia[/E1], BR-Ib/ BR-Ib, and also [E2]BR-Ia[/E2]/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[210, 215]], "entity_1_idx_in_text_with_entity_marker": [214, 219], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[240, 245]], "entity_2_idx_in_text_with_entity_marker": [253, 258], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p59", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ [E1]BR-Ia[/E1], BR-Ib/ BR-Ib, and also BR-Ia/ [E2]BR-Ib[/E2]) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ia", "entity_1_idx": [[210, 215]], "entity_1_idx_in_text_with_entity_marker": [214, 219], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p60", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, [E1]BR-Ib[/E1]/ [E2]BR-Ib[/E2], and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BR-Ib", "entity_1_idx": [[217, 222]], "entity_1_idx_in_text_with_entity_marker": [221, 226], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[224, 229]], "entity_2_idx_in_text_with_entity_marker": [237, 242], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p61", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, [E1]BR-Ib[/E1]/ BR-Ib, and also [E2]BR-Ia[/E2]/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[217, 222]], "entity_1_idx_in_text_with_entity_marker": [221, 226], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[240, 245]], "entity_2_idx_in_text_with_entity_marker": [253, 258], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p62", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, [E1]BR-Ib[/E1]/ BR-Ib, and also BR-Ia/ [E2]BR-Ib[/E2]) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[217, 222]], "entity_1_idx_in_text_with_entity_marker": [221, 226], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p63", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ [E1]BR-Ib[/E1], and also [E2]BR-Ia[/E2]/ BR-Ib) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[224, 229]], "entity_1_idx_in_text_with_entity_marker": [228, 233], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ia", "entity_2_idx": [[240, 245]], "entity_2_idx_in_text_with_entity_marker": [253, 258], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p64", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ [E1]BR-Ib[/E1], and also BR-Ia/ [E2]BR-Ib[/E2]) oligomers in the absence of ligand.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BR-Ib", "entity_1_idx": [[224, 229]], "entity_1_idx_in_text_with_entity_marker": [228, 233], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s367_AIMed.d42.s367.p65", "text": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also BR-Ia/ BR-Ib) oligomers in the absence of ligand.", "text_with_entity_marker": "Using antibody-mediated immunofluorescence copatching of epitope-tagged receptors, we provide evidence in live cells for preexisting heteromeric (BR-II/BR-Ia and BR-II/BR-Ib) and homomeric (BR-II/BR-II, BR-Ia/ BR-Ia, BR-Ib/ BR-Ib, and also [E1]BR-Ia[/E1]/ [E2]BR-Ib[/E2]) oligomers in the absence of ligand.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BR-Ia", "entity_1_idx": [[240, 245]], "entity_1_idx_in_text_with_entity_marker": [244, 249], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-Ib", "entity_2_idx": [[247, 252]], "entity_2_idx_in_text_with_entity_marker": [260, 265], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s368_AIMed.d42.s368.p0", "text": "BMP-2 binding significantly increased hetero- and homo-oligomerization (except for the BR-II homo-oligomer, which binds ligand poorly in the absence of BR-I).", "text_with_entity_marker": "[E1]BMP-2[/E1] binding significantly increased hetero- and homo-oligomerization (except for the [E2]BR-II[/E2] homo-oligomer, which binds ligand poorly in the absence of BR-I).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMP-2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-II", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s368_AIMed.d42.s368.p1", "text": "BMP-2 binding significantly increased hetero- and homo-oligomerization (except for the BR-II homo-oligomer, which binds ligand poorly in the absence of BR-I).", "text_with_entity_marker": "[E1]BMP-2[/E1] binding significantly increased hetero- and homo-oligomerization (except for the BR-II homo-oligomer, which binds ligand poorly in the absence of [E2]BR-I[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-I", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d42.s368_AIMed.d42.s368.p2", "text": "BMP-2 binding significantly increased hetero- and homo-oligomerization (except for the BR-II homo-oligomer, which binds ligand poorly in the absence of BR-I).", "text_with_entity_marker": "BMP-2 binding significantly increased hetero- and homo-oligomerization (except for the [E1]BR-II[/E1] homo-oligomer, which binds ligand poorly in the absence of [E2]BR-I[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BR-II", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BR-I", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1746_AIMed.d203.s1746.p0", "text": "A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist.", "text_with_entity_marker": "A new cytokine-receptor binding mode revealed by the crystal structure of the [E1-E2]IL-1[/E1] receptor[/E2] with an antagonist.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1[/E1] receptor", "entity_2_idx": [[78, 91]], "entity_2_idx_in_text_with_entity_marker": [85, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1747_AIMed.d203.s1747.p0", "text": "Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1).", "text_with_entity_marker": "Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines [E1]interleukin-1[/E1] ([E2]IL-1[/E2]) and tumour necrosis factor-alpha (ref. 1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1", "entity_1_idx": [[205, 218]], "entity_1_idx_in_text_with_entity_marker": [209, 222], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[220, 224]], "entity_2_idx_in_text_with_entity_marker": [233, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1747_AIMed.d203.s1747.p1", "text": "Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1).", "text_with_entity_marker": "Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines [E1]interleukin-1[/E1] (IL-1) and [E2]tumour necrosis factor-alpha[/E2] (ref. 1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-1", "entity_1_idx": [[205, 218]], "entity_1_idx_in_text_with_entity_marker": [209, 222], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tumour necrosis factor-alpha", "entity_2_idx": [[230, 258]], "entity_2_idx_in_text_with_entity_marker": [243, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1747_AIMed.d203.s1747.p2", "text": "Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1).", "text_with_entity_marker": "Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 ([E1]IL-1[/E1]) and [E2]tumour necrosis factor-alpha[/E2] (ref. 1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[220, 224]], "entity_1_idx_in_text_with_entity_marker": [224, 228], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tumour necrosis factor-alpha", "entity_2_idx": [[230, 258]], "entity_2_idx_in_text_with_entity_marker": [243, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p0", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1-E2]IL-1[/E1] receptor[/E2] (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [49, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1[/E1] receptor", "entity_2_idx": [[42, 55]], "entity_2_idx_in_text_with_entity_marker": [49, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p1", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1[/E1] receptor ([E2]IL1R[/E2]) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1R", "entity_2_idx": [[57, 61]], "entity_2_idx_in_text_with_entity_marker": [70, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p2", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1[/E1] receptor (IL1R) exist: the agonists [E2]IL-1alpha[/E2] and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1alpha", "entity_2_idx": [[83, 92]], "entity_2_idx_in_text_with_entity_marker": [96, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p3", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1[/E1] receptor (IL1R) exist: the agonists IL-1alpha and [E2]IL-1beta[/E2] and the IL-1-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[97, 105]], "entity_2_idx_in_text_with_entity_marker": [110, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p4", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1[/E1] receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E2]IL-1[/E2]-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[114, 118]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p5", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1[/E1] receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E2]IL-1-receptor[/E2] antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1-receptor", "entity_2_idx": [[114, 127]], "entity_2_idx_in_text_with_entity_marker": [127, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p6", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1[/E1] receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E2]IL-1-receptor antagonist[/E2] IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1-receptor antagonist", "entity_2_idx": [[114, 138]], "entity_2_idx_in_text_with_entity_marker": [127, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p7", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1[/E1] receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist [E2]IL1RA[/E2] (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[42, 46]], "entity_1_idx_in_text_with_entity_marker": [46, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1RA", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p8", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1 receptor[/E1] ([E2]IL1R[/E2]) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1 receptor", "entity_1_idx": [[42, 55]], "entity_1_idx_in_text_with_entity_marker": [46, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1R", "entity_2_idx": [[57, 61]], "entity_2_idx_in_text_with_entity_marker": [70, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p9", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1 receptor[/E1] (IL1R) exist: the agonists [E2]IL-1alpha[/E2] and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-1 receptor", "entity_1_idx": [[42, 55]], "entity_1_idx_in_text_with_entity_marker": [46, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1alpha", "entity_2_idx": [[83, 92]], "entity_2_idx_in_text_with_entity_marker": [96, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p10", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1 receptor[/E1] (IL1R) exist: the agonists IL-1alpha and [E2]IL-1beta[/E2] and the IL-1-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1 receptor", "entity_1_idx": [[42, 55]], "entity_1_idx_in_text_with_entity_marker": [46, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[97, 105]], "entity_2_idx_in_text_with_entity_marker": [110, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p11", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1 receptor[/E1] (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E2]IL-1[/E2]-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1 receptor", "entity_1_idx": [[42, 55]], "entity_1_idx_in_text_with_entity_marker": [46, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[114, 118]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p12", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1 receptor[/E1] (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E2]IL-1-receptor[/E2] antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1 receptor", "entity_1_idx": [[42, 55]], "entity_1_idx_in_text_with_entity_marker": [46, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1-receptor", "entity_2_idx": [[114, 127]], "entity_2_idx_in_text_with_entity_marker": [127, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p13", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1 receptor[/E1] (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E2]IL-1-receptor antagonist[/E2] IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1 receptor", "entity_1_idx": [[42, 55]], "entity_1_idx_in_text_with_entity_marker": [46, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1-receptor antagonist", "entity_2_idx": [[114, 138]], "entity_2_idx_in_text_with_entity_marker": [127, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p14", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the [E1]IL-1 receptor[/E1] (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist [E2]IL1RA[/E2] (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1 receptor", "entity_1_idx": [[42, 55]], "entity_1_idx_in_text_with_entity_marker": [46, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1RA", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p15", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor ([E1]IL1R[/E1]) exist: the agonists [E2]IL-1alpha[/E2] and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL1R", "entity_1_idx": [[57, 61]], "entity_1_idx_in_text_with_entity_marker": [61, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1alpha", "entity_2_idx": [[83, 92]], "entity_2_idx_in_text_with_entity_marker": [96, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p16", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor ([E1]IL1R[/E1]) exist: the agonists IL-1alpha and [E2]IL-1beta[/E2] and the IL-1-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL1R", "entity_1_idx": [[57, 61]], "entity_1_idx_in_text_with_entity_marker": [61, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[97, 105]], "entity_2_idx_in_text_with_entity_marker": [110, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p17", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor ([E1]IL1R[/E1]) exist: the agonists IL-1alpha and IL-1beta and the [E2]IL-1[/E2]-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL1R", "entity_1_idx": [[57, 61]], "entity_1_idx_in_text_with_entity_marker": [61, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[114, 118]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p18", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor ([E1]IL1R[/E1]) exist: the agonists IL-1alpha and IL-1beta and the [E2]IL-1-receptor[/E2] antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL1R", "entity_1_idx": [[57, 61]], "entity_1_idx_in_text_with_entity_marker": [61, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1-receptor", "entity_2_idx": [[114, 127]], "entity_2_idx_in_text_with_entity_marker": [127, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p19", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor ([E1]IL1R[/E1]) exist: the agonists IL-1alpha and IL-1beta and the [E2]IL-1-receptor antagonist[/E2] IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL1R", "entity_1_idx": [[57, 61]], "entity_1_idx_in_text_with_entity_marker": [61, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1-receptor antagonist", "entity_2_idx": [[114, 138]], "entity_2_idx_in_text_with_entity_marker": [127, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p20", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor ([E1]IL1R[/E1]) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist [E2]IL1RA[/E2] (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL1R", "entity_1_idx": [[57, 61]], "entity_1_idx_in_text_with_entity_marker": [61, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1RA", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p21", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists [E1]IL-1alpha[/E1] and [E2]IL-1beta[/E2] and the IL-1-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[83, 92]], "entity_1_idx_in_text_with_entity_marker": [87, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1beta", "entity_2_idx": [[97, 105]], "entity_2_idx_in_text_with_entity_marker": [110, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p22", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists [E1]IL-1alpha[/E1] and IL-1beta and the [E2]IL-1[/E2]-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[83, 92]], "entity_1_idx_in_text_with_entity_marker": [87, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[114, 118]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p23", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists [E1]IL-1alpha[/E1] and IL-1beta and the [E2]IL-1-receptor[/E2] antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[83, 92]], "entity_1_idx_in_text_with_entity_marker": [87, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1-receptor", "entity_2_idx": [[114, 127]], "entity_2_idx_in_text_with_entity_marker": [127, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p24", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists [E1]IL-1alpha[/E1] and IL-1beta and the [E2]IL-1-receptor antagonist[/E2] IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[83, 92]], "entity_1_idx_in_text_with_entity_marker": [87, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1-receptor antagonist", "entity_2_idx": [[114, 138]], "entity_2_idx_in_text_with_entity_marker": [127, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p25", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists [E1]IL-1alpha[/E1] and IL-1beta and the IL-1-receptor antagonist [E2]IL1RA[/E2] (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1alpha", "entity_1_idx": [[83, 92]], "entity_1_idx_in_text_with_entity_marker": [87, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1RA", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p26", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and [E1]IL-1beta[/E1] and the [E2]IL-1[/E2]-receptor antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[97, 105]], "entity_1_idx_in_text_with_entity_marker": [101, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1", "entity_2_idx": [[114, 118]], "entity_2_idx_in_text_with_entity_marker": [127, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p27", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and [E1]IL-1beta[/E1] and the [E2]IL-1-receptor[/E2] antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[97, 105]], "entity_1_idx_in_text_with_entity_marker": [101, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1-receptor", "entity_2_idx": [[114, 127]], "entity_2_idx_in_text_with_entity_marker": [127, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p28", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and [E1]IL-1beta[/E1] and the [E2]IL-1-receptor antagonist[/E2] IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[97, 105]], "entity_1_idx_in_text_with_entity_marker": [101, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1-receptor antagonist", "entity_2_idx": [[114, 138]], "entity_2_idx_in_text_with_entity_marker": [127, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p29", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and [E1]IL-1beta[/E1] and the IL-1-receptor antagonist [E2]IL1RA[/E2] (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[97, 105]], "entity_1_idx_in_text_with_entity_marker": [101, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1RA", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p30", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E1-E2]IL-1[/E1]-receptor[/E2] antagonist IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[114, 118]], "entity_1_idx_in_text_with_entity_marker": [121, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1[/E1]-receptor", "entity_2_idx": [[114, 127]], "entity_2_idx_in_text_with_entity_marker": [121, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p31", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E1-E2]IL-1[/E1]-receptor antagonist[/E2] IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[114, 118]], "entity_1_idx_in_text_with_entity_marker": [121, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1[/E1]-receptor antagonist", "entity_2_idx": [[114, 138]], "entity_2_idx_in_text_with_entity_marker": [121, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p32", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E1]IL-1[/E1]-receptor antagonist [E2]IL1RA[/E2] (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1", "entity_1_idx": [[114, 118]], "entity_1_idx_in_text_with_entity_marker": [118, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1RA", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p33", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E1-E2]IL-1-receptor[/E1] antagonist[/E2] IL1RA (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1-receptor", "entity_1_idx": [[114, 127]], "entity_1_idx_in_text_with_entity_marker": [121, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-1-receptor[/E1] antagonist", "entity_2_idx": [[114, 138]], "entity_2_idx_in_text_with_entity_marker": [121, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p34", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E1]IL-1-receptor[/E1] antagonist [E2]IL1RA[/E2] (ref. 2).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-1-receptor", "entity_1_idx": [[114, 127]], "entity_1_idx_in_text_with_entity_marker": [118, 131], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1RA", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1748_AIMed.d203.s1748.p35", "text": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).", "text_with_entity_marker": "Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the [E1]IL-1-receptor antagonist[/E1] [E2]IL1RA[/E2] (ref. 2).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1-receptor antagonist", "entity_1_idx": [[114, 138]], "entity_1_idx_in_text_with_entity_marker": [118, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1RA", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1750_AIMed.d203.s1750.p0", "text": "Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA.", "text_with_entity_marker": "Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of [E1]type-I [E2]IL1R[/E1-E2] complexed with IL1RA.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "type-I [E2]IL1R", "entity_1_idx": [[96, 107]], "entity_1_idx_in_text_with_entity_marker": [100, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1R", "entity_2_idx": [[103, 107]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1750_AIMed.d203.s1750.p1", "text": "Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA.", "text_with_entity_marker": "Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I [E1]IL1R[/E1] complexed with [E2]IL1RA[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL1R", "entity_1_idx": [[103, 107]], "entity_1_idx_in_text_with_entity_marker": [107, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1RA", "entity_2_idx": [[123, 128]], "entity_2_idx_in_text_with_entity_marker": [136, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1750_AIMed.d203.s1750.p2", "text": "Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA.", "text_with_entity_marker": "Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of [E1]type-I IL1R[/E1] complexed with [E2]IL1RA[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "type-I IL1R", "entity_1_idx": [[96, 107]], "entity_1_idx_in_text_with_entity_marker": [100, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1RA", "entity_2_idx": [[123, 128]], "entity_2_idx_in_text_with_entity_marker": [136, 141], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d203.s1754_AIMed.d203.s1754.p0", "text": "A region that is important for biological function in IL-1beta, the 'receptor trigger site' is not in direct contact with the receptor in the IL1RA complex.", "text_with_entity_marker": "A region that is important for biological function in [E1]IL-1beta[/E1], the 'receptor trigger site' is not in direct contact with the receptor in the [E2]IL1RA[/E2] complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-1beta", "entity_1_idx": [[54, 62]], "entity_1_idx_in_text_with_entity_marker": [58, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL1RA", "entity_2_idx": [[142, 147]], "entity_2_idx_in_text_with_entity_marker": [155, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1291_AIMed.d152.s1291.p0", "text": "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "text_with_entity_marker": "[E1]TRADD[/E1]-[E2]TRAF2[/E2] and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRADD", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRAF2", "entity_2_idx": [[6, 11]], "entity_2_idx_in_text_with_entity_marker": [19, 24], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1291_AIMed.d152.s1291.p1", "text": "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "text_with_entity_marker": "[E1]TRADD[/E1]-TRAF2 and [E2]TRADD[/E2]-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRADD", "entity_2_idx": [[16, 21]], "entity_2_idx_in_text_with_entity_marker": [29, 34], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1291_AIMed.d152.s1291.p2", "text": "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "text_with_entity_marker": "[E1]TRADD[/E1]-TRAF2 and TRADD-[E2]FADD[/E2] interactions define two distinct TNF receptor 1 signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FADD", "entity_2_idx": [[22, 26]], "entity_2_idx_in_text_with_entity_marker": [35, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1291_AIMed.d152.s1291.p3", "text": "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "text_with_entity_marker": "[E1]TRADD[/E1]-TRAF2 and TRADD-FADD interactions define two distinct [E2]TNF receptor 1[/E2] signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF receptor 1", "entity_2_idx": [[60, 74]], "entity_2_idx_in_text_with_entity_marker": [73, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1291_AIMed.d152.s1291.p4", "text": "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "text_with_entity_marker": "TRADD-[E1]TRAF2[/E1] and [E2]TRADD[/E2]-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRAF2", "entity_1_idx": [[6, 11]], "entity_1_idx_in_text_with_entity_marker": [10, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRADD", "entity_2_idx": [[16, 21]], "entity_2_idx_in_text_with_entity_marker": [29, 34], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1291_AIMed.d152.s1291.p5", "text": "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "text_with_entity_marker": "TRADD-[E1]TRAF2[/E1] and TRADD-[E2]FADD[/E2] interactions define two distinct TNF receptor 1 signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRAF2", "entity_1_idx": [[6, 11]], "entity_1_idx_in_text_with_entity_marker": [10, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FADD", "entity_2_idx": [[22, 26]], "entity_2_idx_in_text_with_entity_marker": [35, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1291_AIMed.d152.s1291.p6", "text": "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "text_with_entity_marker": "TRADD-[E1]TRAF2[/E1] and TRADD-FADD interactions define two distinct [E2]TNF receptor 1[/E2] signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRAF2", "entity_1_idx": [[6, 11]], "entity_1_idx_in_text_with_entity_marker": [10, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF receptor 1", "entity_2_idx": [[60, 74]], "entity_2_idx_in_text_with_entity_marker": [73, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1291_AIMed.d152.s1291.p7", "text": "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "text_with_entity_marker": "TRADD-TRAF2 and [E1]TRADD[/E1]-[E2]FADD[/E2] interactions define two distinct TNF receptor 1 signal transduction pathways.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRADD", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FADD", "entity_2_idx": [[22, 26]], "entity_2_idx_in_text_with_entity_marker": [35, 39], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1291_AIMed.d152.s1291.p8", "text": "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "text_with_entity_marker": "TRADD-TRAF2 and [E1]TRADD[/E1]-FADD interactions define two distinct [E2]TNF receptor 1[/E2] signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF receptor 1", "entity_2_idx": [[60, 74]], "entity_2_idx_in_text_with_entity_marker": [73, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1291_AIMed.d152.s1291.p9", "text": "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.", "text_with_entity_marker": "TRADD-TRAF2 and TRADD-[E1]FADD[/E1] interactions define two distinct [E2]TNF receptor 1[/E2] signal transduction pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[22, 26]], "entity_1_idx_in_text_with_entity_marker": [26, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF receptor 1", "entity_2_idx": [[60, 74]], "entity_2_idx_in_text_with_entity_marker": [73, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1292_AIMed.d152.s1292.p0", "text": "Tumor necrosis factor (TNF) can induce apoptosis and activate NF-kappa B through signaling cascades emanating from TNF receptor 1 (TNFR1).", "text_with_entity_marker": "Tumor necrosis factor (TNF) can induce apoptosis and activate [E1]NF-kappa B[/E1] through signaling cascades emanating from [E2]TNF receptor 1[/E2] (TNFR1).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappa B", "entity_1_idx": [[62, 72]], "entity_1_idx_in_text_with_entity_marker": [66, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF receptor 1", "entity_2_idx": [[115, 129]], "entity_2_idx_in_text_with_entity_marker": [128, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1292_AIMed.d152.s1292.p1", "text": "Tumor necrosis factor (TNF) can induce apoptosis and activate NF-kappa B through signaling cascades emanating from TNF receptor 1 (TNFR1).", "text_with_entity_marker": "Tumor necrosis factor (TNF) can induce apoptosis and activate [E1]NF-kappa B[/E1] through signaling cascades emanating from TNF receptor 1 ([E2]TNFR1[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-kappa B", "entity_1_idx": [[62, 72]], "entity_1_idx_in_text_with_entity_marker": [66, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR1", "entity_2_idx": [[131, 136]], "entity_2_idx_in_text_with_entity_marker": [144, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1292_AIMed.d152.s1292.p2", "text": "Tumor necrosis factor (TNF) can induce apoptosis and activate NF-kappa B through signaling cascades emanating from TNF receptor 1 (TNFR1).", "text_with_entity_marker": "Tumor necrosis factor (TNF) can induce apoptosis and activate NF-kappa B through signaling cascades emanating from [E1]TNF receptor 1[/E1] ([E2]TNFR1[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF receptor 1", "entity_1_idx": [[115, 129]], "entity_1_idx_in_text_with_entity_marker": [119, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR1", "entity_2_idx": [[131, 136]], "entity_2_idx_in_text_with_entity_marker": [144, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1293_AIMed.d152.s1293.p0", "text": "TRADD is a TNFR1-associated signal transducer that is involved in activating both pathways.", "text_with_entity_marker": "[E1]TRADD[/E1] is a [E2]TNFR1[/E2]-associated signal transducer that is involved in activating both pathways.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR1", "entity_2_idx": [[11, 16]], "entity_2_idx_in_text_with_entity_marker": [24, 29], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1294_AIMed.d152.s1294.p0", "text": "Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.", "text_with_entity_marker": "Here we show that [E1]TRADD[/E1] directly interacts with [E2]TRAF2[/E2] and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRADD", "entity_1_idx": [[18, 23]], "entity_1_idx_in_text_with_entity_marker": [22, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRAF2", "entity_2_idx": [[48, 53]], "entity_2_idx_in_text_with_entity_marker": [61, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1294_AIMed.d152.s1294.p1", "text": "Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.", "text_with_entity_marker": "Here we show that [E1]TRADD[/E1] directly interacts with TRAF2 and [E2]FADD[/E2], signal transducers that activate NF-kappa B and induce apoptosis, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRADD", "entity_1_idx": [[18, 23]], "entity_1_idx_in_text_with_entity_marker": [22, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FADD", "entity_2_idx": [[58, 62]], "entity_2_idx_in_text_with_entity_marker": [71, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1294_AIMed.d152.s1294.p2", "text": "Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.", "text_with_entity_marker": "Here we show that [E1]TRADD[/E1] directly interacts with TRAF2 and FADD, signal transducers that activate [E2]NF-kappa B[/E2] and induce apoptosis, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[18, 23]], "entity_1_idx_in_text_with_entity_marker": [22, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[97, 107]], "entity_2_idx_in_text_with_entity_marker": [110, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1294_AIMed.d152.s1294.p3", "text": "Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.", "text_with_entity_marker": "Here we show that TRADD directly interacts with [E1]TRAF2[/E1] and [E2]FADD[/E2], signal transducers that activate NF-kappa B and induce apoptosis, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRAF2", "entity_1_idx": [[48, 53]], "entity_1_idx_in_text_with_entity_marker": [52, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FADD", "entity_2_idx": [[58, 62]], "entity_2_idx_in_text_with_entity_marker": [71, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1294_AIMed.d152.s1294.p4", "text": "Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.", "text_with_entity_marker": "Here we show that TRADD directly interacts with [E1]TRAF2[/E1] and FADD, signal transducers that activate [E2]NF-kappa B[/E2] and induce apoptosis, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRAF2", "entity_1_idx": [[48, 53]], "entity_1_idx_in_text_with_entity_marker": [52, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[97, 107]], "entity_2_idx_in_text_with_entity_marker": [110, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1294_AIMed.d152.s1294.p5", "text": "Here we show that TRADD directly interacts with TRAF2 and FADD, signal transducers that activate NF-kappa B and induce apoptosis, respectively.", "text_with_entity_marker": "Here we show that TRADD directly interacts with TRAF2 and [E1]FADD[/E1], signal transducers that activate [E2]NF-kappa B[/E2] and induce apoptosis, respectively.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[58, 62]], "entity_1_idx_in_text_with_entity_marker": [62, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[97, 107]], "entity_2_idx_in_text_with_entity_marker": [110, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1295_AIMed.d152.s1295.p0", "text": "A TRAF2 mutant lacking its N-terminal RING finger domain is a dominant-negative inhibitor of TNF-mediated NF-kappa B activation, but does not affect TNF-induced apoptosis.", "text_with_entity_marker": "A [E1]TRAF2[/E1] mutant lacking its N-terminal RING finger domain is a dominant-negative inhibitor of TNF-mediated [E2]NF-kappa B[/E2] activation, but does not affect TNF-induced apoptosis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRAF2", "entity_1_idx": [[2, 7]], "entity_1_idx_in_text_with_entity_marker": [6, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[106, 116]], "entity_2_idx_in_text_with_entity_marker": [119, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1296_AIMed.d152.s1296.p0", "text": "Conversely, a FADD mutant lacking its N-terminal 79 amino acids is a dominant-negative inhibitor of TNF-induced apoptosis, but does not inhibit NF-kappa B activation.", "text_with_entity_marker": "Conversely, a [E1]FADD[/E1] mutant lacking its N-terminal 79 amino acids is a dominant-negative inhibitor of TNF-induced apoptosis, but does not inhibit [E2]NF-kappa B[/E2] activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FADD", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[144, 154]], "entity_2_idx_in_text_with_entity_marker": [157, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1297_AIMed.d152.s1297.p0", "text": "Thus, these two TNFR1-TRADD signaling cascades appear to bifurcate at TRADD.", "text_with_entity_marker": "Thus, these two [E1]TNFR1[/E1]-[E2]TRADD[/E2] signaling cascades appear to bifurcate at TRADD.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFR1", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRADD", "entity_2_idx": [[22, 27]], "entity_2_idx_in_text_with_entity_marker": [35, 40], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1297_AIMed.d152.s1297.p1", "text": "Thus, these two TNFR1-TRADD signaling cascades appear to bifurcate at TRADD.", "text_with_entity_marker": "Thus, these two [E1]TNFR1[/E1]-TRADD signaling cascades appear to bifurcate at [E2]TRADD[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNFR1", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRADD", "entity_2_idx": [[70, 75]], "entity_2_idx_in_text_with_entity_marker": [83, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d152.s1297_AIMed.d152.s1297.p2", "text": "Thus, these two TNFR1-TRADD signaling cascades appear to bifurcate at TRADD.", "text_with_entity_marker": "Thus, these two TNFR1-[E1]TRADD[/E1] signaling cascades appear to bifurcate at [E2]TRADD[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRADD", "entity_1_idx": [[22, 27]], "entity_1_idx_in_text_with_entity_marker": [26, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TRADD", "entity_2_idx": [[70, 75]], "entity_2_idx_in_text_with_entity_marker": [83, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1101_AIMed.d129.s1101.p0", "text": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.", "text_with_entity_marker": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of [E1]hsp90[/E1], [E2]hsp70[/E2], and three additional proteins, p54, p50, and p23.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp90", "entity_1_idx": [[96, 101]], "entity_1_idx_in_text_with_entity_marker": [100, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp70", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1101_AIMed.d129.s1101.p1", "text": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.", "text_with_entity_marker": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of [E1]hsp90[/E1], hsp70, and three additional proteins, [E2]p54[/E2], p50, and p23.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp90", "entity_1_idx": [[96, 101]], "entity_1_idx_in_text_with_entity_marker": [100, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p54", "entity_2_idx": [[141, 144]], "entity_2_idx_in_text_with_entity_marker": [154, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1101_AIMed.d129.s1101.p2", "text": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.", "text_with_entity_marker": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of [E1]hsp90[/E1], hsp70, and three additional proteins, p54, [E2]p50[/E2], and p23.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp90", "entity_1_idx": [[96, 101]], "entity_1_idx_in_text_with_entity_marker": [100, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p50", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1101_AIMed.d129.s1101.p3", "text": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.", "text_with_entity_marker": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of [E1]hsp90[/E1], hsp70, and three additional proteins, p54, p50, and [E2]p23[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp90", "entity_1_idx": [[96, 101]], "entity_1_idx_in_text_with_entity_marker": [100, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p23", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1101_AIMed.d129.s1101.p4", "text": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.", "text_with_entity_marker": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, [E1]hsp70[/E1], and three additional proteins, [E2]p54[/E2], p50, and p23.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp70", "entity_1_idx": [[103, 108]], "entity_1_idx_in_text_with_entity_marker": [107, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p54", "entity_2_idx": [[141, 144]], "entity_2_idx_in_text_with_entity_marker": [154, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1101_AIMed.d129.s1101.p5", "text": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.", "text_with_entity_marker": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, [E1]hsp70[/E1], and three additional proteins, p54, [E2]p50[/E2], and p23.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp70", "entity_1_idx": [[103, 108]], "entity_1_idx_in_text_with_entity_marker": [107, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p50", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1101_AIMed.d129.s1101.p6", "text": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.", "text_with_entity_marker": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, [E1]hsp70[/E1], and three additional proteins, p54, p50, and [E2]p23[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp70", "entity_1_idx": [[103, 108]], "entity_1_idx_in_text_with_entity_marker": [107, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p23", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1101_AIMed.d129.s1101.p7", "text": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.", "text_with_entity_marker": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, [E1]p54[/E1], [E2]p50[/E2], and p23.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p54", "entity_1_idx": [[141, 144]], "entity_1_idx_in_text_with_entity_marker": [145, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p50", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1101_AIMed.d129.s1101.p8", "text": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.", "text_with_entity_marker": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, [E1]p54[/E1], p50, and [E2]p23[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p54", "entity_1_idx": [[141, 144]], "entity_1_idx_in_text_with_entity_marker": [145, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p23", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1101_AIMed.d129.s1101.p9", "text": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, p50, and p23.", "text_with_entity_marker": "Immunoprecipitation of unactivated avian progesterone receptor results in the copurification of hsp90, hsp70, and three additional proteins, p54, [E1]p50[/E1], and [E2]p23[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p50", "entity_1_idx": [[146, 149]], "entity_1_idx_in_text_with_entity_marker": [150, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p23", "entity_2_idx": [[155, 158]], "entity_2_idx_in_text_with_entity_marker": [168, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1102_AIMed.d129.s1102.p0", "text": "p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.", "text_with_entity_marker": "[E1]p23[/E1] is also present in immunoaffinity-purified [E2]hsp90[/E2] complexes along with hsp70 and another protein, p60.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p23", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp90", "entity_2_idx": [[47, 52]], "entity_2_idx_in_text_with_entity_marker": [60, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1102_AIMed.d129.s1102.p1", "text": "p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.", "text_with_entity_marker": "[E1]p23[/E1] is also present in immunoaffinity-purified hsp90 complexes along with [E2]hsp70[/E2] and another protein, p60.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p23", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp70", "entity_2_idx": [[74, 79]], "entity_2_idx_in_text_with_entity_marker": [87, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1102_AIMed.d129.s1102.p2", "text": "p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.", "text_with_entity_marker": "[E1]p23[/E1] is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, [E2]p60[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p23", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p60", "entity_2_idx": [[101, 104]], "entity_2_idx_in_text_with_entity_marker": [114, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1102_AIMed.d129.s1102.p3", "text": "p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.", "text_with_entity_marker": "p23 is also present in immunoaffinity-purified [E1]hsp90[/E1] complexes along with [E2]hsp70[/E2] and another protein, p60.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp90", "entity_1_idx": [[47, 52]], "entity_1_idx_in_text_with_entity_marker": [51, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp70", "entity_2_idx": [[74, 79]], "entity_2_idx_in_text_with_entity_marker": [87, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1102_AIMed.d129.s1102.p4", "text": "p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.", "text_with_entity_marker": "p23 is also present in immunoaffinity-purified [E1]hsp90[/E1] complexes along with hsp70 and another protein, [E2]p60[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp90", "entity_1_idx": [[47, 52]], "entity_1_idx_in_text_with_entity_marker": [51, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p60", "entity_2_idx": [[101, 104]], "entity_2_idx_in_text_with_entity_marker": [114, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1102_AIMed.d129.s1102.p5", "text": "p23 is also present in immunoaffinity-purified hsp90 complexes along with hsp70 and another protein, p60.", "text_with_entity_marker": "p23 is also present in immunoaffinity-purified hsp90 complexes along with [E1]hsp70[/E1] and another protein, [E2]p60[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hsp70", "entity_1_idx": [[74, 79]], "entity_1_idx_in_text_with_entity_marker": [78, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p60", "entity_2_idx": [[101, 104]], "entity_2_idx_in_text_with_entity_marker": [114, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1104_AIMed.d129.s1104.p0", "text": "Antibodies to p23 detect similar levels of p23 in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that p23 is a conserved protein of broad tissue distribution.", "text_with_entity_marker": "Antibodies to [E1]p23[/E1] detect similar levels of [E2]p23[/E2] in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that p23 is a conserved protein of broad tissue distribution.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p23", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p23", "entity_2_idx": [[43, 46]], "entity_2_idx_in_text_with_entity_marker": [56, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1104_AIMed.d129.s1104.p1", "text": "Antibodies to p23 detect similar levels of p23 in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that p23 is a conserved protein of broad tissue distribution.", "text_with_entity_marker": "Antibodies to [E1]p23[/E1] detect similar levels of p23 in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that [E2]p23[/E2] is a conserved protein of broad tissue distribution.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p23", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p23", "entity_2_idx": [[202, 205]], "entity_2_idx_in_text_with_entity_marker": [215, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1104_AIMed.d129.s1104.p2", "text": "Antibodies to p23 detect similar levels of p23 in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that p23 is a conserved protein of broad tissue distribution.", "text_with_entity_marker": "Antibodies to p23 detect similar levels of [E1]p23[/E1] in all tissues tested and cross-react with a protein of the same size in mice, rabbits, guinea pigs, humans, and Saccharomyces cerevisiae, indicating that [E2]p23[/E2] is a conserved protein of broad tissue distribution.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p23", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p23", "entity_2_idx": [[202, 205]], "entity_2_idx_in_text_with_entity_marker": [215, 218], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1110_AIMed.d129.s1110.p0", "text": "Bacterially overexpressed human p23 was used to raise several monoclonal antibodies to p23.", "text_with_entity_marker": "Bacterially overexpressed human [E1]p23[/E1] was used to raise several monoclonal antibodies to [E2]p23[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p23", "entity_1_idx": [[32, 35]], "entity_1_idx_in_text_with_entity_marker": [36, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p23", "entity_2_idx": [[87, 90]], "entity_2_idx_in_text_with_entity_marker": [100, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d129.s1111_AIMed.d129.s1111.p0", "text": "These antibodies specifically immunoprecipitate p23 in complex with hsp90 in all tissues tested and can be used to immunoaffinity isolate progesterone receptor complexes from chicken oviduct cytosol.", "text_with_entity_marker": "These antibodies specifically immunoprecipitate [E1]p23[/E1] in complex with [E2]hsp90[/E2] in all tissues tested and can be used to immunoaffinity isolate progesterone receptor complexes from chicken oviduct cytosol.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p23", "entity_1_idx": [[48, 51]], "entity_1_idx_in_text_with_entity_marker": [52, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hsp90", "entity_2_idx": [[68, 73]], "entity_2_idx_in_text_with_entity_marker": [81, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s764_AIMed.d90.s764.p0", "text": "Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).", "text_with_entity_marker": "Multiple proteins physically interact with [E1]PU.1[/E1]. Transcriptional synergy with [E2]NF-IL6 beta[/E2] (C/EBP delta, CRP3).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PU.1", "entity_1_idx": [[43, 47]], "entity_1_idx_in_text_with_entity_marker": [47, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-IL6 beta", "entity_2_idx": [[78, 89]], "entity_2_idx_in_text_with_entity_marker": [91, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s764_AIMed.d90.s764.p1", "text": "Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).", "text_with_entity_marker": "Multiple proteins physically interact with [E1]PU.1[/E1]. Transcriptional synergy with NF-IL6 beta (C/[E2]EBP delta[/E2], CRP3).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PU.1", "entity_1_idx": [[43, 47]], "entity_1_idx_in_text_with_entity_marker": [47, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP delta", "entity_2_idx": [[93, 102]], "entity_2_idx_in_text_with_entity_marker": [106, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s764_AIMed.d90.s764.p2", "text": "Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).", "text_with_entity_marker": "Multiple proteins physically interact with [E1]PU.1[/E1]. Transcriptional synergy with NF-IL6 beta (C/EBP delta, [E2]CRP3[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PU.1", "entity_1_idx": [[43, 47]], "entity_1_idx_in_text_with_entity_marker": [47, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CRP3", "entity_2_idx": [[104, 108]], "entity_2_idx_in_text_with_entity_marker": [117, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s764_AIMed.d90.s764.p3", "text": "Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).", "text_with_entity_marker": "Multiple proteins physically interact with PU.1. Transcriptional synergy with [E1]NF-IL6 beta[/E1] (C/[E2]EBP delta[/E2], CRP3).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-IL6 beta", "entity_1_idx": [[78, 89]], "entity_1_idx_in_text_with_entity_marker": [82, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EBP delta", "entity_2_idx": [[93, 102]], "entity_2_idx_in_text_with_entity_marker": [106, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s764_AIMed.d90.s764.p4", "text": "Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).", "text_with_entity_marker": "Multiple proteins physically interact with PU.1. Transcriptional synergy with [E1]NF-IL6 beta[/E1] (C/EBP delta, [E2]CRP3[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-IL6 beta", "entity_1_idx": [[78, 89]], "entity_1_idx_in_text_with_entity_marker": [82, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CRP3", "entity_2_idx": [[104, 108]], "entity_2_idx_in_text_with_entity_marker": [117, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s764_AIMed.d90.s764.p5", "text": "Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/EBP delta, CRP3).", "text_with_entity_marker": "Multiple proteins physically interact with PU.1. Transcriptional synergy with NF-IL6 beta (C/[E1]EBP delta[/E1], [E2]CRP3[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EBP delta", "entity_1_idx": [[93, 102]], "entity_1_idx_in_text_with_entity_marker": [97, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CRP3", "entity_2_idx": [[104, 108]], "entity_2_idx_in_text_with_entity_marker": [117, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s767_AIMed.d90.s767.p0", "text": "Using radiolabeled PU.1 protein as a probe, we screened a B cell cDNA expression library and isolated a number of clones encoding PU.1 interacting proteins.", "text_with_entity_marker": "Using radiolabeled [E1]PU.1[/E1] protein as a probe, we screened a B cell cDNA expression library and isolated a number of clones encoding [E2]PU.1[/E2] interacting proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PU.1", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PU.1", "entity_2_idx": [[130, 134]], "entity_2_idx_in_text_with_entity_marker": [143, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s768_AIMed.d90.s768.p0", "text": "Three of these clones encode DNA binding proteins (NF-IL6 beta, HMG I/Y, and SSRP), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.", "text_with_entity_marker": "Three of these clones encode DNA binding proteins ([E1]NF-IL6 beta[/E1], [E2]HMG I/Y[/E2], and SSRP), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-IL6 beta", "entity_1_idx": [[51, 62]], "entity_1_idx_in_text_with_entity_marker": [55, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HMG I/Y", "entity_2_idx": [[64, 71]], "entity_2_idx_in_text_with_entity_marker": [77, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s768_AIMed.d90.s768.p1", "text": "Three of these clones encode DNA binding proteins (NF-IL6 beta, HMG I/Y, and SSRP), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.", "text_with_entity_marker": "Three of these clones encode DNA binding proteins ([E1]NF-IL6 beta[/E1], HMG I/Y, and [E2]SSRP[/E2]), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-IL6 beta", "entity_1_idx": [[51, 62]], "entity_1_idx_in_text_with_entity_marker": [55, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SSRP", "entity_2_idx": [[77, 81]], "entity_2_idx_in_text_with_entity_marker": [90, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s768_AIMed.d90.s768.p2", "text": "Three of these clones encode DNA binding proteins (NF-IL6 beta, HMG I/Y, and SSRP), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.", "text_with_entity_marker": "Three of these clones encode DNA binding proteins (NF-IL6 beta, [E1]HMG I/Y[/E1], and [E2]SSRP[/E2]), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HMG I/Y", "entity_1_idx": [[64, 71]], "entity_1_idx_in_text_with_entity_marker": [68, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SSRP", "entity_2_idx": [[77, 81]], "entity_2_idx_in_text_with_entity_marker": [90, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s769_AIMed.d90.s769.p0", "text": "We have characterized the physical and functional interactions between PU.1 and NF-IL6 beta, a leucine zipper transcription factor implicated in inflammatory responses.", "text_with_entity_marker": "We have characterized the physical and functional interactions between [E1]PU.1[/E1] and [E2]NF-IL6 beta[/E2], a leucine zipper transcription factor implicated in inflammatory responses.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PU.1", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-IL6 beta", "entity_2_idx": [[80, 91]], "entity_2_idx_in_text_with_entity_marker": [93, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s770_AIMed.d90.s770.p0", "text": "We found that deletion of the carboxyl-terminal 28 amino acids of PU.1 disrupted PU.1-NF-IL6 beta physical interaction.", "text_with_entity_marker": "We found that deletion of the carboxyl-terminal 28 amino acids of [E1]PU.1[/E1] disrupted [E2]PU.1[/E2]-NF-IL6 beta physical interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PU.1", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PU.1", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s770_AIMed.d90.s770.p1", "text": "We found that deletion of the carboxyl-terminal 28 amino acids of PU.1 disrupted PU.1-NF-IL6 beta physical interaction.", "text_with_entity_marker": "We found that deletion of the carboxyl-terminal 28 amino acids of [E1]PU.1[/E1] disrupted PU.1-[E2]NF-IL6 beta[/E2] physical interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PU.1", "entity_1_idx": [[66, 70]], "entity_1_idx_in_text_with_entity_marker": [70, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-IL6 beta", "entity_2_idx": [[86, 97]], "entity_2_idx_in_text_with_entity_marker": [99, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s770_AIMed.d90.s770.p2", "text": "We found that deletion of the carboxyl-terminal 28 amino acids of PU.1 disrupted PU.1-NF-IL6 beta physical interaction.", "text_with_entity_marker": "We found that deletion of the carboxyl-terminal 28 amino acids of PU.1 disrupted [E1]PU.1[/E1]-[E2]NF-IL6 beta[/E2] physical interaction.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PU.1", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-IL6 beta", "entity_2_idx": [[86, 97]], "entity_2_idx_in_text_with_entity_marker": [99, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s773_AIMed.d90.s773.p0", "text": "In transient expression assays, we found that PU.1 and NF-IL6 beta can functionally cooperate to synergistically activate transcription.", "text_with_entity_marker": "In transient expression assays, we found that [E1]PU.1[/E1] and [E2]NF-IL6 beta[/E2] can functionally cooperate to synergistically activate transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PU.1", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-IL6 beta", "entity_2_idx": [[55, 66]], "entity_2_idx_in_text_with_entity_marker": [68, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d90.s774_AIMed.d90.s774.p0", "text": "Electrophoretic mobility shift assays showed that PU.1 and NF-IL6 beta can simultaneously bind to adjacent DNA binding sites, but apparently do not influence the kinetics or affinity of each other's DNA binding.", "text_with_entity_marker": "Electrophoretic mobility shift assays showed that [E1]PU.1[/E1] and [E2]NF-IL6 beta[/E2] can simultaneously bind to adjacent DNA binding sites, but apparently do not influence the kinetics or affinity of each other's DNA binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PU.1", "entity_1_idx": [[50, 54]], "entity_1_idx_in_text_with_entity_marker": [54, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-IL6 beta", "entity_2_idx": [[59, 70]], "entity_2_idx_in_text_with_entity_marker": [72, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1372_AIMed.d163.s1372.p0", "text": "Enhanced degradation of EGF receptors by a sorting nexin, SNX1.", "text_with_entity_marker": "Enhanced degradation of [E1]EGF[/E1] receptors by a sorting [E2]nexin[/E2], SNX1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EGF", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "nexin", "entity_2_idx": [[51, 56]], "entity_2_idx_in_text_with_entity_marker": [64, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1372_AIMed.d163.s1372.p1", "text": "Enhanced degradation of EGF receptors by a sorting nexin, SNX1.", "text_with_entity_marker": "Enhanced degradation of [E1]EGF[/E1] receptors by a sorting nexin, [E2]SNX1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EGF", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNX1", "entity_2_idx": [[58, 62]], "entity_2_idx_in_text_with_entity_marker": [71, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1372_AIMed.d163.s1372.p2", "text": "Enhanced degradation of EGF receptors by a sorting nexin, SNX1.", "text_with_entity_marker": "Enhanced degradation of EGF receptors by a sorting [E1]nexin[/E1], [E2]SNX1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "nexin", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNX1", "entity_2_idx": [[58, 62]], "entity_2_idx_in_text_with_entity_marker": [71, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1374_AIMed.d163.s1374.p0", "text": "A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.", "text_with_entity_marker": "A protein, [E1]sorting nexin-1[/E1] ([E2]SNX1[/E2]), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sorting nexin-1", "entity_1_idx": [[11, 26]], "entity_1_idx_in_text_with_entity_marker": [15, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNX1", "entity_2_idx": [[28, 32]], "entity_2_idx_in_text_with_entity_marker": [41, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1374_AIMed.d163.s1374.p1", "text": "A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.", "text_with_entity_marker": "A protein, [E1]sorting nexin-1[/E1] (SNX1), was identified in a human cell line that bound to a region of the [E2]epidermal growth factor receptor[/E2] (EGFR) containing the lysosomal targeting code.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "sorting nexin-1", "entity_1_idx": [[11, 26]], "entity_1_idx_in_text_with_entity_marker": [15, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "epidermal growth factor receptor", "entity_2_idx": [[101, 133]], "entity_2_idx_in_text_with_entity_marker": [114, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1374_AIMed.d163.s1374.p2", "text": "A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.", "text_with_entity_marker": "A protein, [E1]sorting nexin-1[/E1] (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor ([E2]EGFR[/E2]) containing the lysosomal targeting code.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "sorting nexin-1", "entity_1_idx": [[11, 26]], "entity_1_idx_in_text_with_entity_marker": [15, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EGFR", "entity_2_idx": [[135, 139]], "entity_2_idx_in_text_with_entity_marker": [148, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1374_AIMed.d163.s1374.p3", "text": "A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.", "text_with_entity_marker": "A protein, sorting nexin-1 ([E1]SNX1[/E1]), was identified in a human cell line that bound to a region of the [E2]epidermal growth factor receptor[/E2] (EGFR) containing the lysosomal targeting code.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "SNX1", "entity_1_idx": [[28, 32]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "epidermal growth factor receptor", "entity_2_idx": [[101, 133]], "entity_2_idx_in_text_with_entity_marker": [114, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1374_AIMed.d163.s1374.p4", "text": "A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.", "text_with_entity_marker": "A protein, sorting nexin-1 ([E1]SNX1[/E1]), was identified in a human cell line that bound to a region of the epidermal growth factor receptor ([E2]EGFR[/E2]) containing the lysosomal targeting code.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "SNX1", "entity_1_idx": [[28, 32]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EGFR", "entity_2_idx": [[135, 139]], "entity_2_idx_in_text_with_entity_marker": [148, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1374_AIMed.d163.s1374.p5", "text": "A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.", "text_with_entity_marker": "A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the [E1]epidermal growth factor receptor[/E1] ([E2]EGFR[/E2]) containing the lysosomal targeting code.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "epidermal growth factor receptor", "entity_1_idx": [[101, 133]], "entity_1_idx_in_text_with_entity_marker": [105, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EGFR", "entity_2_idx": [[135, 139]], "entity_2_idx_in_text_with_entity_marker": [148, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1375_AIMed.d163.s1375.p0", "text": "SNX1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of SNX1 decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.", "text_with_entity_marker": "[E1]SNX1[/E1] contains a region of homology to a yeast vacuolar sorting protein, and overexpression of [E2]SNX1[/E2] decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SNX1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SNX1", "entity_2_idx": [[94, 98]], "entity_2_idx_in_text_with_entity_marker": [107, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1375_AIMed.d163.s1375.p1", "text": "SNX1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of SNX1 decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.", "text_with_entity_marker": "[E1]SNX1[/E1] contains a region of homology to a yeast vacuolar sorting protein, and overexpression of SNX1 decreased the amount of [E2]EGFR[/E2] on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SNX1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EGFR", "entity_2_idx": [[123, 127]], "entity_2_idx_in_text_with_entity_marker": [136, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1375_AIMed.d163.s1375.p2", "text": "SNX1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of SNX1 decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.", "text_with_entity_marker": "SNX1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of [E1]SNX1[/E1] decreased the amount of [E2]EGFR[/E2] on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SNX1", "entity_1_idx": [[94, 98]], "entity_1_idx_in_text_with_entity_marker": [98, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EGFR", "entity_2_idx": [[123, 127]], "entity_2_idx_in_text_with_entity_marker": [136, 140], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d163.s1376_AIMed.d163.s1376.p0", "text": "Thus, SNX1 is likely to play a role in sorting EGFR to lysosomes.", "text_with_entity_marker": "Thus, [E1]SNX1[/E1] is likely to play a role in sorting [E2]EGFR[/E2] to lysosomes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SNX1", "entity_1_idx": [[6, 10]], "entity_1_idx_in_text_with_entity_marker": [10, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EGFR", "entity_2_idx": [[47, 51]], "entity_2_idx_in_text_with_entity_marker": [60, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d96.s808_AIMed.d96.s808.p0", "text": "It binds homophilically, i.e., PTPmu on the surface of one cell binds to PTPmu on an apposing cell, and the binding site lies within the immunoglobulin domain.", "text_with_entity_marker": "It binds homophilically, i.e., [E1]PTPmu[/E1] on the surface of one cell binds to [E2]PTPmu[/E2] on an apposing cell, and the binding site lies within the immunoglobulin domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PTPmu", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTPmu", "entity_2_idx": [[73, 78]], "entity_2_idx_in_text_with_entity_marker": [86, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d96.s811_AIMed.d96.s811.p0", "text": "In this article, we demonstrate that PTPmu associates with a complex containing cadherins, alpha- and beta-catenin in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.", "text_with_entity_marker": "In this article, we demonstrate that [E1]PTPmu[/E1] associates with a complex containing [E2]cadherins, alpha[/E2]- and beta-catenin in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTPmu", "entity_1_idx": [[37, 42]], "entity_1_idx_in_text_with_entity_marker": [41, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cadherins, alpha", "entity_2_idx": [[80, 96]], "entity_2_idx_in_text_with_entity_marker": [93, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d96.s811_AIMed.d96.s811.p1", "text": "In this article, we demonstrate that PTPmu associates with a complex containing cadherins, alpha- and beta-catenin in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.", "text_with_entity_marker": "In this article, we demonstrate that [E1]PTPmu[/E1] associates with a complex containing cadherins, alpha- and [E2]beta-catenin[/E2] in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PTPmu", "entity_1_idx": [[37, 42]], "entity_1_idx_in_text_with_entity_marker": [41, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[102, 114]], "entity_2_idx_in_text_with_entity_marker": [115, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d96.s811_AIMed.d96.s811.p2", "text": "In this article, we demonstrate that PTPmu associates with a complex containing cadherins, alpha- and beta-catenin in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.", "text_with_entity_marker": "In this article, we demonstrate that PTPmu associates with a complex containing [E1]cadherins, alpha[/E1]- and [E2]beta-catenin[/E2] in mink lung (MvLu) cells, and in rat heart, lung, and brain tissues.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cadherins, alpha", "entity_1_idx": [[80, 96]], "entity_1_idx_in_text_with_entity_marker": [84, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[102, 114]], "entity_2_idx_in_text_with_entity_marker": [115, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d96.s813_AIMed.d96.s813.p0", "text": "In vitro binding studies demonstrated that the intracellular segment of PTPmu binds directly to the intracellular domain of E-cadherin, but not to alpha- or beta-catenin.", "text_with_entity_marker": "In vitro binding studies demonstrated that the intracellular segment of [E1]PTPmu[/E1] binds directly to the intracellular domain of [E2]E-cadherin[/E2], but not to alpha- or beta-catenin.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PTPmu", "entity_1_idx": [[72, 77]], "entity_1_idx_in_text_with_entity_marker": [76, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E-cadherin", "entity_2_idx": [[124, 134]], "entity_2_idx_in_text_with_entity_marker": [137, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d96.s813_AIMed.d96.s813.p1", "text": "In vitro binding studies demonstrated that the intracellular segment of PTPmu binds directly to the intracellular domain of E-cadherin, but not to alpha- or beta-catenin.", "text_with_entity_marker": "In vitro binding studies demonstrated that the intracellular segment of [E1]PTPmu[/E1] binds directly to the intracellular domain of E-cadherin, but not to alpha- or [E2]beta-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTPmu", "entity_1_idx": [[72, 77]], "entity_1_idx_in_text_with_entity_marker": [76, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[157, 169]], "entity_2_idx_in_text_with_entity_marker": [170, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d96.s813_AIMed.d96.s813.p2", "text": "In vitro binding studies demonstrated that the intracellular segment of PTPmu binds directly to the intracellular domain of E-cadherin, but not to alpha- or beta-catenin.", "text_with_entity_marker": "In vitro binding studies demonstrated that the intracellular segment of PTPmu binds directly to the intracellular domain of [E1]E-cadherin[/E1], but not to alpha- or [E2]beta-catenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E-cadherin", "entity_1_idx": [[124, 134]], "entity_1_idx_in_text_with_entity_marker": [128, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[157, 169]], "entity_2_idx_in_text_with_entity_marker": [170, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d96.s815_AIMed.d96.s815.p0", "text": "After pervanadate treatment of MvLu cells, which inhibits cellular tyrosine phosphatase activity including PTPmu, the cadherins associated with PTPmu are now found in a tyrosine-phosphorylated form, indicating that the cadherins may be an endogenous substrate for PTPmu.", "text_with_entity_marker": "After pervanadate treatment of MvLu cells, which inhibits cellular tyrosine phosphatase activity including [E1]PTPmu[/E1], the cadherins associated with [E2]PTPmu[/E2] are now found in a tyrosine-phosphorylated form, indicating that the cadherins may be an endogenous substrate for PTPmu.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTPmu", "entity_1_idx": [[107, 112]], "entity_1_idx_in_text_with_entity_marker": [111, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTPmu", "entity_2_idx": [[144, 149]], "entity_2_idx_in_text_with_entity_marker": [157, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d96.s815_AIMed.d96.s815.p1", "text": "After pervanadate treatment of MvLu cells, which inhibits cellular tyrosine phosphatase activity including PTPmu, the cadherins associated with PTPmu are now found in a tyrosine-phosphorylated form, indicating that the cadherins may be an endogenous substrate for PTPmu.", "text_with_entity_marker": "After pervanadate treatment of MvLu cells, which inhibits cellular tyrosine phosphatase activity including [E1]PTPmu[/E1], the cadherins associated with PTPmu are now found in a tyrosine-phosphorylated form, indicating that the cadherins may be an endogenous substrate for [E2]PTPmu[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTPmu", "entity_1_idx": [[107, 112]], "entity_1_idx_in_text_with_entity_marker": [111, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTPmu", "entity_2_idx": [[264, 269]], "entity_2_idx_in_text_with_entity_marker": [277, 282], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d96.s815_AIMed.d96.s815.p2", "text": "After pervanadate treatment of MvLu cells, which inhibits cellular tyrosine phosphatase activity including PTPmu, the cadherins associated with PTPmu are now found in a tyrosine-phosphorylated form, indicating that the cadherins may be an endogenous substrate for PTPmu.", "text_with_entity_marker": "After pervanadate treatment of MvLu cells, which inhibits cellular tyrosine phosphatase activity including PTPmu, the cadherins associated with [E1]PTPmu[/E1] are now found in a tyrosine-phosphorylated form, indicating that the cadherins may be an endogenous substrate for [E2]PTPmu[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PTPmu", "entity_1_idx": [[144, 149]], "entity_1_idx_in_text_with_entity_marker": [148, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PTPmu", "entity_2_idx": [[264, 269]], "entity_2_idx_in_text_with_entity_marker": [277, 282], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d98.s832_AIMed.d98.s832.p0", "text": "Raf-1, which is known to bind 14-3-3 proteins, has recently been shown to associate with cdc25A and to stimulate its phosphatase activity.", "text_with_entity_marker": "[E1]Raf-1[/E1], which is known to bind 14-3-3 proteins, has recently been shown to associate with [E2]cdc25A[/E2] and to stimulate its phosphatase activity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf-1", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25A", "entity_2_idx": [[89, 95]], "entity_2_idx_in_text_with_entity_marker": [102, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d98.s833_AIMed.d98.s833.p0", "text": "14-3-3 protein, however, has no effect on the cdc25A-kinase activity of Raf-1.", "text_with_entity_marker": "14-3-3 protein, however, has no effect on the [E1]cdc25A[/E1]-kinase activity of [E2]Raf-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cdc25A", "entity_1_idx": [[46, 52]], "entity_1_idx_in_text_with_entity_marker": [50, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[72, 77]], "entity_2_idx_in_text_with_entity_marker": [85, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d98.s834_AIMed.d98.s834.p0", "text": "Instead, 14-3-3 may facilitate the association of cdc25 with Raf-1 in vivo, participating in the linkage between mitogenic signaling and the cell cycle machinery.", "text_with_entity_marker": "Instead, 14-3-3 may facilitate the association of [E1]cdc25[/E1] with [E2]Raf-1[/E2] in vivo, participating in the linkage between mitogenic signaling and the cell cycle machinery.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cdc25", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [54, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Raf-1", "entity_2_idx": [[61, 66]], "entity_2_idx_in_text_with_entity_marker": [74, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d56.s494_AIMed.d56.s494.p0", "text": "Cloning of TRAP, a ligand for CD40 on human T cells.", "text_with_entity_marker": "Cloning of [E1]TRAP[/E1], a ligand for [E2]CD40[/E2] on human T cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRAP", "entity_1_idx": [[11, 15]], "entity_1_idx_in_text_with_entity_marker": [15, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD40", "entity_2_idx": [[30, 34]], "entity_2_idx_in_text_with_entity_marker": [43, 47], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d56.s495_AIMed.d56.s495.p0", "text": "A cDNA clone, designated TRAP (TNF-related activation protein) was isolated from a collection of T cell activation genes.", "text_with_entity_marker": "A cDNA clone, designated [E1]TRAP[/E1] ([E2]TNF-related activation protein[/E2]) was isolated from a collection of T cell activation genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRAP", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-related activation protein", "entity_2_idx": [[31, 61]], "entity_2_idx_in_text_with_entity_marker": [44, 74], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d56.s499_AIMed.d56.s499.p0", "text": "TRAP is highly similar to an identified murine CD40 ligand both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/lymphotoxin.", "text_with_entity_marker": "[E1]TRAP[/E1] is highly similar to an identified murine [E2]CD40 ligand[/E2] both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/lymphotoxin.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRAP", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD40 ligand", "entity_2_idx": [[47, 58]], "entity_2_idx_in_text_with_entity_marker": [60, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d56.s499_AIMed.d56.s499.p1", "text": "TRAP is highly similar to an identified murine CD40 ligand both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/lymphotoxin.", "text_with_entity_marker": "[E1]TRAP[/E1] is highly similar to an identified murine CD40 ligand both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/[E2]lymphotoxin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TRAP", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "lymphotoxin", "entity_2_idx": [[171, 182]], "entity_2_idx_in_text_with_entity_marker": [184, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d56.s499_AIMed.d56.s499.p2", "text": "TRAP is highly similar to an identified murine CD40 ligand both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/lymphotoxin.", "text_with_entity_marker": "TRAP is highly similar to an identified murine [E1]CD40 ligand[/E1] both at the cDNA (82.8% identity) and the protein (77.4% identity) levels, and related to tumor necrosis factor/[E2]lymphotoxin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD40 ligand", "entity_1_idx": [[47, 58]], "entity_1_idx_in_text_with_entity_marker": [51, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "lymphotoxin", "entity_2_idx": [[171, 182]], "entity_2_idx_in_text_with_entity_marker": [184, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d56.s500_AIMed.d56.s500.p0", "text": "Expressed in a murine myeloma, TRAP was identified as a ligand for CD40 by binding to a soluble CD40 construct.", "text_with_entity_marker": "Expressed in a murine myeloma, [E1]TRAP[/E1] was identified as a ligand for [E2]CD40[/E2] by binding to a soluble CD40 construct.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRAP", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD40", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d56.s500_AIMed.d56.s500.p1", "text": "Expressed in a murine myeloma, TRAP was identified as a ligand for CD40 by binding to a soluble CD40 construct.", "text_with_entity_marker": "Expressed in a murine myeloma, [E1]TRAP[/E1] was identified as a ligand for CD40 by binding to a soluble [E2]CD40[/E2] construct.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TRAP", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD40", "entity_2_idx": [[96, 100]], "entity_2_idx_in_text_with_entity_marker": [109, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d56.s500_AIMed.d56.s500.p2", "text": "Expressed in a murine myeloma, TRAP was identified as a ligand for CD40 by binding to a soluble CD40 construct.", "text_with_entity_marker": "Expressed in a murine myeloma, TRAP was identified as a ligand for [E1]CD40[/E1] by binding to a soluble [E2]CD40[/E2] construct.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD40", "entity_1_idx": [[67, 71]], "entity_1_idx_in_text_with_entity_marker": [71, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD40", "entity_2_idx": [[96, 100]], "entity_2_idx_in_text_with_entity_marker": [109, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d122.s1036_AIMed.d122.s1036.p0", "text": "In previous studies (Scott, J. D., Stofko, R. E., McDonald, J. R., Comer, J. D., Vitalis, E. A., and Mangili J. (1990) J. Biol. Chem. 265, 21561-21566) we have shown that dimerization of RII alpha was required for interaction with the cytoskeletal component microtubule-associated protein 2.", "text_with_entity_marker": "In previous studies (Scott, J. D., Stofko, R. E., McDonald, J. R., Comer, J. D., Vitalis, E. A., and Mangili J. (1990) J. Biol. Chem. 265, 21561-21566) we have shown that dimerization of [E1]RII alpha[/E1] was required for interaction with the cytoskeletal component [E2]microtubule-associated protein 2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RII alpha", "entity_1_idx": [[187, 196]], "entity_1_idx_in_text_with_entity_marker": [191, 200], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "microtubule-associated protein 2", "entity_2_idx": [[258, 290]], "entity_2_idx_in_text_with_entity_marker": [271, 303], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d122.s1041_AIMed.d122.s1041.p0", "text": "Measurement of RII alpha I3A,I5A interaction with the human thyroid AKAP, Ht 31, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.", "text_with_entity_marker": "Measurement of [E1]RII alpha[/E1] I3A,I5A interaction with the human [E2]thyroid AKAP[/E2], Ht 31, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RII alpha", "entity_1_idx": [[15, 24]], "entity_1_idx_in_text_with_entity_marker": [19, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "thyroid AKAP", "entity_2_idx": [[60, 72]], "entity_2_idx_in_text_with_entity_marker": [73, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d122.s1041_AIMed.d122.s1041.p1", "text": "Measurement of RII alpha I3A,I5A interaction with the human thyroid AKAP, Ht 31, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.", "text_with_entity_marker": "Measurement of [E1]RII alpha[/E1] I3A,I5A interaction with the human thyroid AKAP, [E2]Ht 31[/E2], by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RII alpha", "entity_1_idx": [[15, 24]], "entity_1_idx_in_text_with_entity_marker": [19, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ht 31", "entity_2_idx": [[74, 79]], "entity_2_idx_in_text_with_entity_marker": [87, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d122.s1041_AIMed.d122.s1041.p2", "text": "Measurement of RII alpha I3A,I5A interaction with the human thyroid AKAP, Ht 31, by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.", "text_with_entity_marker": "Measurement of RII alpha I3A,I5A interaction with the human [E1]thyroid AKAP[/E1], [E2]Ht 31[/E2], by two independent methods suggests that mutation of isoleucines 3 and 5 decreases affinity by at least 6-fold.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "thyroid AKAP", "entity_1_idx": [[60, 72]], "entity_1_idx_in_text_with_entity_marker": [64, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ht 31", "entity_2_idx": [[74, 79]], "entity_2_idx_in_text_with_entity_marker": [87, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p0", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins ([E1]procollagen I[/E1], [E2]collagenase[/E2], elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "procollagen I", "entity_1_idx": [[78, 91]], "entity_1_idx_in_text_with_entity_marker": [82, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "collagenase", "entity_2_idx": [[93, 104]], "entity_2_idx_in_text_with_entity_marker": [106, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p1", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins ([E1]procollagen I[/E1], collagenase, [E2]elastin[/E2], hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "procollagen I", "entity_1_idx": [[78, 91]], "entity_1_idx_in_text_with_entity_marker": [82, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "elastin", "entity_2_idx": [[106, 113]], "entity_2_idx_in_text_with_entity_marker": [119, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p2", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins ([E1]procollagen I[/E1], collagenase, elastin, [E2]hyaluronic acid synthase 2[/E2], hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "procollagen I", "entity_1_idx": [[78, 91]], "entity_1_idx_in_text_with_entity_marker": [82, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hyaluronic acid synthase 2", "entity_2_idx": [[115, 141]], "entity_2_idx_in_text_with_entity_marker": [128, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p3", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins ([E1]procollagen I[/E1], collagenase, elastin, hyaluronic acid synthase 2, [E2]hyaluronidase[/E2], fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "procollagen I", "entity_1_idx": [[78, 91]], "entity_1_idx_in_text_with_entity_marker": [82, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hyaluronidase", "entity_2_idx": [[143, 156]], "entity_2_idx_in_text_with_entity_marker": [156, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p4", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins ([E1]procollagen I[/E1], collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, [E2]fibronectin[/E2], cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "procollagen I", "entity_1_idx": [[78, 91]], "entity_1_idx_in_text_with_entity_marker": [82, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibronectin", "entity_2_idx": [[158, 169]], "entity_2_idx_in_text_with_entity_marker": [171, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p5", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins ([E1]procollagen I[/E1], collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, [E2]cd44[/E2], fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "procollagen I", "entity_1_idx": [[78, 91]], "entity_1_idx_in_text_with_entity_marker": [82, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cd44", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p6", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins ([E1]procollagen I[/E1], collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, [E2]fibromodulin[/E2], and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "procollagen I", "entity_1_idx": [[78, 91]], "entity_1_idx_in_text_with_entity_marker": [82, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibromodulin", "entity_2_idx": [[177, 189]], "entity_2_idx_in_text_with_entity_marker": [190, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p7", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins ([E1]procollagen I[/E1], collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and [E2]decorin[/E2]) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "procollagen I", "entity_1_idx": [[78, 91]], "entity_1_idx_in_text_with_entity_marker": [82, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "decorin", "entity_2_idx": [[195, 202]], "entity_2_idx_in_text_with_entity_marker": [208, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p8", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, [E1]collagenase[/E1], [E2]elastin[/E2], hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "collagenase", "entity_1_idx": [[93, 104]], "entity_1_idx_in_text_with_entity_marker": [97, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "elastin", "entity_2_idx": [[106, 113]], "entity_2_idx_in_text_with_entity_marker": [119, 126], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p9", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, [E1]collagenase[/E1], elastin, [E2]hyaluronic acid synthase 2[/E2], hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "collagenase", "entity_1_idx": [[93, 104]], "entity_1_idx_in_text_with_entity_marker": [97, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hyaluronic acid synthase 2", "entity_2_idx": [[115, 141]], "entity_2_idx_in_text_with_entity_marker": [128, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p10", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, [E1]collagenase[/E1], elastin, hyaluronic acid synthase 2, [E2]hyaluronidase[/E2], fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "collagenase", "entity_1_idx": [[93, 104]], "entity_1_idx_in_text_with_entity_marker": [97, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hyaluronidase", "entity_2_idx": [[143, 156]], "entity_2_idx_in_text_with_entity_marker": [156, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p11", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, [E1]collagenase[/E1], elastin, hyaluronic acid synthase 2, hyaluronidase, [E2]fibronectin[/E2], cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "collagenase", "entity_1_idx": [[93, 104]], "entity_1_idx_in_text_with_entity_marker": [97, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibronectin", "entity_2_idx": [[158, 169]], "entity_2_idx_in_text_with_entity_marker": [171, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p12", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, [E1]collagenase[/E1], elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, [E2]cd44[/E2], fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "collagenase", "entity_1_idx": [[93, 104]], "entity_1_idx_in_text_with_entity_marker": [97, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cd44", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p13", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, [E1]collagenase[/E1], elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, [E2]fibromodulin[/E2], and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "collagenase", "entity_1_idx": [[93, 104]], "entity_1_idx_in_text_with_entity_marker": [97, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibromodulin", "entity_2_idx": [[177, 189]], "entity_2_idx_in_text_with_entity_marker": [190, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p14", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, [E1]collagenase[/E1], elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and [E2]decorin[/E2]) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "collagenase", "entity_1_idx": [[93, 104]], "entity_1_idx_in_text_with_entity_marker": [97, 108], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "decorin", "entity_2_idx": [[195, 202]], "entity_2_idx_in_text_with_entity_marker": [208, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p15", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, [E1]elastin[/E1], [E2]hyaluronic acid synthase 2[/E2], hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "elastin", "entity_1_idx": [[106, 113]], "entity_1_idx_in_text_with_entity_marker": [110, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hyaluronic acid synthase 2", "entity_2_idx": [[115, 141]], "entity_2_idx_in_text_with_entity_marker": [128, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p16", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, [E1]elastin[/E1], hyaluronic acid synthase 2, [E2]hyaluronidase[/E2], fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "elastin", "entity_1_idx": [[106, 113]], "entity_1_idx_in_text_with_entity_marker": [110, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hyaluronidase", "entity_2_idx": [[143, 156]], "entity_2_idx_in_text_with_entity_marker": [156, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p17", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, [E1]elastin[/E1], hyaluronic acid synthase 2, hyaluronidase, [E2]fibronectin[/E2], cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "elastin", "entity_1_idx": [[106, 113]], "entity_1_idx_in_text_with_entity_marker": [110, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibronectin", "entity_2_idx": [[158, 169]], "entity_2_idx_in_text_with_entity_marker": [171, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p18", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, [E1]elastin[/E1], hyaluronic acid synthase 2, hyaluronidase, fibronectin, [E2]cd44[/E2], fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "elastin", "entity_1_idx": [[106, 113]], "entity_1_idx_in_text_with_entity_marker": [110, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cd44", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p19", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, [E1]elastin[/E1], hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, [E2]fibromodulin[/E2], and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "elastin", "entity_1_idx": [[106, 113]], "entity_1_idx_in_text_with_entity_marker": [110, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibromodulin", "entity_2_idx": [[177, 189]], "entity_2_idx_in_text_with_entity_marker": [190, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p20", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, [E1]elastin[/E1], hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and [E2]decorin[/E2]) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "elastin", "entity_1_idx": [[106, 113]], "entity_1_idx_in_text_with_entity_marker": [110, 117], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "decorin", "entity_2_idx": [[195, 202]], "entity_2_idx_in_text_with_entity_marker": [208, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p21", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, [E1]hyaluronic acid synthase 2[/E1], [E2]hyaluronidase[/E2], fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hyaluronic acid synthase 2", "entity_1_idx": [[115, 141]], "entity_1_idx_in_text_with_entity_marker": [119, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hyaluronidase", "entity_2_idx": [[143, 156]], "entity_2_idx_in_text_with_entity_marker": [156, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p22", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, [E1]hyaluronic acid synthase 2[/E1], hyaluronidase, [E2]fibronectin[/E2], cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hyaluronic acid synthase 2", "entity_1_idx": [[115, 141]], "entity_1_idx_in_text_with_entity_marker": [119, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibronectin", "entity_2_idx": [[158, 169]], "entity_2_idx_in_text_with_entity_marker": [171, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p23", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, [E1]hyaluronic acid synthase 2[/E1], hyaluronidase, fibronectin, [E2]cd44[/E2], fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hyaluronic acid synthase 2", "entity_1_idx": [[115, 141]], "entity_1_idx_in_text_with_entity_marker": [119, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cd44", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p24", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, [E1]hyaluronic acid synthase 2[/E1], hyaluronidase, fibronectin, cd44, [E2]fibromodulin[/E2], and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hyaluronic acid synthase 2", "entity_1_idx": [[115, 141]], "entity_1_idx_in_text_with_entity_marker": [119, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibromodulin", "entity_2_idx": [[177, 189]], "entity_2_idx_in_text_with_entity_marker": [190, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p25", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, [E1]hyaluronic acid synthase 2[/E1], hyaluronidase, fibronectin, cd44, fibromodulin, and [E2]decorin[/E2]) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hyaluronic acid synthase 2", "entity_1_idx": [[115, 141]], "entity_1_idx_in_text_with_entity_marker": [119, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "decorin", "entity_2_idx": [[195, 202]], "entity_2_idx_in_text_with_entity_marker": [208, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p26", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, [E1]hyaluronidase[/E1], [E2]fibronectin[/E2], cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hyaluronidase", "entity_1_idx": [[143, 156]], "entity_1_idx_in_text_with_entity_marker": [147, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibronectin", "entity_2_idx": [[158, 169]], "entity_2_idx_in_text_with_entity_marker": [171, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p27", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, [E1]hyaluronidase[/E1], fibronectin, [E2]cd44[/E2], fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hyaluronidase", "entity_1_idx": [[143, 156]], "entity_1_idx_in_text_with_entity_marker": [147, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cd44", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p28", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, [E1]hyaluronidase[/E1], fibronectin, cd44, [E2]fibromodulin[/E2], and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hyaluronidase", "entity_1_idx": [[143, 156]], "entity_1_idx_in_text_with_entity_marker": [147, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibromodulin", "entity_2_idx": [[177, 189]], "entity_2_idx_in_text_with_entity_marker": [190, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p29", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, [E1]hyaluronidase[/E1], fibronectin, cd44, fibromodulin, and [E2]decorin[/E2]) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hyaluronidase", "entity_1_idx": [[143, 156]], "entity_1_idx_in_text_with_entity_marker": [147, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "decorin", "entity_2_idx": [[195, 202]], "entity_2_idx_in_text_with_entity_marker": [208, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p30", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, [E1]fibronectin[/E1], [E2]cd44[/E2], fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "fibronectin", "entity_1_idx": [[158, 169]], "entity_1_idx_in_text_with_entity_marker": [162, 173], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cd44", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p31", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, [E1]fibronectin[/E1], cd44, [E2]fibromodulin[/E2], and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "fibronectin", "entity_1_idx": [[158, 169]], "entity_1_idx_in_text_with_entity_marker": [162, 173], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibromodulin", "entity_2_idx": [[177, 189]], "entity_2_idx_in_text_with_entity_marker": [190, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p32", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, [E1]fibronectin[/E1], cd44, fibromodulin, and [E2]decorin[/E2]) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "fibronectin", "entity_1_idx": [[158, 169]], "entity_1_idx_in_text_with_entity_marker": [162, 173], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "decorin", "entity_2_idx": [[195, 202]], "entity_2_idx_in_text_with_entity_marker": [208, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p33", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, [E1]cd44[/E1], [E2]fibromodulin[/E2], and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cd44", "entity_1_idx": [[171, 175]], "entity_1_idx_in_text_with_entity_marker": [175, 179], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fibromodulin", "entity_2_idx": [[177, 189]], "entity_2_idx_in_text_with_entity_marker": [190, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p34", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, [E1]cd44[/E1], fibromodulin, and [E2]decorin[/E2]) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cd44", "entity_1_idx": [[171, 175]], "entity_1_idx_in_text_with_entity_marker": [175, 179], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "decorin", "entity_2_idx": [[195, 202]], "entity_2_idx_in_text_with_entity_marker": [208, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d24.s200_AIMed.d24.s200.p35", "text": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "text_with_entity_marker": "Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, [E1]fibromodulin[/E1], and [E2]decorin[/E2]) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "fibromodulin", "entity_1_idx": [[177, 189]], "entity_1_idx_in_text_with_entity_marker": [181, 193], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "decorin", "entity_2_idx": [[195, 202]], "entity_2_idx_in_text_with_entity_marker": [208, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d133.s1132_AIMed.d133.s1132.p0", "text": "JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.", "text_with_entity_marker": "[E1]JNK1[/E1]: a protein kinase stimulated by UV light and [E2]Ha-Ras[/E2] that binds and phosphorylates the c-Jun activation domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JNK1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Ha-Ras", "entity_2_idx": [[50, 56]], "entity_2_idx_in_text_with_entity_marker": [63, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d133.s1132_AIMed.d133.s1132.p1", "text": "JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.", "text_with_entity_marker": "[E1]JNK1[/E1]: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the [E2]c-Jun[/E2] activation domain.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "JNK1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[91, 96]], "entity_2_idx_in_text_with_entity_marker": [104, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d133.s1132_AIMed.d133.s1132.p2", "text": "JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.", "text_with_entity_marker": "JNK1: a protein kinase stimulated by UV light and [E1]Ha-Ras[/E1] that binds and phosphorylates the [E2]c-Jun[/E2] activation domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ha-Ras", "entity_1_idx": [[50, 56]], "entity_1_idx_in_text_with_entity_marker": [54, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[91, 96]], "entity_2_idx_in_text_with_entity_marker": [104, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d133.s1133_AIMed.d133.s1133.p0", "text": "The ultraviolet (UV) response of mammalian cells is characterized by a rapid and selective increase in gene expression mediated by AP-1 and NF-kappa B.", "text_with_entity_marker": "The ultraviolet (UV) response of mammalian cells is characterized by a rapid and selective increase in gene expression mediated by [E1]AP-1[/E1] and [E2]NF-kappa B[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AP-1", "entity_1_idx": [[131, 135]], "entity_1_idx_in_text_with_entity_marker": [135, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NF-kappa B", "entity_2_idx": [[140, 150]], "entity_2_idx_in_text_with_entity_marker": [153, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d133.s1134_AIMed.d133.s1134.p0", "text": "The effect on AP-1 transcriptional activity results, in part, from enhanced phosphorylation of the c-Jun NH2-terminal activation domain.", "text_with_entity_marker": "The effect on [E1]AP-1[/E1] transcriptional activity results, in part, from enhanced phosphorylation of the [E2]c-Jun[/E2] NH2-terminal activation domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AP-1", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[99, 104]], "entity_2_idx_in_text_with_entity_marker": [112, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d133.s1135_AIMed.d133.s1135.p0", "text": "Here, we describe the molecular cloning and characterization of JNK1, a distant relative of the MAP kinase group that is activated by dual phosphorylation at Thr and Tyr during the UV response.", "text_with_entity_marker": "Here, we describe the molecular cloning and characterization of [E1]JNK1[/E1], a distant relative of the [E2]MAP kinase[/E2] group that is activated by dual phosphorylation at Thr and Tyr during the UV response.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "JNK1", "entity_1_idx": [[64, 68]], "entity_1_idx_in_text_with_entity_marker": [68, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase", "entity_2_idx": [[96, 106]], "entity_2_idx_in_text_with_entity_marker": [109, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d133.s1136_AIMed.d133.s1136.p0", "text": "Significantly, Ha-Ras partially activates JNK1 and potentiates the activation caused by UV.", "text_with_entity_marker": "Significantly, [E1]Ha-Ras[/E1] partially activates [E2]JNK1[/E2] and potentiates the activation caused by UV.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Ha-Ras", "entity_1_idx": [[15, 21]], "entity_1_idx_in_text_with_entity_marker": [19, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "JNK1", "entity_2_idx": [[42, 46]], "entity_2_idx_in_text_with_entity_marker": [55, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d133.s1137_AIMed.d133.s1137.p0", "text": "JNK1 binds to the c-Jun transactivation domain and phosphorylates it on Ser-63 and Ser-73.", "text_with_entity_marker": "[E1]JNK1[/E1] binds to the [E2]c-Jun[/E2] transactivation domain and phosphorylates it on Ser-63 and Ser-73.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "JNK1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[18, 23]], "entity_2_idx_in_text_with_entity_marker": [31, 36], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1456_AIMed.d173.s1456.p0", "text": "The kinetics of amyloid fibril formation by beta-amyloid peptide (Abeta) are typical of a nucleation-dependent polymerization mechanism.", "text_with_entity_marker": "The kinetics of amyloid fibril formation by [E1]beta-amyloid peptide[/E1] ([E2]Abeta[/E2]) are typical of a nucleation-dependent polymerization mechanism.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta-amyloid peptide", "entity_1_idx": [[44, 64]], "entity_1_idx_in_text_with_entity_marker": [48, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1459_AIMed.d173.s1459.p0", "text": "Fusion proteins were created by linking the Abeta fragment to a LexA DNA-binding domain (bait) and also to a B42 transactivation domain (prey).", "text_with_entity_marker": "Fusion proteins were created by linking the [E1]Abeta[/E1] fragment to a [E2]LexA[/E2] DNA-binding domain (bait) and also to a B42 transactivation domain (prey).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Abeta", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LexA", "entity_2_idx": [[64, 68]], "entity_2_idx_in_text_with_entity_marker": [77, 81], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1459_AIMed.d173.s1459.p1", "text": "Fusion proteins were created by linking the Abeta fragment to a LexA DNA-binding domain (bait) and also to a B42 transactivation domain (prey).", "text_with_entity_marker": "Fusion proteins were created by linking the [E1]Abeta[/E1] fragment to a LexA DNA-binding domain (bait) and also to a [E2]B42[/E2] transactivation domain (prey).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Abeta", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B42", "entity_2_idx": [[109, 112]], "entity_2_idx_in_text_with_entity_marker": [122, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1459_AIMed.d173.s1459.p2", "text": "Fusion proteins were created by linking the Abeta fragment to a LexA DNA-binding domain (bait) and also to a B42 transactivation domain (prey).", "text_with_entity_marker": "Fusion proteins were created by linking the Abeta fragment to a [E1]LexA[/E1] DNA-binding domain (bait) and also to a [E2]B42[/E2] transactivation domain (prey).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[64, 68]], "entity_1_idx_in_text_with_entity_marker": [68, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B42", "entity_2_idx": [[109, 112]], "entity_2_idx_in_text_with_entity_marker": [122, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1460_AIMed.d173.s1460.p0", "text": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.", "text_with_entity_marker": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring [E1]lacZ[/E1] ([E2]beta-galactosidase[/E2]) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lacZ", "entity_1_idx": [[120, 124]], "entity_1_idx_in_text_with_entity_marker": [124, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta-galactosidase", "entity_2_idx": [[126, 144]], "entity_2_idx_in_text_with_entity_marker": [139, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1460_AIMed.d173.s1460.p1", "text": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.", "text_with_entity_marker": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring [E1]lacZ[/E1] (beta-galactosidase) and [E2]LEU2[/E2] (leucine utilization) genes under the control of LexA-dependent operators.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lacZ", "entity_1_idx": [[120, 124]], "entity_1_idx_in_text_with_entity_marker": [124, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LEU2", "entity_2_idx": [[150, 154]], "entity_2_idx_in_text_with_entity_marker": [163, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1460_AIMed.d173.s1460.p2", "text": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.", "text_with_entity_marker": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring [E1]lacZ[/E1] (beta-galactosidase) and LEU2 ([E2]leucine utilization[/E2]) genes under the control of LexA-dependent operators.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lacZ", "entity_1_idx": [[120, 124]], "entity_1_idx_in_text_with_entity_marker": [124, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "leucine utilization", "entity_2_idx": [[156, 175]], "entity_2_idx_in_text_with_entity_marker": [169, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1460_AIMed.d173.s1460.p3", "text": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.", "text_with_entity_marker": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ ([E1]beta-galactosidase[/E1]) and [E2]LEU2[/E2] (leucine utilization) genes under the control of LexA-dependent operators.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta-galactosidase", "entity_1_idx": [[126, 144]], "entity_1_idx_in_text_with_entity_marker": [130, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LEU2", "entity_2_idx": [[150, 154]], "entity_2_idx_in_text_with_entity_marker": [163, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1460_AIMed.d173.s1460.p4", "text": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.", "text_with_entity_marker": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ ([E1]beta-galactosidase[/E1]) and LEU2 ([E2]leucine utilization[/E2]) genes under the control of LexA-dependent operators.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta-galactosidase", "entity_1_idx": [[126, 144]], "entity_1_idx_in_text_with_entity_marker": [130, 148], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "leucine utilization", "entity_2_idx": [[156, 175]], "entity_2_idx_in_text_with_entity_marker": [169, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1460_AIMed.d173.s1460.p5", "text": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and LEU2 (leucine utilization) genes under the control of LexA-dependent operators.", "text_with_entity_marker": "Protein-protein interactions were measured by expression of these fusion proteins in Saccharomyces cerevisiae harboring lacZ (beta-galactosidase) and [E1]LEU2[/E1] ([E2]leucine utilization[/E2]) genes under the control of LexA-dependent operators.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEU2", "entity_1_idx": [[150, 154]], "entity_1_idx_in_text_with_entity_marker": [154, 158], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "leucine utilization", "entity_2_idx": [[156, 175]], "entity_2_idx_in_text_with_entity_marker": [169, 188], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p0", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "[E1]LexA[/E1] protein fused to the Drosophila protein [E2]bicoid[/E2] (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bicoid", "entity_2_idx": [[45, 51]], "entity_2_idx_in_text_with_entity_marker": [58, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p1", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "[E1]LexA[/E1] protein fused to the Drosophila protein bicoid ([E2]LexA[/E2]-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LexA", "entity_2_idx": [[53, 57]], "entity_2_idx_in_text_with_entity_marker": [66, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p2", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "[E1]LexA[/E1] protein fused to the Drosophila protein bicoid (LexA-[E2]bicoid[/E2]) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bicoid", "entity_2_idx": [[58, 64]], "entity_2_idx_in_text_with_entity_marker": [71, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p3", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "[E1]LexA[/E1] protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the [E2]B42[/E2] fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B42", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p4", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "[E1]LexA[/E1] protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to [E2]Abeta[/E2], indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p5", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "[E1]LexA[/E1] protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed [E2]Abeta[/E2]-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p6", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "[E1]LexA[/E1] protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-[E2]Abeta[/E2] interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p7", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein [E1]bicoid[/E1] ([E2]LexA[/E2]-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bicoid", "entity_1_idx": [[45, 51]], "entity_1_idx_in_text_with_entity_marker": [49, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LexA", "entity_2_idx": [[53, 57]], "entity_2_idx_in_text_with_entity_marker": [66, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p8", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein [E1]bicoid[/E1] (LexA-[E2]bicoid[/E2]) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bicoid", "entity_1_idx": [[45, 51]], "entity_1_idx_in_text_with_entity_marker": [49, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bicoid", "entity_2_idx": [[58, 64]], "entity_2_idx_in_text_with_entity_marker": [71, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p9", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein [E1]bicoid[/E1] (LexA-bicoid) failed to interact with the [E2]B42[/E2] fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bicoid", "entity_1_idx": [[45, 51]], "entity_1_idx_in_text_with_entity_marker": [49, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B42", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p10", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein [E1]bicoid[/E1] (LexA-bicoid) failed to interact with the B42 fragment fused to [E2]Abeta[/E2], indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bicoid", "entity_1_idx": [[45, 51]], "entity_1_idx_in_text_with_entity_marker": [49, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p11", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein [E1]bicoid[/E1] (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed [E2]Abeta[/E2]-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bicoid", "entity_1_idx": [[45, 51]], "entity_1_idx_in_text_with_entity_marker": [49, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p12", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein [E1]bicoid[/E1] (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-[E2]Abeta[/E2] interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bicoid", "entity_1_idx": [[45, 51]], "entity_1_idx_in_text_with_entity_marker": [49, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p13", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid ([E1]LexA[/E1]-[E2]bicoid[/E2]) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[53, 57]], "entity_1_idx_in_text_with_entity_marker": [57, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "bicoid", "entity_2_idx": [[58, 64]], "entity_2_idx_in_text_with_entity_marker": [71, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p14", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid ([E1]LexA[/E1]-bicoid) failed to interact with the [E2]B42[/E2] fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[53, 57]], "entity_1_idx_in_text_with_entity_marker": [57, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B42", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p15", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid ([E1]LexA[/E1]-bicoid) failed to interact with the B42 fragment fused to [E2]Abeta[/E2], indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[53, 57]], "entity_1_idx_in_text_with_entity_marker": [57, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p16", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid ([E1]LexA[/E1]-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed [E2]Abeta[/E2]-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[53, 57]], "entity_1_idx_in_text_with_entity_marker": [57, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p17", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid ([E1]LexA[/E1]-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-[E2]Abeta[/E2] interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[53, 57]], "entity_1_idx_in_text_with_entity_marker": [57, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p18", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid (LexA-[E1]bicoid[/E1]) failed to interact with the [E2]B42[/E2] fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bicoid", "entity_1_idx": [[58, 64]], "entity_1_idx_in_text_with_entity_marker": [62, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B42", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p19", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid (LexA-[E1]bicoid[/E1]) failed to interact with the B42 fragment fused to [E2]Abeta[/E2], indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bicoid", "entity_1_idx": [[58, 64]], "entity_1_idx_in_text_with_entity_marker": [62, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p20", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid (LexA-[E1]bicoid[/E1]) failed to interact with the B42 fragment fused to Abeta, indicating that the observed [E2]Abeta[/E2]-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bicoid", "entity_1_idx": [[58, 64]], "entity_1_idx_in_text_with_entity_marker": [62, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p21", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid (LexA-[E1]bicoid[/E1]) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-[E2]Abeta[/E2] interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "bicoid", "entity_1_idx": [[58, 64]], "entity_1_idx_in_text_with_entity_marker": [62, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p22", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the [E1]B42[/E1] fragment fused to [E2]Abeta[/E2], indicating that the observed Abeta-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "B42", "entity_1_idx": [[94, 97]], "entity_1_idx_in_text_with_entity_marker": [98, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p23", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the [E1]B42[/E1] fragment fused to Abeta, indicating that the observed [E2]Abeta[/E2]-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "B42", "entity_1_idx": [[94, 97]], "entity_1_idx_in_text_with_entity_marker": [98, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p24", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the [E1]B42[/E1] fragment fused to Abeta, indicating that the observed Abeta-[E2]Abeta[/E2] interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "B42", "entity_1_idx": [[94, 97]], "entity_1_idx_in_text_with_entity_marker": [98, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p25", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to [E1]Abeta[/E1], indicating that the observed [E2]Abeta[/E2]-Abeta interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Abeta", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[152, 157]], "entity_2_idx_in_text_with_entity_marker": [165, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p26", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to [E1]Abeta[/E1], indicating that the observed Abeta-[E2]Abeta[/E2] interaction was specific.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Abeta", "entity_1_idx": [[116, 121]], "entity_1_idx_in_text_with_entity_marker": [120, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1462_AIMed.d173.s1462.p27", "text": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed Abeta-Abeta interaction was specific.", "text_with_entity_marker": "LexA protein fused to the Drosophila protein bicoid (LexA-bicoid) failed to interact with the B42 fragment fused to Abeta, indicating that the observed [E1]Abeta[/E1]-[E2]Abeta[/E2] interaction was specific.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Abeta", "entity_1_idx": [[152, 157]], "entity_1_idx_in_text_with_entity_marker": [156, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1463_AIMed.d173.s1463.p0", "text": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "text_with_entity_marker": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing [E1]LexA[/E1]-[E2]Abeta[/E2] bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[110, 114]], "entity_1_idx_in_text_with_entity_marker": [114, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1463_AIMed.d173.s1463.p1", "text": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "text_with_entity_marker": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing [E1]LexA[/E1]-Abeta bait when the [E2]B42[/E2] transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[110, 114]], "entity_1_idx_in_text_with_entity_marker": [114, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B42", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1463_AIMed.d173.s1463.p2", "text": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "text_with_entity_marker": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing [E1]LexA[/E1]-Abeta bait when the B42 transactivation domain was fused to an [E2]Abeta[/E2] fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LexA", "entity_1_idx": [[110, 114]], "entity_1_idx_in_text_with_entity_marker": [114, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1463_AIMed.d173.s1463.p3", "text": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "text_with_entity_marker": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-[E1]Abeta[/E1] bait when the [E2]B42[/E2] transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Abeta", "entity_1_idx": [[115, 120]], "entity_1_idx_in_text_with_entity_marker": [119, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "B42", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1463_AIMed.d173.s1463.p4", "text": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "text_with_entity_marker": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-[E1]Abeta[/E1] bait when the B42 transactivation domain was fused to an [E2]Abeta[/E2] fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Abeta", "entity_1_idx": [[115, 120]], "entity_1_idx_in_text_with_entity_marker": [119, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d173.s1463_AIMed.d173.s1463.p5", "text": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the B42 transactivation domain was fused to an Abeta fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "text_with_entity_marker": "Specificity was further shown by the finding that no significant interaction was observed in yeast expressing LexA-Abeta bait when the [E1]B42[/E1] transactivation domain was fused to an [E2]Abeta[/E2] fragment with Phe-Phe at residues 19 and 20 replaced by Thr-Thr (AbetaTT), a finding that is consistent with in vitro observations made by others.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "B42", "entity_1_idx": [[135, 138]], "entity_1_idx_in_text_with_entity_marker": [139, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Abeta", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1072_AIMed.d126.s1072.p0", "text": "The rates of commitment to renaturation of rhodanese and glutamine synthetase in the presence of the groE chaperonins.", "text_with_entity_marker": "The rates of commitment to renaturation of [E1]rhodanese[/E1] and [E2]glutamine synthetase[/E2] in the presence of the groE chaperonins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "rhodanese", "entity_1_idx": [[43, 52]], "entity_1_idx_in_text_with_entity_marker": [47, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "glutamine synthetase", "entity_2_idx": [[57, 77]], "entity_2_idx_in_text_with_entity_marker": [70, 90], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1074_AIMed.d126.s1074.p0", "text": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.", "text_with_entity_marker": "Using immunoprecipitation techniques, we have determined the rates at which [E1]rhodanese[/E1] and [E2]glutamine synthetase[/E2] (GS) are released from groEL in a form committed to refold to active enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "rhodanese", "entity_1_idx": [[76, 85]], "entity_1_idx_in_text_with_entity_marker": [80, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "glutamine synthetase", "entity_2_idx": [[90, 110]], "entity_2_idx_in_text_with_entity_marker": [103, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1074_AIMed.d126.s1074.p1", "text": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.", "text_with_entity_marker": "Using immunoprecipitation techniques, we have determined the rates at which [E1]rhodanese[/E1] and glutamine synthetase ([E2]GS[/E2]) are released from groEL in a form committed to refold to active enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "rhodanese", "entity_1_idx": [[76, 85]], "entity_1_idx_in_text_with_entity_marker": [80, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GS", "entity_2_idx": [[112, 114]], "entity_2_idx_in_text_with_entity_marker": [125, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1074_AIMed.d126.s1074.p2", "text": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.", "text_with_entity_marker": "Using immunoprecipitation techniques, we have determined the rates at which [E1]rhodanese[/E1] and glutamine synthetase (GS) are released from [E2]groEL[/E2] in a form committed to refold to active enzyme.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "rhodanese", "entity_1_idx": [[76, 85]], "entity_1_idx_in_text_with_entity_marker": [80, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1074_AIMed.d126.s1074.p3", "text": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.", "text_with_entity_marker": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and [E1]glutamine synthetase[/E1] ([E2]GS[/E2]) are released from groEL in a form committed to refold to active enzyme.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "glutamine synthetase", "entity_1_idx": [[90, 110]], "entity_1_idx_in_text_with_entity_marker": [94, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GS", "entity_2_idx": [[112, 114]], "entity_2_idx_in_text_with_entity_marker": [125, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1074_AIMed.d126.s1074.p4", "text": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.", "text_with_entity_marker": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and [E1]glutamine synthetase[/E1] (GS) are released from [E2]groEL[/E2] in a form committed to refold to active enzyme.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "glutamine synthetase", "entity_1_idx": [[90, 110]], "entity_1_idx_in_text_with_entity_marker": [94, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1074_AIMed.d126.s1074.p5", "text": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.", "text_with_entity_marker": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase ([E1]GS[/E1]) are released from [E2]groEL[/E2] in a form committed to refold to active enzyme.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GS", "entity_1_idx": [[112, 114]], "entity_1_idx_in_text_with_entity_marker": [116, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1075_AIMed.d126.s1075.p0", "text": "Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable \"folding arrested\" complexes with groEL.", "text_with_entity_marker": "[E1]Rhodanese[/E1] and [E2]glutamine synthetase[/E2] were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable \"folding arrested\" complexes with groEL.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rhodanese", "entity_1_idx": [[0, 9]], "entity_1_idx_in_text_with_entity_marker": [4, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "glutamine synthetase", "entity_2_idx": [[14, 34]], "entity_2_idx_in_text_with_entity_marker": [27, 47], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1075_AIMed.d126.s1075.p1", "text": "Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable \"folding arrested\" complexes with groEL.", "text_with_entity_marker": "[E1]Rhodanese[/E1] and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable \"folding arrested\" complexes with [E2]groEL[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Rhodanese", "entity_1_idx": [[0, 9]], "entity_1_idx_in_text_with_entity_marker": [4, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1075_AIMed.d126.s1075.p2", "text": "Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable \"folding arrested\" complexes with groEL.", "text_with_entity_marker": "Rhodanese and [E1]glutamine synthetase[/E1] were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable \"folding arrested\" complexes with [E2]groEL[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "glutamine synthetase", "entity_1_idx": [[14, 34]], "entity_1_idx_in_text_with_entity_marker": [18, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1078_AIMed.d126.s1078.p0", "text": "At 25 degrees C, the rate profiles indicate the release and commitment to folding of GS to its native state occurs far earlier (t1/2 < 1 min) than for rhodanese (t1/2 = 5 min).", "text_with_entity_marker": "At 25 degrees C, the rate profiles indicate the release and commitment to folding of [E1]GS[/E1] to its native state occurs far earlier (t1/2 < 1 min) than for [E2]rhodanese[/E2] (t1/2 = 5 min).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GS", "entity_1_idx": [[85, 87]], "entity_1_idx_in_text_with_entity_marker": [89, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "rhodanese", "entity_2_idx": [[151, 160]], "entity_2_idx_in_text_with_entity_marker": [164, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1080_AIMed.d126.s1080.p0", "text": "In contrast, the renaturation rate for rhodanese with the groE chaperonins mirrored the committed renaturation rates following groEL depletion.", "text_with_entity_marker": "In contrast, the renaturation rate for [E1]rhodanese[/E1] with the groE chaperonins mirrored the committed renaturation rates following [E2]groEL[/E2] depletion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "rhodanese", "entity_1_idx": [[39, 48]], "entity_1_idx_in_text_with_entity_marker": [43, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[127, 132]], "entity_2_idx_in_text_with_entity_marker": [140, 145], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1081_AIMed.d126.s1081.p0", "text": "This suggests that rhodanese must interact with groEL throughout most of its folding reaction before it acquires a folding competent (groE independent) state.", "text_with_entity_marker": "This suggests that [E1]rhodanese[/E1] must interact with [E2]groEL[/E2] throughout most of its folding reaction before it acquires a folding competent (groE independent) state.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "rhodanese", "entity_1_idx": [[19, 28]], "entity_1_idx_in_text_with_entity_marker": [23, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[48, 53]], "entity_2_idx_in_text_with_entity_marker": [61, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1082_AIMed.d126.s1082.p0", "text": "If current models of chaperonin mechanism are correct, rhodanese undergoes more rebinding and release cycles than does GS.", "text_with_entity_marker": "If current models of chaperonin mechanism are correct, [E1]rhodanese[/E1] undergoes more rebinding and release cycles than does [E2]GS[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "rhodanese", "entity_1_idx": [[55, 64]], "entity_1_idx_in_text_with_entity_marker": [59, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GS", "entity_2_idx": [[119, 121]], "entity_2_idx_in_text_with_entity_marker": [132, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d144.s1216_AIMed.d144.s1216.p0", "text": "The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit.", "text_with_entity_marker": "The [E1]retinoblastoma protein[/E1] associates with the [E2]protein phosphatase type 1[/E2] catalytic subunit.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "retinoblastoma protein", "entity_1_idx": [[4, 26]], "entity_1_idx_in_text_with_entity_marker": [8, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein phosphatase type 1", "entity_2_idx": [[47, 73]], "entity_2_idx_in_text_with_entity_marker": [60, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d144.s1217_AIMed.d144.s1217.p0", "text": "The retinoblastoma protein (p110RB) interacts with many cellular proteins in complexes potentially important for its growth-suppressing function.", "text_with_entity_marker": "The [E1]retinoblastoma protein[/E1] ([E2]p110RB[/E2]) interacts with many cellular proteins in complexes potentially important for its growth-suppressing function.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinoblastoma protein", "entity_1_idx": [[4, 26]], "entity_1_idx_in_text_with_entity_marker": [8, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p110RB", "entity_2_idx": [[28, 34]], "entity_2_idx_in_text_with_entity_marker": [41, 47], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d144.s1219_AIMed.d144.s1219.p0", "text": "One clone encodes a novel type 1 protein phosphatase catalytic subunit (PP-1 alpha 2), which differs from the originally defined PP-1 alpha by an amino-terminal 11-amino-acid insert.", "text_with_entity_marker": "One clone encodes a novel [E1]type 1 protein phosphatase[/E1] catalytic subunit ([E2]PP-1 alpha 2[/E2]), which differs from the originally defined PP-1 alpha by an amino-terminal 11-amino-acid insert.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "type 1 protein phosphatase", "entity_1_idx": [[26, 52]], "entity_1_idx_in_text_with_entity_marker": [30, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP-1 alpha 2", "entity_2_idx": [[72, 84]], "entity_2_idx_in_text_with_entity_marker": [85, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d144.s1219_AIMed.d144.s1219.p1", "text": "One clone encodes a novel type 1 protein phosphatase catalytic subunit (PP-1 alpha 2), which differs from the originally defined PP-1 alpha by an amino-terminal 11-amino-acid insert.", "text_with_entity_marker": "One clone encodes a novel [E1]type 1 protein phosphatase[/E1] catalytic subunit (PP-1 alpha 2), which differs from the originally defined [E2]PP-1 alpha[/E2] by an amino-terminal 11-amino-acid insert.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "type 1 protein phosphatase", "entity_1_idx": [[26, 52]], "entity_1_idx_in_text_with_entity_marker": [30, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP-1 alpha", "entity_2_idx": [[129, 139]], "entity_2_idx_in_text_with_entity_marker": [142, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d144.s1219_AIMed.d144.s1219.p2", "text": "One clone encodes a novel type 1 protein phosphatase catalytic subunit (PP-1 alpha 2), which differs from the originally defined PP-1 alpha by an amino-terminal 11-amino-acid insert.", "text_with_entity_marker": "One clone encodes a novel type 1 protein phosphatase catalytic subunit ([E1]PP-1 alpha 2[/E1]), which differs from the originally defined [E2]PP-1 alpha[/E2] by an amino-terminal 11-amino-acid insert.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PP-1 alpha 2", "entity_1_idx": [[72, 84]], "entity_1_idx_in_text_with_entity_marker": [76, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP-1 alpha", "entity_2_idx": [[129, 139]], "entity_2_idx_in_text_with_entity_marker": [142, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d144.s1220_AIMed.d144.s1220.p0", "text": "In vitro-binding assays demonstrated that PP-1 alpha isoforms preferentially bind the hypophosphorylated form of p110RB.", "text_with_entity_marker": "In vitro-binding assays demonstrated that [E1]PP-1 alpha[/E1] isoforms preferentially bind the hypophosphorylated form of [E2]p110RB[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PP-1 alpha", "entity_1_idx": [[42, 52]], "entity_1_idx_in_text_with_entity_marker": [46, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p110RB", "entity_2_idx": [[113, 119]], "entity_2_idx_in_text_with_entity_marker": [126, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d144.s1221_AIMed.d144.s1221.p0", "text": "Moreover, similar p110RB sequences are required for binding PP-1 alpha 2 and SV40 large T antigen.", "text_with_entity_marker": "Moreover, similar [E1]p110RB[/E1] sequences are required for binding [E2]PP-1 alpha 2[/E2] and SV40 large T antigen.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p110RB", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP-1 alpha 2", "entity_2_idx": [[60, 72]], "entity_2_idx_in_text_with_entity_marker": [73, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d144.s1221_AIMed.d144.s1221.p1", "text": "Moreover, similar p110RB sequences are required for binding PP-1 alpha 2 and SV40 large T antigen.", "text_with_entity_marker": "Moreover, similar [E1]p110RB[/E1] sequences are required for binding PP-1 alpha 2 and [E2]SV40 large T antigen[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p110RB", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SV40 large T antigen", "entity_2_idx": [[77, 97]], "entity_2_idx_in_text_with_entity_marker": [90, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d144.s1221_AIMed.d144.s1221.p2", "text": "Moreover, similar p110RB sequences are required for binding PP-1 alpha 2 and SV40 large T antigen.", "text_with_entity_marker": "Moreover, similar p110RB sequences are required for binding [E1]PP-1 alpha 2[/E1] and [E2]SV40 large T antigen[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PP-1 alpha 2", "entity_1_idx": [[60, 72]], "entity_1_idx_in_text_with_entity_marker": [64, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SV40 large T antigen", "entity_2_idx": [[77, 97]], "entity_2_idx_in_text_with_entity_marker": [90, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1244_AIMed.d147.s1244.p0", "text": "Characterization of the retinoblastoma binding proteins RBP1 and RBP2.", "text_with_entity_marker": "Characterization of the [E1]retinoblastoma[/E1] binding proteins [E2]RBP1[/E2] and RBP2.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "retinoblastoma", "entity_1_idx": [[24, 38]], "entity_1_idx_in_text_with_entity_marker": [28, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP1", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1244_AIMed.d147.s1244.p1", "text": "Characterization of the retinoblastoma binding proteins RBP1 and RBP2.", "text_with_entity_marker": "Characterization of the [E1]retinoblastoma[/E1] binding proteins RBP1 and [E2]RBP2[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "retinoblastoma", "entity_1_idx": [[24, 38]], "entity_1_idx_in_text_with_entity_marker": [28, 42], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP2", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1244_AIMed.d147.s1244.p2", "text": "Characterization of the retinoblastoma binding proteins RBP1 and RBP2.", "text_with_entity_marker": "Characterization of the retinoblastoma binding proteins [E1]RBP1[/E1] and [E2]RBP2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP1", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP2", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1245_AIMed.d147.s1245.p0", "text": "The retinoblastoma gene product, pRB, regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins.", "text_with_entity_marker": "The [E1]retinoblastoma[/E1] gene product, [E2]pRB[/E2], regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinoblastoma", "entity_1_idx": [[4, 18]], "entity_1_idx_in_text_with_entity_marker": [8, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRB", "entity_2_idx": [[33, 36]], "entity_2_idx_in_text_with_entity_marker": [46, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1248_AIMed.d147.s1248.p0", "text": "We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, RBP1 and RBP2, cloned originally by their interaction with pRB.", "text_with_entity_marker": "We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, [E1]RBP1[/E1] and [E2]RBP2[/E2], cloned originally by their interaction with pRB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP1", "entity_1_idx": [[101, 105]], "entity_1_idx_in_text_with_entity_marker": [105, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP2", "entity_2_idx": [[110, 114]], "entity_2_idx_in_text_with_entity_marker": [123, 127], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1248_AIMed.d147.s1248.p1", "text": "We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, RBP1 and RBP2, cloned originally by their interaction with pRB.", "text_with_entity_marker": "We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, [E1]RBP1[/E1] and RBP2, cloned originally by their interaction with [E2]pRB[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RBP1", "entity_1_idx": [[101, 105]], "entity_1_idx_in_text_with_entity_marker": [105, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRB", "entity_2_idx": [[160, 163]], "entity_2_idx_in_text_with_entity_marker": [173, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1248_AIMed.d147.s1248.p2", "text": "We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, RBP1 and RBP2, cloned originally by their interaction with pRB.", "text_with_entity_marker": "We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, RBP1 and [E1]RBP2[/E1], cloned originally by their interaction with [E2]pRB[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RBP2", "entity_1_idx": [[110, 114]], "entity_1_idx_in_text_with_entity_marker": [114, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRB", "entity_2_idx": [[160, 163]], "entity_2_idx_in_text_with_entity_marker": [173, 176], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p0", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the [E1]RBP1[/E1] and [E2]RBP2[/E2] genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP1", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP2", "entity_2_idx": [[29, 33]], "entity_2_idx_in_text_with_entity_marker": [42, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p1", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the [E1]RBP1[/E1] and RBP2 genes are ubiquitously expressed, large (200 kDa for [E2]RBP1[/E2] and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP1", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP1", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p2", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the [E1]RBP1[/E1] and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for [E2]RBP2[/E2]) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP1", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP2", "entity_2_idx": [[108, 112]], "entity_2_idx_in_text_with_entity_marker": [121, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p3", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the RBP1 and [E1]RBP2[/E1] genes are ubiquitously expressed, large (200 kDa for [E2]RBP1[/E2] and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP2", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP1", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p4", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the RBP1 and [E1]RBP2[/E1] genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for [E2]RBP2[/E2]) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP2", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP2", "entity_2_idx": [[108, 112]], "entity_2_idx_in_text_with_entity_marker": [121, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p5", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for [E1]RBP1[/E1] and 195 kDa for [E2]RBP2[/E2]) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP1", "entity_1_idx": [[87, 91]], "entity_1_idx_in_text_with_entity_marker": [91, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP2", "entity_2_idx": [[108, 112]], "entity_2_idx_in_text_with_entity_marker": [121, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1250_AIMed.d147.s1250.p0", "text": "In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein.", "text_with_entity_marker": "In addition we have been able to identify complexes of [E1]pRB[/E1] and [E2]RBP1[/E2] in vivo that are dissociated in the presence of purified human papillomavirus E7 protein.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pRB", "entity_1_idx": [[55, 58]], "entity_1_idx_in_text_with_entity_marker": [59, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP1", "entity_2_idx": [[63, 67]], "entity_2_idx_in_text_with_entity_marker": [76, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1250_AIMed.d147.s1250.p1", "text": "In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein.", "text_with_entity_marker": "In addition we have been able to identify complexes of [E1]pRB[/E1] and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus [E2]E7[/E2] protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[55, 58]], "entity_1_idx_in_text_with_entity_marker": [59, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E7", "entity_2_idx": [[146, 148]], "entity_2_idx_in_text_with_entity_marker": [159, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1250_AIMed.d147.s1250.p2", "text": "In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein.", "text_with_entity_marker": "In addition we have been able to identify complexes of pRB and [E1]RBP1[/E1] in vivo that are dissociated in the presence of purified human papillomavirus [E2]E7[/E2] protein.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RBP1", "entity_1_idx": [[63, 67]], "entity_1_idx_in_text_with_entity_marker": [67, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E7", "entity_2_idx": [[146, 148]], "entity_2_idx_in_text_with_entity_marker": [159, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s554_AIMed.d65.s554.p0", "text": "Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.", "text_with_entity_marker": "Cross-family dimerization of transcription factors [E1]Fos[/E1]/[E2]Jun[/E2] and ATF/CREB alters DNA binding specificity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fos", "entity_1_idx": [[51, 54]], "entity_1_idx_in_text_with_entity_marker": [55, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jun", "entity_2_idx": [[55, 58]], "entity_2_idx_in_text_with_entity_marker": [68, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s554_AIMed.d65.s554.p1", "text": "Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.", "text_with_entity_marker": "Cross-family dimerization of transcription factors [E1]Fos[/E1]/Jun and [E2]ATF[/E2]/CREB alters DNA binding specificity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[51, 54]], "entity_1_idx_in_text_with_entity_marker": [55, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ATF", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s554_AIMed.d65.s554.p2", "text": "Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.", "text_with_entity_marker": "Cross-family dimerization of transcription factors [E1]Fos[/E1]/Jun and ATF/[E2]CREB[/E2] alters DNA binding specificity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[51, 54]], "entity_1_idx_in_text_with_entity_marker": [55, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s554_AIMed.d65.s554.p3", "text": "Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.", "text_with_entity_marker": "Cross-family dimerization of transcription factors Fos/[E1]Jun[/E1] and [E2]ATF[/E2]/CREB alters DNA binding specificity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jun", "entity_1_idx": [[55, 58]], "entity_1_idx_in_text_with_entity_marker": [59, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ATF", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s554_AIMed.d65.s554.p4", "text": "Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.", "text_with_entity_marker": "Cross-family dimerization of transcription factors Fos/[E1]Jun[/E1] and ATF/[E2]CREB[/E2] alters DNA binding specificity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jun", "entity_1_idx": [[55, 58]], "entity_1_idx_in_text_with_entity_marker": [59, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s554_AIMed.d65.s554.p5", "text": "Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.", "text_with_entity_marker": "Cross-family dimerization of transcription factors Fos/Jun and [E1]ATF[/E1]/[E2]CREB[/E2] alters DNA binding specificity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ATF", "entity_1_idx": [[63, 66]], "entity_1_idx_in_text_with_entity_marker": [67, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s555_AIMed.d65.s555.p0", "text": "The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "text_with_entity_marker": "The [E1]Fos[/E1]/[E2]Jun[/E2] and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jun", "entity_2_idx": [[8, 11]], "entity_2_idx_in_text_with_entity_marker": [21, 24], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s555_AIMed.d65.s555.p1", "text": "The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "text_with_entity_marker": "The [E1]Fos[/E1]/Jun and [E2]ATF[/E2]/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ATF", "entity_2_idx": [[16, 19]], "entity_2_idx_in_text_with_entity_marker": [29, 32], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s555_AIMed.d65.s555.p2", "text": "The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "text_with_entity_marker": "The [E1]Fos[/E1]/Jun and ATF/[E2]CREB[/E2] families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[20, 24]], "entity_2_idx_in_text_with_entity_marker": [33, 37], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s555_AIMed.d65.s555.p3", "text": "The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "text_with_entity_marker": "The Fos/[E1]Jun[/E1] and [E2]ATF[/E2]/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jun", "entity_1_idx": [[8, 11]], "entity_1_idx_in_text_with_entity_marker": [12, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ATF", "entity_2_idx": [[16, 19]], "entity_2_idx_in_text_with_entity_marker": [29, 32], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s555_AIMed.d65.s555.p4", "text": "The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "text_with_entity_marker": "The Fos/[E1]Jun[/E1] and ATF/[E2]CREB[/E2] families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jun", "entity_1_idx": [[8, 11]], "entity_1_idx_in_text_with_entity_marker": [12, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[20, 24]], "entity_2_idx_in_text_with_entity_marker": [33, 37], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s555_AIMed.d65.s555.p5", "text": "The Fos/Jun and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "text_with_entity_marker": "The Fos/Jun and [E1]ATF[/E1]/[E2]CREB[/E2] families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ATF", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[20, 24]], "entity_2_idx_in_text_with_entity_marker": [33, 37], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s558_AIMed.d65.s558.p0", "text": "Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "text_with_entity_marker": "Although [E1]Fos[/E1]/[E2]Jun[/E2] and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[9, 12]], "entity_1_idx_in_text_with_entity_marker": [13, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jun", "entity_2_idx": [[13, 16]], "entity_2_idx_in_text_with_entity_marker": [26, 29], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s558_AIMed.d65.s558.p1", "text": "Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "text_with_entity_marker": "Although [E1]Fos[/E1]/Jun and [E2]ATF[/E2]/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[9, 12]], "entity_1_idx_in_text_with_entity_marker": [13, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ATF", "entity_2_idx": [[21, 24]], "entity_2_idx_in_text_with_entity_marker": [34, 37], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s558_AIMed.d65.s558.p2", "text": "Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "text_with_entity_marker": "Although [E1]Fos[/E1]/Jun and ATF/[E2]CREB[/E2] were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[9, 12]], "entity_1_idx_in_text_with_entity_marker": [13, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[25, 29]], "entity_2_idx_in_text_with_entity_marker": [38, 42], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s558_AIMed.d65.s558.p3", "text": "Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "text_with_entity_marker": "Although Fos/[E1]Jun[/E1] and [E2]ATF[/E2]/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jun", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ATF", "entity_2_idx": [[21, 24]], "entity_2_idx_in_text_with_entity_marker": [34, 37], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s558_AIMed.d65.s558.p4", "text": "Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "text_with_entity_marker": "Although Fos/[E1]Jun[/E1] and ATF/[E2]CREB[/E2] were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jun", "entity_1_idx": [[13, 16]], "entity_1_idx_in_text_with_entity_marker": [17, 20], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[25, 29]], "entity_2_idx_in_text_with_entity_marker": [38, 42], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s558_AIMed.d65.s558.p5", "text": "Although Fos/Jun and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "text_with_entity_marker": "Although Fos/Jun and [E1]ATF[/E1]/[E2]CREB[/E2] were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ATF", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[25, 29]], "entity_2_idx_in_text_with_entity_marker": [38, 42], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s560_AIMed.d65.s560.p0", "text": "These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.", "text_with_entity_marker": "These findings indicate that the [E1]Fos[/E1]/[E2]Jun[/E2] and ATF/CREB families of transcription factors are not as distinct as was previously thought.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[33, 36]], "entity_1_idx_in_text_with_entity_marker": [37, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jun", "entity_2_idx": [[37, 40]], "entity_2_idx_in_text_with_entity_marker": [50, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s560_AIMed.d65.s560.p1", "text": "These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.", "text_with_entity_marker": "These findings indicate that the [E1]Fos[/E1]/Jun and [E2]ATF[/E2]/CREB families of transcription factors are not as distinct as was previously thought.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[33, 36]], "entity_1_idx_in_text_with_entity_marker": [37, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ATF", "entity_2_idx": [[45, 48]], "entity_2_idx_in_text_with_entity_marker": [58, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s560_AIMed.d65.s560.p2", "text": "These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.", "text_with_entity_marker": "These findings indicate that the [E1]Fos[/E1]/Jun and ATF/[E2]CREB[/E2] families of transcription factors are not as distinct as was previously thought.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fos", "entity_1_idx": [[33, 36]], "entity_1_idx_in_text_with_entity_marker": [37, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[49, 53]], "entity_2_idx_in_text_with_entity_marker": [62, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s560_AIMed.d65.s560.p3", "text": "These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.", "text_with_entity_marker": "These findings indicate that the Fos/[E1]Jun[/E1] and [E2]ATF[/E2]/CREB families of transcription factors are not as distinct as was previously thought.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jun", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ATF", "entity_2_idx": [[45, 48]], "entity_2_idx_in_text_with_entity_marker": [58, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s560_AIMed.d65.s560.p4", "text": "These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.", "text_with_entity_marker": "These findings indicate that the Fos/[E1]Jun[/E1] and ATF/[E2]CREB[/E2] families of transcription factors are not as distinct as was previously thought.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jun", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[49, 53]], "entity_2_idx_in_text_with_entity_marker": [62, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d65.s560_AIMed.d65.s560.p5", "text": "These findings indicate that the Fos/Jun and ATF/CREB families of transcription factors are not as distinct as was previously thought.", "text_with_entity_marker": "These findings indicate that the Fos/Jun and [E1]ATF[/E1]/[E2]CREB[/E2] families of transcription factors are not as distinct as was previously thought.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ATF", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CREB", "entity_2_idx": [[49, 53]], "entity_2_idx_in_text_with_entity_marker": [62, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1879_AIMed.d217.s1879.p0", "text": "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.", "text_with_entity_marker": "Characterization of [E1]Fas[/E1] ([E2]Apo-1[/E2], CD95)-Fas ligand interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[20, 23]], "entity_1_idx_in_text_with_entity_marker": [24, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Apo-1", "entity_2_idx": [[25, 30]], "entity_2_idx_in_text_with_entity_marker": [38, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1879_AIMed.d217.s1879.p1", "text": "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.", "text_with_entity_marker": "Characterization of [E1]Fas[/E1] (Apo-1, [E2]CD95[/E2])-Fas ligand interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[20, 23]], "entity_1_idx_in_text_with_entity_marker": [24, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95", "entity_2_idx": [[32, 36]], "entity_2_idx_in_text_with_entity_marker": [45, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1879_AIMed.d217.s1879.p2", "text": "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.", "text_with_entity_marker": "Characterization of [E1]Fas[/E1] (Apo-1, CD95)-[E2]Fas[/E2] ligand interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[20, 23]], "entity_1_idx_in_text_with_entity_marker": [24, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[38, 41]], "entity_2_idx_in_text_with_entity_marker": [51, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1879_AIMed.d217.s1879.p3", "text": "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.", "text_with_entity_marker": "Characterization of [E1]Fas[/E1] (Apo-1, CD95)-[E2]Fas ligand[/E2] interaction.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fas", "entity_1_idx": [[20, 23]], "entity_1_idx_in_text_with_entity_marker": [24, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[38, 48]], "entity_2_idx_in_text_with_entity_marker": [51, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1879_AIMed.d217.s1879.p4", "text": "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.", "text_with_entity_marker": "Characterization of Fas ([E1]Apo-1[/E1], [E2]CD95[/E2])-Fas ligand interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Apo-1", "entity_1_idx": [[25, 30]], "entity_1_idx_in_text_with_entity_marker": [29, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD95", "entity_2_idx": [[32, 36]], "entity_2_idx_in_text_with_entity_marker": [45, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1879_AIMed.d217.s1879.p5", "text": "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.", "text_with_entity_marker": "Characterization of Fas ([E1]Apo-1[/E1], CD95)-[E2]Fas[/E2] ligand interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Apo-1", "entity_1_idx": [[25, 30]], "entity_1_idx_in_text_with_entity_marker": [29, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[38, 41]], "entity_2_idx_in_text_with_entity_marker": [51, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1879_AIMed.d217.s1879.p6", "text": "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.", "text_with_entity_marker": "Characterization of Fas ([E1]Apo-1[/E1], CD95)-[E2]Fas ligand[/E2] interaction.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Apo-1", "entity_1_idx": [[25, 30]], "entity_1_idx_in_text_with_entity_marker": [29, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[38, 48]], "entity_2_idx_in_text_with_entity_marker": [51, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1879_AIMed.d217.s1879.p7", "text": "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.", "text_with_entity_marker": "Characterization of Fas (Apo-1, [E1]CD95[/E1])-[E2]Fas[/E2] ligand interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD95", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[38, 41]], "entity_2_idx_in_text_with_entity_marker": [51, 54], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1879_AIMed.d217.s1879.p8", "text": "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.", "text_with_entity_marker": "Characterization of Fas (Apo-1, [E1]CD95[/E1])-[E2]Fas ligand[/E2] interaction.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD95", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[38, 48]], "entity_2_idx_in_text_with_entity_marker": [51, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1879_AIMed.d217.s1879.p9", "text": "Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.", "text_with_entity_marker": "Characterization of Fas (Apo-1, CD95)-[E1-E2]Fas[/E1] ligand[/E2] interaction.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [45, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas[/E1] ligand", "entity_2_idx": [[38, 48]], "entity_2_idx_in_text_with_entity_marker": [45, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1880_AIMed.d217.s1880.p0", "text": "The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).", "text_with_entity_marker": "The death-inducing receptor [E1]Fas[/E1] is activated when cross-linked by the type II membrane protein [E2]Fas[/E2] ligand (FasL).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[95, 98]], "entity_2_idx_in_text_with_entity_marker": [108, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1880_AIMed.d217.s1880.p1", "text": "The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).", "text_with_entity_marker": "The death-inducing receptor [E1]Fas[/E1] is activated when cross-linked by the type II membrane protein [E2]Fas ligand[/E2] (FasL).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fas", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas ligand", "entity_2_idx": [[95, 105]], "entity_2_idx_in_text_with_entity_marker": [108, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1880_AIMed.d217.s1880.p2", "text": "The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).", "text_with_entity_marker": "The death-inducing receptor [E1]Fas[/E1] is activated when cross-linked by the type II membrane protein Fas ligand ([E2]FasL[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fas", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1880_AIMed.d217.s1880.p3", "text": "The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).", "text_with_entity_marker": "The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein [E1-E2]Fas[/E1] ligand[/E2] (FasL).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[95, 98]], "entity_1_idx_in_text_with_entity_marker": [102, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas[/E1] ligand", "entity_2_idx": [[95, 105]], "entity_2_idx_in_text_with_entity_marker": [102, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1880_AIMed.d217.s1880.p4", "text": "The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).", "text_with_entity_marker": "The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein [E1]Fas[/E1] ligand ([E2]FasL[/E2]).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fas", "entity_1_idx": [[95, 98]], "entity_1_idx_in_text_with_entity_marker": [99, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1880_AIMed.d217.s1880.p5", "text": "The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein Fas ligand (FasL).", "text_with_entity_marker": "The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein [E1]Fas ligand[/E1] ([E2]FasL[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas ligand", "entity_1_idx": [[95, 105]], "entity_1_idx_in_text_with_entity_marker": [99, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[107, 111]], "entity_2_idx_in_text_with_entity_marker": [120, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1881_AIMed.d217.s1881.p0", "text": "When human soluble FasL (sFasL, containing the extracellular portion) was expressed in human embryo kidney 293 cells, the three N-linked glycans of each FasL monomer were found to be essential for efficient secretion.", "text_with_entity_marker": "When human soluble [E1]FasL[/E1] (sFasL, containing the extracellular portion) was expressed in human embryo kidney 293 cells, the three N-linked glycans of each [E2]FasL[/E2] monomer were found to be essential for efficient secretion.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FasL", "entity_1_idx": [[19, 23]], "entity_1_idx_in_text_with_entity_marker": [23, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[153, 157]], "entity_2_idx_in_text_with_entity_marker": [166, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1882_AIMed.d217.s1882.p0", "text": "Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.", "text_with_entity_marker": "Based on the structure of the closely related [E1]lymphotoxin alpha[/E1]-[E2]tumor necrosis factor receptor I[/E2] complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "lymphotoxin alpha", "entity_1_idx": [[46, 63]], "entity_1_idx_in_text_with_entity_marker": [50, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "tumor necrosis factor receptor I", "entity_2_idx": [[64, 96]], "entity_2_idx_in_text_with_entity_marker": [77, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1882_AIMed.d217.s1882.p1", "text": "Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.", "text_with_entity_marker": "Based on the structure of the closely related [E1]lymphotoxin alpha[/E1]-tumor necrosis factor receptor I complex, a molecular model of the [E2]FasL[/E2] homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin alpha", "entity_1_idx": [[46, 63]], "entity_1_idx_in_text_with_entity_marker": [50, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[131, 135]], "entity_2_idx_in_text_with_entity_marker": [144, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1882_AIMed.d217.s1882.p2", "text": "Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.", "text_with_entity_marker": "Based on the structure of the closely related [E1]lymphotoxin alpha[/E1]-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three [E2]Fas[/E2] molecules was generated using knowledge-based protein modeling methods.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "lymphotoxin alpha", "entity_1_idx": [[46, 63]], "entity_1_idx_in_text_with_entity_marker": [50, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[162, 165]], "entity_2_idx_in_text_with_entity_marker": [175, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1882_AIMed.d217.s1882.p3", "text": "Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.", "text_with_entity_marker": "Based on the structure of the closely related lymphotoxin alpha-[E1]tumor necrosis factor receptor I[/E1] complex, a molecular model of the [E2]FasL[/E2] homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor receptor I", "entity_1_idx": [[64, 96]], "entity_1_idx_in_text_with_entity_marker": [68, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FasL", "entity_2_idx": [[131, 135]], "entity_2_idx_in_text_with_entity_marker": [144, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1882_AIMed.d217.s1882.p4", "text": "Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.", "text_with_entity_marker": "Based on the structure of the closely related lymphotoxin alpha-[E1]tumor necrosis factor receptor I[/E1] complex, a molecular model of the FasL homotrimer bound to three [E2]Fas[/E2] molecules was generated using knowledge-based protein modeling methods.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor receptor I", "entity_1_idx": [[64, 96]], "entity_1_idx_in_text_with_entity_marker": [68, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[162, 165]], "entity_2_idx_in_text_with_entity_marker": [175, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1882_AIMed.d217.s1882.p5", "text": "Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.", "text_with_entity_marker": "Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the [E1]FasL[/E1] homotrimer bound to three [E2]Fas[/E2] molecules was generated using knowledge-based protein modeling methods.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FasL", "entity_1_idx": [[131, 135]], "entity_1_idx_in_text_with_entity_marker": [135, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[162, 165]], "entity_2_idx_in_text_with_entity_marker": [175, 178], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1885_AIMed.d217.s1885.p0", "text": "Mutants P206R, P206D, and P206F displayed reduced cytotoxicity toward Fas-positive cells with a concomitant decrease in the binding affinity for the recombinant Fas-immunoglobulin Fc fusion proteins.", "text_with_entity_marker": "Mutants P206R, P206D, and P206F displayed reduced cytotoxicity toward [E1]Fas[/E1]-positive cells with a concomitant decrease in the binding affinity for the recombinant [E2]Fas[/E2]-immunoglobulin Fc fusion proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fas", "entity_1_idx": [[70, 73]], "entity_1_idx_in_text_with_entity_marker": [74, 77], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[161, 164]], "entity_2_idx_in_text_with_entity_marker": [174, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d217.s1886_AIMed.d217.s1886.p0", "text": "Although the cytotoxic activity of mutant Y218D was unaltered, mutant Y218R was inactive, correlating with the prediction that Tyr-218 of FasL interacts with a cluster of three basic amino acid side chains of Fas.", "text_with_entity_marker": "Although the cytotoxic activity of mutant Y218D was unaltered, mutant Y218R was inactive, correlating with the prediction that Tyr-218 of [E1]FasL[/E1] interacts with a cluster of three basic amino acid side chains of [E2]Fas[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FasL", "entity_1_idx": [[138, 142]], "entity_1_idx_in_text_with_entity_marker": [142, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[209, 212]], "entity_2_idx_in_text_with_entity_marker": [222, 225], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
